

2014 Product Catalog



Innovative Research of America

Time Release Pellets for Biomedical Research

www.innovsrch.com

INNOVATIVE RESEARCH OF AMERICA

Most scientists agree that the three essential parameters in the success of a biomedical experiment are:

- A. The scientific problem formulated in a defined question.
- B. The laboratory animal, healthy and untraumatized.
- C. The process of active product delivery; the most problematic variable of all three!

For a third of a century, Innovative Research of America has assumed the leadership role in improved time release technology. The main mission is to standardize the technology of drug delivery. Our proven Time Release Hormone and Drug Pellets help investigators take charge of product delivery and expand their abilities to do meaningful and reproducible research.

ADVANTAGES OF THE PELLET DELIVERY SYSTEM

- a ready-to-administer pellet for a simple subcutaneous implantation.
- a convenient long-term controlled product release in laboratory animals.
- a better method to avoid the “peak and valley” effects produced by conventional delivery methods.
- a new system to extend the product life against spontaneous and host-related breakdown.
- a dependable way to minimize the experimental variables.
- a more reliable approach for productive and reproducible research.



Ushering In The Age Of Innovative Research

HORMONE AND DRUG PELLETS FOR BIOMEDICAL RESEARCH

Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives. However, most scientists continue to labor with unreliable injectables to conduct their research.

Because of this inadequacy, biomedical research is as confusing as it is challenging and as frustrating as it is creative. The options of scientists to address scientific questions are not only dependent, but are also limited by the process of active product delivery. Traditionally, product delivery into the experimental animal has been the procedure most subject to variables and the most difficult to standardize effectively. The very process of having to accurately administer drugs to experimental animals can become a logistic nightmare for scientists.

CHANGING THE TIME COURSE OF DRUG DELIVERY

The good news is that times have changed. Our proven *Drug Delivery Technology* is helping investigators eliminate the need for unreliable, intermittent injections. Since 1980, Innovative Research of America has been the leader in supplying scientists with long term continuous release pellets embedded with active products. Our technology provides finished products, in a ready-to-implant form, utilizing our Matrix-Driven Delivery (MDD) Pellet System. The pellets are intended for, although not limited to, simple subcutaneous implantation in laboratory animals.

We Tell Time-Release Pellets What Time It Is



Find a Product in this Catalog.....	5
Ordering Information / General Policy & Terms	6, 7, 44, 84
Sales of Anabolic Steroids	8
Category Index.....	10-15
Alkaloids	Estrogens
Amino Acids	Fatty Acids
Androgens	Nucleotide Related Products
Antibiotics	Progestins
Anti-Inflammatory Agents	Prostaglandins
Anti-Neoplastics	Thyroids
Catecholamines	Vitamins
Corticoids and Diuretics	
Placebo Pellets Information / Price Schedules.....	17-19
Alphabetical Product Listing.....	21-42
Stock Pellet Price Schedules.....	45-71
Pellets for Immuno-Deficient Mice	
17 β -Estradiol / Tamoxifen & Sample References.....	73-77
Androgens / Anti-Androgens & Sample References.....	78-80
Trochar & Recommended Implantation Procedure	81, 123
Doxycycline & Tetracycline Pellets in Mice	85-86
Hormone + Hormone Pellets	89-92
Custom Pellets.....	93-108
Selected References	109-122
Order Forms.....	Back of Catalog
Patents.....	Inside Back Cover

**For further assistance, view our website at:
www.innovsrch.com*



We Add Time To Your Day

PRODUCT DESIGN AND FEATURES

The unique engineering of the (MDD) Pellet System integrates the three principles of diffusion, erosion and concentration gradients. It generates a finished pellet with a biodegradable matrix that effectively and continuously releases the active product in the animal.

The pellet delivery system can help the investigator take charge of standardizing and reproducing research results. It helps overcome problems commonly encountered by researchers who employ conventional delivery methods.

The *Pellet Implantation Methodology* provides solutions to:

- ... consistency in timing repeated product administrations.
- ... controlling the amount of product administered.
- ... stability of the product preparation.
- ... safety of the experimenter.
- ... neurophysiological trauma to the animal from excessive handling.
- ... freeing valuable research time.
- ... eliminating unnecessary and unstimulating laboratory practices.

Scientists from several research disciplines have documented in scientific literature that our Pellet Delivery System is effective, consistent, reproducible, economical, reliable, and safe for the animal. See Selected References on pages 109-122.

Only Time Release Pellets Really Know What Time It Is



PRODUCT SPECIFICATIONS

AVAILABLE SHAPES AND SIZES

Stock pellets are round and range in diameter from 1/8" (3 mm) to 1/2" (1.25 cm) depending on the dose and the release rate. Our Custom Pellets Department will also design various pellet shapes and smaller sizes (Page 94) to meet your research needs. Please refer to the **Custom Pellets** section on pages 93-108.

AVAILABLE DOSAGES

Most of the stock products in this catalog are available in 20 different dosages ranging from 1 microgram (0.001 mg) per pellet up to 200 milligrams (200 mg) per pellet within the specified release rate. Doses of pellets listed in this catalog reflect the total amount of net active product released over the indicated period of time.

AVAILABLE RELEASE RATES

Stock products are designed to release continuously for 21 days, 60 days, or 90 days. Please refer to our **Custom Pellets** section on pages 93-108 for other release rates tailored for the duration of the experiment.

AVAILABLE PRODUCTS

In our continuing quest to make available new stock items that are particularly in demand, we have added several products to the original categories. In addition to the listed pelletized products, Innovative Research of America has an efficient Custom Pellets Department to prepare products that are not available as stock items.

SELECTED REFERENCES

A sample of publications that employed our delivery system in a broad spectrum of products can be found on pages 109-122.



Consistent Dose-Dependent Release

FINDING A PRODUCT IN THIS CATALOG

The PRODUCTS in this catalog are arranged in ALPHABETICAL ORDER and are identified by a CATALOG NUMBER and a PRICE SCHEDULE with a PAGE NUMBER.

The catalog number and price schedule reflect a release rate of 21 days, 60 days, or 90 days.

To illustrate with 17 β -Estradiol as an example:

EXAMPLE

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
17 β - Estradiol	E - 121	B-21/48	SE - 121	B-60/49	NE - 121	B-90/50

The above example indicates that 17 β -Estradiol is available in three release forms each having a different catalog number and price code, i.e.

E - 121 is a 21-day release form with a price code of B-21, found on page 48.

SE - 121 is a 60-day release form with a price code of B-60, found on page 49.

NE - 121 is a 90-day release form with a price code of B-90, found on page 50.

The PAGE NUMBER next to the PRICE SCHEDULE indicates the page where the actual price for the product appears.

When ordering please use the PRODUCT NAME, CATALOG NUMBER, RELEASE RATE and DOSE. Most products are available in 20 different dosages. Products are sold in Lots of 25, 50, 100, and 200 pellets. Please indicate the quantity of pellets being ordered.

Beginning on Page 10 we have grouped some of our catalog items in related categories alphabetically. We hope the listing will help in noting items of potential interest.

Time-Release Pellets... Always On Time



ORDERING INFORMATION

• Mail

Innovative Research of America, Inc.
2 North Tamiami Trail
Suite 404
Sarasota, Florida 34236 USA

• Phone

(941) 365-1406
(941) 365-1506
(800) 421-8171 (USA/Canada)

• Fax

(941) 365-1703
(941) 365-1803
(800) 643-4345 (USA/Canada)
(800) 648-6030 (USA/Canada)

• Internet / E-Mail

<http://www.innovrsrch.com> (website)
pellets@innovrsrch.com (e-mail)

IRA's website features our company profile,
the latest product technology and **on-line ordering**.



AMERICAN EXPRESS,
VISA AND MASTERCARD ACCEPTED.



Purchase Order Forms are in the back of the
catalog.



Custom Pellets Information Form on page 95.

THE DIFFERENCE IS
CONSISTENCY AND UNIFORMITY.



Bank Wire Payment Information

Payment via bank wire should be directed as follows:

BB&T Bank
1800 Second St., Suite 100
Sarasota, Florida 34236
Routing # (ABA) 263191387
Electronic Transfers # 263191387

In favor of:
Innovative Research of America
2 North Tamiami Trail
Suite 404
Sarasota, FL 34236
Checking Account: #0000147816154
Swift Code: BRBTUS33



Ushering In The Age Of Innovative Research

GENERAL POLICY AND TERMS

POLICY

All products in this catalog are sold for investigational use in laboratory animals only and are not intended for diagnostic or drug use.

Sales are made to qualified research scientists and recognized institutions.

Products that you receive because of your error are not returnable for credit.

Any product shipped to you that includes an error on our part may be returned to us immediately for replacement. Prices are subject to change without notice.

TERMS

30 days net/FOB Sarasota, Florida USA.

Prepayment in U. S. Dollars through a U.S. Bank is required on all orders from outside the United States until credit is established.

Bank Wire Payment Information can be found on the International Order Form located in the back of this catalog. In addition to bank wires and institutional checks, **we also accept payment by Mastercard, Visa and American Express.**

Please provide your account number, the name on the card and expiration date when placing an order.

Recipient is responsible for all duties and taxes on any orders shipped outside of the United States.

SHIPPING

All orders of stock items will be shipped within seven days from receipt of order.

Custom Pellet orders will be shipped within 4-6 weeks.

Standing orders will be shipped upon customer request and invoicing will be concurrent with shipments.

Orders are shipped via Federal Express. Shipping and handling is added based on the invoice total.

Recipient is responsible for all duties and taxes on any orders shipped outside of the United States.

The Pellets Save Time Scientists Never Have



SALE OF CONTROLLED ANABOLIC STEROIDS within the United States

(Telephone orders will not be accepted - orders & copy of DEA license may be mailed or faxed)

Before we can prepare any orders of Anabolic Steroid Pellets, the Drug Enforcement Administration (DEA) requires us to obtain:

1. A valid photocopy of the investigator's DEA Registration containing Schedule 3N.
2. A written Purchase Order showing the investigator's DEA Registration Number and proper shipping address.

CONTACT INNOVATIVE RESEARCH OF AMERICA
BY PHONE, MAIL, FAX OR E-MAIL
FOR MORE ORDERING INFORMATION - SEE PAGE 6

SALE OF CONTROLLED ANABOLIC STEROIDS outside the United States (International)

**WE NO LONGER SHIP ANABOLIC STEROIDS
outside the United States (International)**

DEA Controlled Anabolic Steroids

Androstenediol	19-Nortestosterone 17-Decanoate
Androstenedione	19-Nortestosterone 17-Dipropionate
5 α -Dihydrotestosterone	Stanozolol
Fluoxymesterone	Testosterone
Mesterolone	Testosterone Acetate
Mesterone	Testosterone Benzoate
Methandriol	Testosterone Cypionate
Methandriol Dipropionate	Testosterone Enanthate
19-Nortestosterone	Testosterone 17 β -Hemisuccinate
	Testosterone Propionate



Time Release Pellets ... Always On Time

See pages 73-80 regarding
Hormone/Anti-Hormone products
for Immuno-Deficient Mice
and specific references.



Your Research Time Is Under Your Control



CATEGORY INDEX

On the following 6 pages, we have grouped some of our Catalog items in related categories. Hopefully this listing will help in noting items of potential interest.

ALKALOIDS

cis-Aconitic Acid	Calycanthine	Nicotinic Acid	Strychnine
trans-Aconitic Acid	(-) Cotinine	Noscapine	Theobromine
Aconitine	Crotaline	L-Phenylephrine	Theophylline
Anisodamine	Cytisine	Physostigmine (Eserine)	Tomatidine
Anisodine	Dihydroergotamine	Puerarin	Tomatine
Arecoline	Emetine	Quinidine	Tropine
Atropine	Eserine (Physostigmine)	Quinine	Tropinone
Atropine Methyl Bromide	Eucatropine	Scopine	Veratrine
Berberine	(+) Glaucine	Securinine	Vincamine
Boldine	Homatropine	Solasodine	Yohimbine
Bromocriptine Mesylate	L-Hyoscyamine	(-) Sparteine	
Brucine	Nicotine	Spermidine	
		Spermine	

AMINO ACIDS

N-Acetyl-L-Cysteine	D-Cysteine	L-Isoleucine	L-Serine
N-Acetyl-L-Glutamine	L-Cysteine	D-Leucine	D-Threonine
N-Acetylimidazole	D-Cystine	L-Leucine	L-Threonine
β -Alanine	L-Cystine	D-Lysine	D-Tryptophan
D-Alanine	D-Glutamic Acid	L-Lysine	L-Tryptophan
L-Alanine	L-Glutamic Acid	D-Methionine	D-Tyrosine
D-Arginine	D-Glutamine	L-Methionine	L-Tyrosine
L-Arginine	L-Glutamine	D-Phenylalanine	D-Valine
D-Asparagine	Glycine	L-Phenylalanine	L-Valine
L-Asparagine	D-Histidine	D-Proline	
D-Aspartic Acid	L-Histidine	L-Proline	
L-Aspartic Acid	D-Isoleucine	D-Serine	

ANDROGENS

Androstenediol	Methandriol Dipropionate
Androstenedione	Methyl Androstenediol (Methandriol)
5 α -Androsterone	Methyl Testosterone (Mesterolone)
5 β -Androsterone	Nandrolone (19-Nortestosterone)
Cyproterone Acetate	19-Nortestosterone (Nandrolone)
Dehydroepiandrosterone	19-Nortestosterone 17-Decanoate
Dehydroepiandrosterone Acetate	19-Nortestosterone 17-Dipropionate
Dehydroepiandrosterone Sulfate	19-Nortestosterone 17-Propionate
5 α -Dihydrotestosterone	Stanozolol
5 β -Dihydrotestosterone	Testosterone
Fluoxymesterone	Testosterone Acetate
Flutamide	Testosterone Benzoate
Gossypol Acetate	Testosterone Cypionate
Mesterolone (Methyl Testosterone)	Testosterone Enanthate
Mesterone	Testosterone 17 β -Hemisuccinate
Methandriol (Methyl Androstendiol)	Testosterone Propionate



Reliable Delivery System For Global Discoveries

CATEGORY INDEX (continued)

ANTIBIOTICS

Acetarsone	Cinnarizine	Neomycin Sulfate
Albendazole	Clofoctol	Novobiocin
Amantadine	Clotrimazole	Nystatin (Mycostatin)
6-Aminopenicillanic Acid	Cloxacillin	Oxytetracycline
Amoxicillin	Colchicine	D-Penicillamine
Amphotericin B	D-Cycloserine	DL-Penicillamine
Ampicillin	Diaveridine	L-Penicillamine
Bacitracin	Dicloxacillin	Penicillin-G (Benzylpenicillin)
Beclomethasone	Doxycycline	Piromedic Acid
Benzylpenicillinic Acid	Econazole	Polymyxin B Sulfate
Cefadroxil	Enoxacin	Primaquine
Cefamandole	Erythromycin	Puromycin
Cefazolin	Ethambutol	Pyrazinamide
Cefmetazole	Flumequine	Quinacrine
Cefoperazone	Geneticin	Rifampicin
Cefotaxime	Gentamicin Sulfate	Rifamycin
Cefoxitin	Gramicidin	Spiramycin
Cefsulodin	Guaifenesin	Streptomycin Sulfate
Ceftriaxone	Indoprofen	Sulfabenzamide
Cephalexin	Isoxicam	Tetracycline
Cephaloglycin	Ketoprofen	Thiabendazole
Cephalothin	Melphalan	Thiacetazone
Cephapirin	Metronidazole	Thiamphenicol
Chloramphenicol	Minocycline	Vancomycin
Chloramphenicol Base	Monensin	Xanthinol Nicotinate
Chlorpheniramine	Moxalactam	
Cinchonidine	Mycostatin (Nystatin)	

ANTI-INFLAMMATORY AGENTS

Allopurinol	Indomethacin	Phenylbutazone
Aspirin	Levamisole	Piroxicam
Chloroquine	Meclizine	Probenecid
Diclofenac	Mefenamic Acid	Sulfinpyrazone
Flufenamic Acid	Naproxen	Sulindac
Flurbiprofen	Niflumic Acid	Zomepirac
Ibuprofen	Nimesulide	

We Add A Little Time To Your Day



CATEGORY INDEX (continued)

ANTI-NEOPLASTICS

Actinomycin D (Dactinomycin)	Doxorubicin (Adriamycin)	Oncovin (Vincristine)
Adriamycin (Doxorubicin)	5-Fluorouracil	cis-Platinum
Asparaginase	Kanamycin	trans-Platinum
Busulfan (Myleran)	Lomustine	Streptozotocin
Chlorambucil	Mechlorethamine	6-Thioguanine
Cyclophosphamide (Cytoxan)	6-Mercaptopurine	Velban (Vinblastine)
Cytarabine (Cytosine Arabinoside)	Methotrexate	Vinblastine (Velban)
Cytoxan (Cyclophosphamide)	Mithramycin A	Vincristine (Oncovin)
Dactinomycin (Actinomycin D)	Mitomycin C	
Daunorubicin (Daunomycin)	Myleran (Busulfan)	

CATECHOLAMINES AND RELATED PRODUCTS

Acebutolol	Digoxin	Meclofenoxate (Centrophoxine)
Acetopromazine (Acepromazine)	Dimenhydrinate	Methoxamine
Acepromazine (Acetopromazine)	Disopyramide (Anti-arrhythmic)	Methyl L-Dopa
N-Acetylprocainamide	D-Dopa	Metoclopramide
Ajmaline	DL-Dopa	Metoprolol
Alprenolol	L-Dopa	Minoxidil
Aminophylline	Dopamine (3-Hydroxytyramine)	Nadolol
Amiodarone	Doxepin	Naloxone
Amitriptyline	Doxylamine	Naltrexone
Amrinone	Drofenine	Naphazoline
Antazoline	Edrophonium	Neostigmine
Atenolol	Enalapril	Nifedipine
Caffeine	Ephedrine	Nifenazone
Captopril	Epinephrine	Norepinephrine
Carbamazepine	Epinine (Deoxyepinephrine)	Nortriptyline
Carbinoxamine	Flunarizine	Ouabain
Centrophoxine (Meclofenoxate)	Forskolin	Papaverine
Chlorcyclizine	Guanabenz	Perphenazine
Chlorothiazide	Guanethidine	Phenelzine
Chlorpromazine	Haloperidol	Pheniramine
Chlorthalidone	Harmaline	Pindolol
Chlorzoxazone	Harmine	Prazosin
Cimetidine	Histamine	Procainamide
Clomipramine	Hydralazine	Promethazine
Clonidine	5-Hydroxydopamine	Propranolol
Glopamide	6-Hydroxydopamine	Pyrilamine
Cromolyn	5-Hydroxy-L-Tryptophan	Rescinnamine
Cyclizine	3-Hydroxytyramine (Dopamine)	Reserpine
Cymarin	Imipramine (Anti-depressant)	Salbutamol
Cyproheptadine	Isoproterenol	Serotonin
Deoxyepinephrine (Epinine)	Isoxsuprine	Timolol
Desipramine	Khellin	Tolazoline
Digitonin	Labetalol	Tranlycypromine
Digitoxin	Lanatoside C	Tripelennamine
	Lidocaine	Verapamil



It's Time For Clear, Consistent Results

CATEGORY INDEX (continued)

CORTICOIDS AND DIURETICS

Acetazolamide	Deoxycorticosterone	Hydrocortisone 21-Acetate
d-Aldosterone	Deoxycorticosterone Acetate (DOCA)	Hydrocortisone 21-Hemisuccinate
Adrenal Cortex Acetone Powder	Desoximetasone	Hydrocortisone 21-Phosphate
Adrenosterone	Dexamethasone	D-Mannitol
Aminonide	Dexamethasone 21-Acetate	Methazolamide
Amiloride	Ethacrynic Acid	Methyl Prednisolone
Aminoglutethimide	Fludrocortisone	Metyrapone
Betamethasone	Fludrocortisone Acetate	Prednisolone
Cortexolone	Flumethasone	Prednisone
Cortexolone Acetate	Flunisolide	Spirolactone
Corticosterone	Fluocinolone	Triamcinolone
Corticosterone 21-Acetate	Furosemide	Triamcinolone Acetonide
Cortisone	Hydrochlorothiazide	Triamcinolone Diacetate
Cortisone Acetate	Hydrocortisone	Triamterene
Demeclocycline		

ESTROGENS AND ANTI-ESTROGENS

Chlorotrianisene	β -Estradiol 17-Cypionate	Estrone Hemisuccinate
Dienestrol (Dehydrostilbestrol)	β -Estradiol Diacetate	Estrone 3-Methyl Ether
Dienestrol Diacetate	β -Estradiol Dipropionate	Estrone 3-Sulfate
Diethylstilbestrol	β -Estradiol 3-Methyl Ether	17 α -Ethinylestradiol
d-Equilenin	β -Estradiol Propionate	Hexestrol (Dihydro-DES)
Equilin	β -Estradiol 17-Valerate	Mestranol (17 α -Ethinylestradiol 3-Methyl Ether)
Equilin-Methyl Ether	Estriol	Nafoxidine
17 α -Estradiol	Estriol 3-Benzyl Ether	Tamoxifen (Free Base)
17 β -Estradiol	Estriol Triacetate	Tamoxifen Citrate
β -Estradiol 17-Acetate	Estrone	
β -Estradiol 3-Benzoate	Estrone Acetate	

When Reliability Counts



CATEGORY INDEX (continued)

FATTY ACIDS

Arachidic Acid (saturated)
Arachidonic Acid (unsaturated)
Lauric Acid (saturated)
Lignoceric Acid (contains 24 carbon atoms)
Linoleic Acid (unsaturated)
Linolenic Acid (unsaturated)
Myristic Acid (saturated)
Nervonic Acid (contains 24 carbon atoms)
Oleic Acid (unsaturated)
Palmitic Acid (saturated)
Palmitoleic Acid (unsaturated)
Sodium Butyrate
Stearic Acid (saturated)

NUCLEOTIDE RELATED PRODUCTS

Adenosine
8-Azaadenine
5-Azacytidine
5-Azacytosine
8-Azaguanine
8-Azahypoxanthine
7-Azaindole
6-Azathymine
5-Azauracil
6-Azauracil
6-Azauridine
8-Bromoadenosine 3':5'-Cyclic Monophosphate
5-Bromo-2'-Deoxyuridine
Cytosine
3-Deazauracil
3-Deazauridine
N⁶O²-Dibutyryladenosine-3':5'-Cyclic Monophosphate
Guanosine
Hydroxyurea
5-Iodo-2'-Deoxyuridine
Thymidine
Uridine

PROGESTINS

Chlormadinone Acetate
Clomiphene Citrate
Danazol (Weak progestin)
16-Dehydropregnenolone
16-Dehydropregnenolone Acetate
16-Dehydroprogestosterone
Ethinisterone
17 α -Hydroxypregnenolone
11 α -Hydroxyprogesterone
17 α -Hydroxyprogesterone
Medroxyprogesterone Acetate
Megestrol Acetate
Norethindrone
Norethindrone Acetate
Norethynodrel
Norgestrel
Pregnenolone
Progesterone



Use Time To Your Advantage

CATEGORY INDEX (continued)

PROSTAGLANDINS

Prostaglandin A₁
Prostaglandin A₂
Prostaglandin B₁
Prostaglandin B₂
Prostaglandin D₂

Prostaglandin E₁
Prostaglandin E₂
Prostaglandin F_{1α}
Prostaglandin F_{2α}
Prostaglandin I₂ (Prostacyclin)

THYROIDS

3,5-Diiodo-DL-Thyronine
3,5-Diiodo-L-Thyronine
Methimazole (Antithyroid)
Methyl Thiouracil (Antithyroid)
Potassium Iodide
6-n-Propyl-2-Thiouracil (Antithyroid)
Sodium Iodide
Thiobarbital

Thyroglobulin
Thyroid Releasing Hormone
Thyroid Stimulating Hormone
DL-Thyronine
D-Thyroxine
L-Thyroxine
3,3', 5-Triiodo-DL-Thyronine
3,3', 5-Triiodo-L-Thyronine

VITAMINS

Acetyl-L-Carnitine
DL-Carnitine
β-Carotene
7-Dehydrocholesterol (Provitamin D₂)
Ergosterol (Provitamin D)
Folic Acid
Folinic Acid
Inositol
DL-α-Lipoic Acid (Oxidized thioctic acid)
Niacin
Niacinamide
Retinal (Vitamin A Aldehyde)
Retinoic Acid (All trans)
13-cis-Retinoic Acid
Retinol

Retinol Acetate
Retinol Palmitate
Vitamin B₁ (Thiamine)
Vitamin B₂ (Riboflavin)
Vitamin B₆ (Pyridoxine)
Vitamin B₁₂ (Cyanocobalamin)
Vitamin C (Ascorbic acid)
Vitamin D₂ (Ergocalciferol)
Vitamin D₃ (Cholecalciferol)
Vitamin E (Tocopherol)
Vitamin H (d-Biotin)
Vitamin K₁
Vitamin K₃ (Menadione)

Consistent Results With Consistent Release



ADVANTAGES OF OUR MDD PELLET SYSTEM

- ◆ **Saves time**
- ◆ **Ready-to-implant**
- ◆ **Insures controlled product release over time**
- ◆ **Avoids “peak and valley” effects**
- ◆ **Guarantees consistent product preparation**
- ◆ **Extends product life against spontaneous breakdown**
- ◆ **Extends product life against host-related breakdown**
- ◆ **Minimizes experimental variables**
- ◆ **Insures safety of the researcher**
- ◆ **Reduces neurophysiological trauma to the animal/
no excessive handling**
- ◆ **Generates more meaningful and reproducible results**
- ◆ **Superior to conventional delivery methods**
- ◆ **Enhances experimental efficiency**
- ◆ **Frees valuable time for creative research**
- ◆ **Saves money**



Time-Release Pellets... Always On Time

IRA

PLACEBO / CONTROL PELLETS

Placebo/Control pellets are used in experiments as the proper control to interpret biological results obtained with pellets containing active product.

Matching Placebo pellets contain all the components of the hormone or drug pellet except the active product itself. The carrier-binder excipients of the matrix include Cholesterol, Lactose, Celluloses, Phosphates and Stearates.

Stock Placebo pellets are available in 20 different doses corresponding to those of active product pellets. Each dose is offered in either 21 Day, 60 Day, or 90 Day Release form.

Although the matrixes in Placebo pellets have a different composition for different active products, they are all assigned the same catalog number and are offered at the same price schedule.

When inquiring or placing an order, please specify the active product you wish to correspond the Placebo pellets for. Please see the following examples:

Catalog No.	Description	Dose in mg/pellet	Release in Days
C-111	Placebo for "Active Product"*	_____ mg/pellet	21 Day
SC-111	Placebo for "Active Product"*	_____ mg/pellet	60 Day
NC-111	Placebo for "Active Product"*	_____ mg/pellet	90 Day

*In place of "Active Product" specify the hormone or drug you are utilizing in your study.

The following three pages are universal dose /price schedules in all three release rates (21 Day, 60 Day, and 90 Day) and are applicable as a matching Placebo for all products in the catalog except special physical size and preparations (page 94) which can be found under the Custom Pellet section on pages 93-108.

**Please inquire directly with us if further assistance is required regarding a product of interest.*

Use Placebo Pellets For Proper Control



PLACEBO PELLETS

PRICE SCHEDULE

Cat. No. C-111

TWENTY-ONE DAY RELEASE

Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$697	\$1362	\$2649	\$4816
0.010	\$697	\$1362	\$2649	\$4816
0.025	\$697	\$1362	\$2649	\$4816
0.05	\$697	\$1362	\$2649	\$4816
0.1	\$697	\$1362	\$2649	\$4816
0.25	\$697	\$1362	\$2649	\$4816
0.5	\$697	\$1362	\$2649	\$4816
1.5	\$697	\$1362	\$2649	\$4816
2.5	\$697	\$1362	\$2649	\$4816
5.0	\$697	\$1362	\$2649	\$4816
7.5	\$702	\$1379	\$2674	\$4858
10.0	\$702	\$1379	\$2674	\$4858
15.0	\$702	\$1379	\$2674	\$4858
25.0	\$707	\$1386	\$2674	\$4875
35.0	\$707	\$1386	\$2674	\$4875
50.0	\$707	\$1386	\$2674	\$4875
75.0	\$707	\$1386	\$2674	\$4875
100.0	\$718	\$1406	\$2734	\$4945
150.0	\$718	\$1406	\$2734	\$4945
200.0	\$723	\$1415	\$2744	\$4964

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

Sixty and Ninety day price schedules are on the following two pages.

Timing Is Everything



PLACEBO PELLETS

PRICE SCHEDULE

Cat. No. SC-111

SIXTY-DAY-RELEASE

Dose mg/pellet	PRICE/NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$731	\$1418	\$2751	\$4974
0.010	\$731	\$1418	\$2751	\$4974
0.025	\$731	\$1418	\$2751	\$4974
0.05	\$731	\$1418	\$2751	\$4974
0.1	\$731	\$1418	\$2751	\$4974
0.25	\$731	\$1418	\$2751	\$4974
0.5	\$731	\$1418	\$2751	\$4974
1.5	\$731	\$1418	\$2751	\$4974
2.5	\$731	\$1418	\$2751	\$4974
5.0	\$731	\$1418	\$2751	\$4974
7.5	\$738	\$1444	\$2789	\$5038
10.0	\$738	\$1444	\$2789	\$5038
15.0	\$738	\$1444	\$2789	\$5038
25.0	\$744	\$1454	\$2804	\$5063
35.0	\$744	\$1454	\$2804	\$5063
50.0	\$744	\$1454	\$2804	\$5063
75.0	\$744	\$1454	\$2804	\$5063
100.0	\$762	\$1484	\$2879	\$5168
150.0	\$762	\$1484	\$2879	\$5168
200.0	\$770	\$1498	\$2894	\$5197

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*



Consistent Dose-Dependent

PLACEBO PELLETS


PRICE SCHEDULE

Cat. No. NC-111

NINETY DAY RELEASE

Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$764	\$1474	\$2849	\$5128
0.010	\$764	\$1474	\$2849	\$5128
0.025	\$764	\$1474	\$2849	\$5128
0.05	\$764	\$1474	\$2849	\$5128
0.1	\$764	\$1474	\$2849	\$5128
0.25	\$764	\$1474	\$2849	\$5128
0.5	\$764	\$1474	\$2849	\$5128
1.5	\$764	\$1474	\$2849	\$5128
2.5	\$764	\$1474	\$2849	\$5128
5.0	\$764	\$1474	\$2849	\$5128
7.5	\$774	\$1508	\$2903	\$5216
10.0	\$774	\$1508	\$2903	\$5216
15.0	\$774	\$1508	\$2903	\$5216
25.0	\$782	\$1522	\$2923	\$5250
35.0	\$782	\$1522	\$2923	\$5250
50.0	\$782	\$1522	\$2923	\$5250
75.0	\$782	\$1522	\$2923	\$5250
100.0	\$806	\$1562	\$3023	\$5390
150.0	\$806	\$1562	\$3023	\$5390
200.0	\$816	\$1580	\$3043	\$5428

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*



The Research Puzzle Need Not Be Unsolved




IRA


TIME RELEASE PELLETS FOR BIOMEDICAL RESEARCH IN LABORATORY ANIMALS

Multi-Step Injections Are a Continuous Pain in DRUG DELIVERY

One-Step Continuous Release Pellets Are the Best Alternative



Time Release Pellets for Biomedical Research from IRA



PELLETS
FOR
INNOVATIVE
RESEARCH

100 mg 50 mg 25 mg 15 mg 5 mg 0.5 mg 0.1 mg

Our Team at IRA is working to meet the responsibility that Innovative Science demands and Innovative Scientists deserve.



Active Product Delivery To All Corners Of The Earth

The **PRODUCT NAMES** in this catalog are arranged in **ALPHABETICAL ORDER** and are identified by their individual **CATALOG NUMBERS** including a **PRICE SCHEDULE** and corresponding **PAGE NUMBER**. The catalog number and price schedule reflect a release rate of 21 Days, 60 Days, or 90 Days.

To illustrate with Acetazolamide as an example, please view the following table:

Product Name	21 Day Release		60 Day Release		90 Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
Acetazolamide	D-111	C21 / 51	SD-111	C60 / 52	ND-111	C90 / 53

The above example indicates the stock product Acetazolamide is available in three release forms each having a different catalog number and price code, i.e.

D-111 is a 21 Day Release form with a price code of C-21, found on page 51.
SD-111 is a 60 Day Release form with a price code of C-60, found on page 52.
ND-111 is a 90 Day Release form with a price code of C-90, found on page 53.

The **PAGE NUMBER** next to the **PRICE SCHEDULE** indicates the page where the actual price for the product appears.

When placing an order, please include the **PRODUCT NAME**, **CATALOG NUMBER**, **DOSE IN MG/PELLET** and **RELEASE RATE**. Most of our products are available in 20 different doses. Products are normally sold in lots of 25, 50, 100, and 200 pellets. Please indicate the quantity of pellets to be ordered.

Beginning on page 10, we have grouped some of our catalog items by related categories alphabetically. We hope the listing will help in noting items of potential interest.

**Please inquire directly with us if further assistance is required regarding a product of interest.*

Maximum Flexibility





ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release			60-Day Release			90-Day Release		
	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number
Acebutolol	C-101		B-21/48	SC-101		B-60/49	NC-101		B-90/50
2-Acetamidofluorene (2-AAF)	A-102		A-21/45	SA-102		A-60/46	NA-102		A-90/47
Acetarsone	B-165		B-21/48	SB-165		B-60/49	NB-165		B-90/50
Acetazolamide	D-111		C-21/51	SD-111		C-60/52	ND-111		C-90/53
Acetopromazine	C-102		B-21/48	SC-102		B-60/49	NC-102		B-90/50
Acetyl-L-Carnitine	V-272		B-21/48	SV-272		B-60/49	NV-272		B-90/50
N-Acetyl-L-Cysteine	Q-212		B-21/48	SQ-212		B-60/49	NQ-212		B-90/50
N-Acetyl-L-Glutamine	Q-272		B-21/48	SQ-272		B-60/49	NQ-272		B-90/50
N-Acetylimidazole	Q-273		B-21/48	SQ-273		B-60/49	NQ-273		B-90/50
N-Acetylprocainamide	C-106		A-21/45	SC-106		A-60/46	NC-106		A-90/47
cis-Aconitic Acid	K-111		B-21/48	SK-111		B-60/49	NK-111		B-90/50
trans-Aconitic Acid	K-112		C-21/51	SK-112		C-60/52	NK-112		C-90/53
Aconitine	K-113		E-21/57	SK-113		E-60/58	NK-113		E-90/59
Actinomycin D (Dactinomycin)	Z-110		H-21/60	SZ-110		H-60/61	NZ-110		H-90/62
Adenosine	N-111		C-21/51	SN-111		C-60/52	NN-111		C-90/53
Adrenal Cortex Acetone Powder	G-116		B-21/48	SG-116		B-60/49	NG-116		B-90/50
Adrenosterone	G-117		B-21/48	SG-117		B-60/49	NG-117		B-90/50
Adriamycin (Doxorubicin)	Z-180		H-21/60	SZ-180		H-60/61	NZ-180		H-90/62
Ajmaline	C-135		B-21/48	SC-135		B-60/49	NC-135		B-90/50
β -Alanine	Q-131		C-21/51	SQ-131		C-60/52	NQ-131		C-90/53
D-Alanine	Q-111		B-21/48	SQ-111		B-60/49	NQ-111		B-90/50
L-Alanine	Q-121		C-21/51	SQ-121		C-60/52	NQ-121		C-90/53
Albendazole	B-166		B-21/48	SB-166		B-60/49	NB-166		B-90/50
d-Aldosterone	M-151		H-21/60	SM-151		H-60/61	NM-151		H-90/62
Allopurinol	I-111		B-21/48	SI-111		B-60/49	NI-111		B-90/50
Alloxan	A-103		A-21/45	SA-103		A-60/46	NA-103		A-90/47
Alprenolol	C-431		D-21/54	SC-431		D-60/55	NC-431		D-90/56

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
Althiazide	A-104	B-21/48	SA-104	B-60/49	NA-104	B-90/50
Amantadine	B-167	B-21/48	SB-167	B-60/49	NB-167	B-90/50
Amcinonide	G-118	A-21/45	SG-118	A-60/46	NG-118	A-90/47
Amiloride	D-181	B-21/48	SD-181	B-60/49	ND-181	B-90/50
Aminoacetonitrile	A-105	B-21/48	SA-105	B-60/49	NA-105	B-90/50
α -Aminoacetophenone	A-106	A-21/45	SA-106	A-60/46	NA-106	A-90/47
m-Aminoacetophenone	A-107	B-21/48	SA-107	B-60/49	NA-107	B-90/50
p-Aminoacetophenone	A-108	B-21/48	SA-108	B-60/49	NA-108	B-90/50
Aminoglutethimide	G-281	D-21/54	SG-281	D-60/55	NG-281	D-90/56
6-Aminopenicillanic Acid	B-111	B-21/48	SB-111	B-60/49	NB-111	B-90/50
Aminophylline	C-125	C-21/51	SC-125	C-60/52	NC-125	C-90/53
Aminopyrine	A-109	B-21/48	SA-109	B-60/49	NA-109	B-90/50
Amiodarone	A-112	B-21/48	SA-112	B-60/49	NA-112	B-90/50
Amitriptyline	C-451	C-21/51	SC-451	C-60/52	NC-451	C-90/53
Amoxicillin	B-112	B-21/48	SB-112	B-60/49	NB-112	B-90/50
Amphotericin B	B-113	D-21/54	SB-113	D-60/55	NB-113	D-90/56
Ampicillin	B-114	B-21/48	SB-114	B-60/49	NB-114	B-90/50
Amrinone	C-107	A-21/45	SC-107	A-60/46	NC-107	A-90/47
Androstenediol (See Controlled Substances Page 8)	A-131	B-21/48	SA-131	B-60/49	NA-131	B-90/50
Androstenedione (See Controlled Substances Page 8)	A-121	B-21/48	SA-121	B-60/49	NA-121	B-90/50
5 α -Androsterone	A-141	C-21/51	SA-141	C-60/52	NA-141	C-90/53
5 β -Androsterone	A-101	D-21/54	SA-101	D-60/55	NA-101	D-90/56
Anisodamine	K-114	B-21/48	SK-114	B-60/49	NK-114	B-90/50
Anisodine	K-115	B-21/48	SK-115	B-60/49	NK-115	B-90/50
Antazoline	C-461	C-21/51	SC-461	C-60/52	NC-461	C-90/53
Arachidic Acid	F-111	A-21/45	SF-111	A-60/46	NF-111	A-90/47
Arachidonic Acid	F-161	A-21/45	SF-161	A-60/46	NF-161	A-90/47

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ise

ule/
ber

/50

/50

/47

/50

/50

/47

/50

/50

/56

/50

/53

/50

/50

/53

/50

/56

/50

/47

/50

/50

/53

/56

/50

/50

/53

/47

/47

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Page Schedule/ Number	Catalog Number	Price Page Schedule/ Number	Catalog Number	Price Page Schedule/ Number
Arecoline	K-116	C-21/51	SK-116	C-60/52	NK-116	C-90/53
D-Arginine	Q-141	B-21/48	SQ-141	B-60/49	NQ-141	B-90/50
L-Arginine	Q-151	C-21/51	SQ-151	C-60/52	NQ-151	C-90/53
Asparaginase	Z-120	H-21/60	SZ-120	H-60/61	NZ-120	H-90/62
D-Asparagine	Q-161	C-21/51	SQ-161	C-60/52	NQ-161	C-90/53
L-Asparagine	Q-171	C-21/51	SQ-171	C-60/52	NQ-171	C-90/53
D-Aspartic Acid	Q-181	C-21/51	SQ-181	C-60/52	NQ-181	C-90/53
L-Aspartic Acid	Q-191	C-21/51	SQ-191	C-60/52	NQ-191	C-90/53
Aspirin	X-121	C-21/51	SX-121	C-60/52	NX-121	C-90/53
Atenolol	C-221	B-21/48	SC-221	B-60/49	NC-221	B-90/50
Atropine	K-117	C-21/51	SK-117	C-60/52	NK-117	C-90/53
Atropine Methyl Bromide	K-118	C-21/51	SK-118	C-60/52	NK-118	C-90/53
8-Azaadenine	N-121	B-21/48	SN-121	B-60/49	NN-121	B-90/50
5-Azacytidine	N-131	A-21/45	SN-131	A-60/46	NN-131	A-90/47
5-Azacytosine	N-141	C-21/51	SN-141	C-60/52	NN-141	C-90/53
8-Azaguanine	N-151	C-21/51	SN-151	C-60/52	NN-151	C-90/53
8-Azahypoxanthine	N-161	C-21/51	SN-161	C-60/52	NN-161	C-90/53
7-Azaindole	N-171	B-21/48	SN-171	B-60/49	NN-171	B-90/50
6-Azathymine	N-181	B-21/48	SN-181	B-60/49	NN-181	B-90/50
5-Azauracil	N-191	B-21/48	SN-191	B-60/49	NN-191	B-90/50
6-Azauracil	N-201	C-21/51	SN-201	C-60/52	NN-201	C-90/53
6-Azauridine	N-211	B-21/48	SN-211	B-60/49	NN-211	B-90/50
Bacitracin	B-115	B-21/48	SB-115	B-60/49	NB-115	B-90/50
Baclofen	B-110	A-21/45	SB-110	A-60/46	NB-110	A-90/47
Beclomethasone	B-116	D-21/54	SB-116	D-60/55	NB-116	D-90/56
Benzylpenicillanic Acid	B-117	D-21/54	SB-117	D-60/55	NB-117	D-90/56
Berberine	K-119	C-21/51	SK-119	C-60/52	NK-119	C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
Betamethasone	G-191	L-21/63	SG-191	L-60/64	NG-191	L-90/65
Boldine	K-120	C-21/51	SK-120	C-60/52	NK-120	C-90/53
8-Bromoadenosine 3':5' Cyclic Monophosphate	N-221	M-21/66	SN-221	M-60-67	NN-221	M-90/68
Bromocriptine Mesylate	C-231	E-21/57	SC-231	E-60/58	NC-231	E-90/59
5-Bromo-2'-Deoxyuridine (BrdU)	N-231	B-21/48	SN-231	B-60/49	NN-231	B-90/50
Brucine	K-122	C-21/51	SK-122	C-60/52	NK-122	C-90/53
Busulfan (Myleran)	Z-130	B-21/48	SZ-130	B-60/49	NZ-130	B-90/50
Caffeine	C-191	C-21/51	SC-191	C-60/52	NC-191	C-90/53
Calycanthine	K-123	B-21/48	SK-123	B-60/49	NK-123	B-90/50
Camptothecin	C-116	E-21/57	SC-116	E-60/58	NC-116	E-90/59
Captopril	C-117	B-21/48	SC-117	B-60/49	NC-117	B-90/50
Carbamazepine	C-113	C-21/51	SC-113	C-60/52	NC-113	C-90/53
Carbinoxamine	C-471	C-21/51	SC-471	C-60/52	NC-471	C-90/53
DL-Carnitine	V-271	C-21/51	SV-271	C-60/52	NV-271	C-90/53
β-Carotene	V-215	C-21/51	SV-215	C-60/52	NV-215	C-90/53
Casodex (bicalutamide)	We can custom make any dose and any release time. (PLEASE INQUIRE)					
Cefadroxil	B-170	A-21/45	SB-170	A-60/46	NB-170	A-90/47
Cefamandole	B-171	A-21/45	SB-171	A-60/46	NB-171	A-90/47
Cefazolin	B-172	A-21/45	SB-172	A-60/46	NB-172	A-90/47
Cefmetazole	B-173	A-21/45	SB-173	A-60/46	NB-173	A-90/47
Cefoperazone	B-174	A-21/45	SB-174	A-60/46	NB-174	A-90/47
Cefotaxime	B-175	A-21/45	SB-175	A-60/46	NB-175	A-90/47
Cefoxitin	B-176	A-21/45	SB-176	A-60/46	NB-176	A-90/47
Cefsulodin	B-177	A-21/45	SB-177	A-60/46	NB-177	A-90/47
Ceftriaxone	B-178	A-21/45	SB-178	A-60/46	NB-178	A-90/47
Centrophenoquine (Meclofenoxate)	C-115	C-21/51	SC-115	C-60/52	NC-115	C-90/53
Cephalexin	B-118	B-21/48	SB-118	B-60/49	NB-118	B-90/50

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

use
Schedule/
Number
1/65
1/53
10/68
1/59
1/50
1/53
1/50
1/53
1/50
1/53
1/50
1/53
1/50
1/53
1/53
1/53
RE)
1/47
1/47
1/47
1/47
1/47
1/47
1/47
1/47
1/47
1/53
1/50

Product	21-Day Release		60-Day Release		90-Day Release				
	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number
Cephaloglycin	B-119		D-21/54	SB-119		D-60/55	NB-119		D-90/56
Cephalothin	B-120		B-21/48	SB-120		B-60/49	NB-120		B-90/50
Cephapirin	B-121		B-21/48	SB-121		B-60/49	NB-121		B-90/50
Chlorambucil	Z-140		A-21/45	SZ-140		A-60/46	NZ-140		A-90/47
Chloramphenicol	X-131		C-21/51	SX-131		C-60/52	NX-131		C-90/53
Chloramphenicol Base	B-123		C-21/51	SB-123		C-60/52	NB-123		C-90/53
Chlorcyclizine	C-145		B-21/48	SC-145		B-60/49	NC-145		B-90/50
Chlormadinone Acetate	P-221		A-21/45	SP-221		A-60/46	NP-221		A-90/47
Chloroquine	I-112		C-21/51	SI-112		C-60/52	NI-112		C-90/53
Chlorothiazide	C-155		C-21/51	SC-155		C-60/52	NC-155		C-90/53
Chlorotrianisene	E-201		C-21/51	SE-201		C-60/52	NE-201		C-90/53
Chlorpheniramine	B-124		C-21/51	SB-124		C-60/52	NB-124		C-90/53
Chlorpromazine	C-241		C-21/51	SC-241		C-60/52	NC-241		C-90/53
Chlorthalidone	C-175		B-21/48	SC-175		B-60/49	NC-175		B-90/50
Chlorzoxazone	C-185		C-21/51	SC-185		C-60/52	NC-185		C-90/53
Cimetidine	C-372		B-21/48	SC-372		B-60/49	NC-372		B-90/50
Cinchonidine	B-154		C-21/51	SB-154		C-60/52	NB-154		C-90/53
Cinnarizine	B-125		C-21/51	SB-125		C-60/52	NB-125		C-90/53
Clemastine	C-120		B-21/48	SC-120		B-60/49	NC-120		B-90/50
Clemizole	C-119		C-21/51	SC-119		C-60/52	NC-119		C-90/53
Clenbuterol	C-118		H-21/60	SC-118		H-60/61	NC-118		H-90/62
Clofoctol	C-104		C-21/51	SC-104		C-60/52	NC-104		C-90/53
Clomiphene Citrate	P-211		B-21/48	SP-211		B-60/49	NP-211		B-90/50
Clomipramine	C-103		C-21/51	SC-103		C-60/52	NC-103		C-90/53
Clonidine	C-251		B-21/48	SC-251		B-60/49	NC-251		B-90/50
Clopamide	C-105		B-21/48	SC-105		B-60/49	NC-105		B-90/50
Clotrimazole	B-126		B-21/48	SB-126		B-60/49	NB-126		B-90/50

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Number Page	Catalog Number	Price Schedule/ Number Page	Catalog Number	Price Schedule/ Number Page
Cloxacillin	B-127	B-21/48	SB-127	B-60/49	NB-127	B-90/50
Colchicine	B-155	A-21/45	SB-155	A-60/46	NB-155	A-90/47
Cortexolone	G-301	B-21/48	SG-301	B-60/49	NG-301	B-90/50
Cortexolone Acetate	G-311	B-21/48	SG-311	B-60/49	NG-311	B-90/50
Corticosterone	G-111	A-21/45	SG-111	A-60/46	NG-111	A-90/47
Corticosterone 21-Acetate	G-171	A-21/45	SG-171	A-60/46	NG-171	A-90/47
Cortisone	G-121	B-21/48	SG-121	B-60/49	NG-121	B-90/50
Cortisone Acetate	G-181	B-21/48	SG-181	B-60/49	NG-181	B-90/50
(-)Cotinine	K-124	A-21/45	SK-124	A-60/46	NK-124	A-90/47
Coumarin (1, 2 Benzopyrone)	C-112	C-21/51	SC-112	C-60/52	NC-112	C-90/53
Cromolyn	C-195	B-21/48	SC-195	B-60/49	NC-195	B-90/50
Crotaline	K-125	D-21/54	SK-125	D-60/55	NK-125	D-90/56
Cyclizine	C-108	A-21/45	SC-108	A-60/46	NC-108	A-90/47
Cyclophosphamide (Cytosan)	Z-150	A-21/45	SZ-150	A-60/46	NZ-150	A-90/47
D-Cycloserine	B-128	B-21/48	SB-128	B-60/49	NB-128	B-90/50
Cymar	C-382	D-21/54	SC-382	D-60/55	NC-382	D-90/56
Cyproheptadine	C-481	A-21/45	SC-481	A-60/46	NC-481	A-90/47
Cyproterone Acetate	C-114	E-21/57	SC-114	E-60/58	NC-114	E-90/59
D-Cysteine	Q-201	C-21/51	SQ-201	C-60/52	NQ-201	C-90/53
L-Cysteine	Q-211	C-21/51	SQ-211	C-60/52	NQ-211	C-90/53
D-Cystine	Q-221	D-21/54	SQ-221	D-60/55	NQ-221	D-90/56
L-Cystine	Q-231	C-21/51	SQ-231	C-60/52	NQ-231	C-90/53
Cytarabine (Cytosine Arabinoside)	Z-160	D-21/54	SZ-160	D-60/55	NZ-160	D-90/56
Cytisine	K-126	E-21/57	SK-126	E-60/58	NK-126	E-90/59
Cytosine	N-241	C-21/51	SN-241	C-60/52	NN-241	C-90/53
Danazol	P-251	D-21/54	SP-251	D-60/55	NP-251	D-90/56
Daunorubicine	Z-170	H-21/60	SZ-170	H-60/61	NZ-170	H-90/62

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Dose/ Schedule/ Number	Product	21-Day Release			60-Day Release			90-Day Release		
		Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number
1/50	3-Deazauracil	N-251		B-21/48	SN-251		B-60/49	NN-251		B-90/50
1/47	3-Deazauridine	N-261		A-21/45	SN-261		A-60/46	NN-261		A-90/47
1/50	Decamethonium Bromide	D-112		B-21/48	SD-112		B-60/49	ND-112		B-90/50
1/50	Defroxamine Mesylate	D-113		D-21/54	SD-113		D-60/55	ND-113		D-90/56
1/47	7-Dehydrocholesterol	V-281		C-21/51	SV-281		C-60/52	NV-281		C-90/53
1/47	Dehydrocholic Acid	D-114		C-21/51	SD-114		C-60/52	ND-114		C-90/53
1/50	Dehydroepiandrosterone (DHEA)	A-111		B-21/48	SA-111		B-60/49	NA-111		B-90/50
1/50	Dehydroepiandrosterone Acetate	D-115		B-21/48	SD-115		B-60/49	ND-115		B-90/50
1/47	Dehydroepiandrosterone Sulfate	D-116		D-21/54	SD-116		D-60/55	ND-116		D-90/56
1/53	16-Dehydropregnenolone	P-271		B-21/48	SP-271		B-60/49	NP-271		B-90/50
1/50	16-Dehydropregnenolone Acetate	P-281		B-21/48	SP-281		B-60/49	NP-281		B-90/50
1/56	16-Dehydroprogesterone	P-261		B-21/48	SP-261		B-60/49	NP-261		B-90/50
1/47	Demeclocycline	D-121		B-21/48	SD-121		B-60/49	ND-121		B-90/50
1/47	Deoxycholic Acid	D-110		C-21/51	SD-110		C-60/52	ND-110		C-90/53
1/50	Deoxycorticosterone (DOC)	M-111		B-21/48	SM-111		B-60/49	NM-111		B-90/50
1/56	Deoxycorticosterone Acetate (DOCA)	M-121		A-21/45	SM-121		A-60/46	NM-121		A-90/47
1/47	Desipramine	C-491		B-21/48	SC-491		B-60/49	NC-491		B-90/50
1/59	Desoximetasone	D-107		D-21/54	SD-107		D-60/55	ND-107		D-90/56
1/53	Dexamethasone	G-131		D-21/54	SG-131		D-60/55	NG-131		D-90/56
1/53	Dexamethasone 21-Acetate	G-201		D-21/54	SG-201		D-60/55	NG-201		D-90/56
1/56	Dexamethasone 21-Phosphate	D-108		D-21/54	SD-108		D-60/55	ND-108		D-90/56
1/53	Diaveridine	B-129		D-21/54	SB-129		D-60/55	NB-129		D-90/56
1/56	N ⁶ -O ² -Dibutyryl adenosine- 3':5'-Cyclic Monophosphate	N-271		L-21/63	SN-271		L-60/64	NN-271		L-90/65
1/59	Diclofenac	X-135		B-21/48	SX-135		B-60/49	NX-135		B-90/50
1/53	Dicloxacillin	B-156		B-21/48	SB-156		B-60/49	NB-156		B-90/50
1/56	Dienestrol	E-181		C-21/51	SE-181		C-60/52	NE-181		C-90/53
1/62	Dienestrol Diacetate	E-191		C-21/51	SE-191		C-60/52	NE-191		C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
Diethylstilbestrol (DES)	E-151	B-21/48	SE-151	B-60/49	NE-151	B-90/50
Digitoxin	C-196	B-21/48	SC-196	B-60/49	NC-196	B-90/50
Digoxin	C-271	B-21/48	SC-271	B-60/49	NC-271	B-90/50
Dihydroergotamine	K-127	E-21/57	SK-127	E-60/58	NK-127	E-90/59
5 α -Dihydrotestosterone <small>(See Controlled Substances Page 8)</small>	Special Dosing For Immuno-Deficient Mice. See pages 78-80					
5 α -Dihydrotestosterone <small>(See Controlled Substances Page 8)</small>	A-161	A-21/45	SA-161	A-60/46	NA-161	A-90/47
5 β -Dihydrotestosterone	D-106	D-21/54	SD-106	D-60/55	ND-106	D-90/56
3,5-Diiodo-DL-Thyronine	T-231	B-21/48	ST-231	B-60/49	NT-231	B-90/50
3,5-Diiodo-L-Thyronine	T-241	B-21/48	ST-241	B-60/49	NT-241	B-90/50
Dimenhydrinate	C-205	C-21/51	SC-205	C-60/52	NC-205	C-90/53
9,10-Dimethyl-1,2-Benzanthracene	D-117	A-21/45	SD-117	A-60/46	ND-117	A-90/47
Dipyridamole	D-101	B-21/48	SD-101	B-60/49	ND-101	B-90/50
Dipyron	D-102	C-21/51	SD-102	C-60/52	ND-102	C-90/53
Disopyramide	C-500	B-21/48	SC-500	B-60/49	NC-500	B-90/50
Disulfiram	D-109	C-21/51	SD-109	C-60/52	ND-109	C-90/53
D-Dopa	C-501	B-21/48	SC-501	B-60/49	NC-501	B-90/50
DL-Dopa	C-502	C-21/51	SC-502	C-60/52	NC-502	C-90/53
L-Dopa	C-503	C-21/51	SC-503	C-60/52	NC-503	C-90/53
Dopamine	C-151	C-21/51	SC-151	C-60/52	NC-151	C-90/53
Doxepin	C-325	B-21/48	SC-325	B-60/49	NC-325	B-90/50
Doxycycline	B-168	A-21/45	SB-168	A-60/46	NB-168	A-90/47
Doxylamine	C-504	C-21/51	SC-504	C-60/52	NC-504	C-90/53
Drofenine	D-103	C-21/51	SD-103	C-60/52	ND-103	C-90/53
Droperidol	D-104	A-21/45	SD-104	A-60/46	ND-104	A-90/47
Dropropizine	D-105	C-21/51	SD-105	C-60/52	ND-105	C-90/53
β -Ecdysone	E-103	H-21/60	SE-103	H-60/61	NE-103	H-90/62
Econazole	B-181	B-21/48	SB-181	B-60/49	NB-181	B-90/50

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release				
	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number			
Edrophonium	C-122		A-21/45	SC-122		A-60/46	NC-122		A-90/47
Emetine	K-128		B-21/48	SK-128		B-60/49	NK-128		B-90/50
Enalapril	C-999		A-21/45	SC-999		A-60/46	NC-999		A-90/47
Enoxacin	B-182		A-21/45	SB-182		A-60/46	NB-182		A-90/47
Ephedrine	C-201		C-21/51	SC-201		C-60/52	NC-201		C-90/53
Epinephrine	C-131		C-21/51	SC-131		C-60/52	NC-131		C-90/53
Epinine (Deoxyepinephrine)	C-141		D-21/54	SC-141		D-60/55	NC-141		D-90/56
d-Equilenin	E-231		D-21/54	SE-231		D-60/55	NE-231		D-90/56
Equilin	E-211		D-21/54	SE-211		D-60/55	NE-211		D-90/56
Equilin-Methyl Ether	E-221		D-21/54	SE-221		D-60/55	NE-221		D-90/56
Ergosterol	V-291		C-21/51	SV-291		C-60/52	NV-291		C-90/53
Erythromycin	B-130		B-21/48	SB-130		B-60/49	NB-130		B-90/50
Esculetin	E-101		B-21/48	SE-101		B-60/49	NE-101		B-90/50
Esculin	E-102		C-21/51	SE-102		C-60/52	NE-102		C-90/53
Eserine (Physostigmine)	K-129		B-21/48	SK-129		B-60/49	NK-129		B-90/50
17 α -Estradiol	E-131		D-21/54	SE-131		D-60/55	NE-131		D-90/56
17 β -Estradiol	Special Dosing For Immuno-Deficient Mice. See pages 73-77.								
17 β -Estradiol	E-121		B-21/48	SE-121		B-60/49	NE-121		B-90/50
β -Estradiol 17-Acetate	E-271		B-21/48	SE-271		B-60/49	NE-271		B-90/50
β -Estradiol 3-Benzoate	E-281		B-21/48	SE-281		B-60/49	NE-281		B-90/50
β -Estradiol 17-Cypionate	E-291		B-21/48	SE-291		B-60/49	NE-291		B-90/50
β -Estradiol Diacetate	E-301		B-21/48	SE-301		B-60/49	NE-301		B-90/50
β -Estradiol Dipropionate	E-311		B-21/48	SE-311		B-60/49	NE-311		B-90/50
β -Estradiol 3-Methyl-Ether	E-321		B-21/48	SE-321		B-60/49	NE-321		B-90/50
17 β -Estradiol+Progesterone (See Page 89)	---		---	---		---	---		---
β -Estradiol Propionate	E-371		D-21/54	SE-371		D-60/55	NE-371		D-90/56
β -Estradiol 17-Valerate	E-203		B-21/48	SE-203		B-60/49	NE-203		B-90/50

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Page Schedule/Number	Catalog Number	Price Page Schedule/Number	Catalog Number	Price Page Schedule/Number
Estriol	E-141	B-21/48	SE-141	B-60/49	NE-141	B-90/50
Estriol 3-Benzyl Ether	E-391	D-21/54	SE-391	D-60/55	NE-391	D-90/56
Estriol Triacetate	E-401	A-21/45	SE-401	A-60/46	NE-401	A-90/47
Estrone	E-111	B-21/48	SE-111	B-60/49	NE-111	B-90/50
Estrone Acetate	E-411	B-21/48	SE-411	B-60/49	NE-411	B-90/50
Estrone Hemisuccinate	E-421	D-21/54	SE-421	D-60/55	NE-421	D-90/56
Estrone 3-Methyl Ether	E-261	B-21/48	SE-261	B-60/49	NE-261	B-90/50
Estrone 3-Sulfate	E-431	A-21/45	SE-431	A-60/46	NE-431	A-90/47
Ethacrynic Acid	D-131	C-21/51	SD-131	C-60/52	ND-131	C-90/53
Ethambutol	B-131	C-21/51	SB-131	C-60/52	NB-131	C-90/53
Ethisterone	P-191	B-21/48	SP-191	B-60/49	NP-191	B-90/50
17 α -Ethinylestradiol	E-241	B-21/48	SE-241	B-60/49	NE-241	B-90/50
Eucatropine	K-130	D-21/54	SK-130	D-60/55	NK-130	D-90/56
Fludrocortisone	M-131	B-21/48	SM-131	B-60/49	NM-131	B-90/50
Fludrocortisone Acetate	M-171	B-21/48	SM-171	B-60/49	NM-171	B-90/50
Flufenamic Acid	X-115	C-21/51	SX-115	C-60/52	NX-115	C-90/53
Flumequine	F-103	C-21/51	SF-103	C-60/52	NF-103	C-90/53
Flumethasone	F-104	L-21/63	SF-104	L-60/64	NF-104	L-90/65
Flunarizine	C-206	C-21/51	SC-206	C-60/52	NC-206	C-90/53
Flunisolide	F-102	D-21/54	SF-102	D-60/55	NF-102	D-90/56
Fluocinolone	F-107	D-21/54	SF-107	D-60/55	NF-107	D-90/56
5-Fluorouracil	Z-190	B-21/48	SZ-190	B-60/49	NZ-190	B-90/50
Fluoxymesterone (See Controlled Substances Page 8)	A-241	A-21/45	SA-241	A-60/46	NA-241	A-90/47
Fluphenazine	F-105	C-21/51	SF-105	C-60/52	NF-105	C-90/53
Flurbiprofen	X-125	B-21/48	SX-125	B-60/49	NX-125	B-90/50
Flutamide	A-152	B-21/48	SA-152	B-60/49	NA-152	B-90/50
Folic Acid	V-301	C-21/51	SV-301	C-60/52	NV-301	C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ase
dule/
nber
1/50
1/56
1/47
1/50
1/50
1/56
1/50
1/47
1/53
1/53
1/50
1/50
1/56
1/50
1/50
1/53
1/53
1/53
1/65
1/53
1/56
1/56
1/50
1/47
1/53
1/50
1/50
1/53

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
Folinic Acid	V-311	D-21/54	SV-311	D-60/55	NV-311	D-90/56
Forskolin	F-106	H-21/60	SF-106	H-60/61	NF-106	H-90/62
Furosemide	D-141	C-21/51	SD-141	C-60/52	ND-141	C-90/53
Geneticin	B-132	D-21/54	SB-132	D-60/55	NB-132	D-90/56
Gentamicin Sulfate	B-133	B-21/48	SB-133	B-60/49	NB-133	B-90/50
Gitoxin	G-104	B-21/48	SG-104	B-60/49	NG-104	B-90/50
Glafenine	G-105	B-21/48	SG-105	B-60/49	NG-105	B-90/50
(+)Glaucine	K-131	D-21/54	SK-131	D-60/55	NK-131	D-90/56
Gliadin	G-106	C-21/51	SG-106	C-60/52	NG-106	C-90/53
Globin	G-107	A-21/45	SG-107	A-60/46	NG-107	A-90/47
D-Glutamic Acid	Q-241	D-21/54	SQ-241	D-60/55	NQ-241	D-90/56
L-Glutamic Acid	Q-251	C-21/51	SQ-251	C-60/52	NQ-251	C-90/53
D-Glutamine	Q-261	D-21/54	SQ-261	D-60/55	NQ-261	D-90/56
L-Glutamine	Q-271	C-21/51	SQ-271	C-60/52	NQ-271	C-90/53
Glutathione (Oxidized)	G-103	B-21/48	SG-103	B-60/49	NG-103	B-90/50
Glutathione (Reduced)	G-102	C-21/51	SG-102	C-60/52	NG-102	C-90/53
Glyburide	G-101	C-21/51	SG-101	C-60/52	NG-101	C-90/53
Glycine	Q-281	C-21/51	SQ-281	C-60/52	NQ-281	C-90/53
Gossypol Acetate	A-291	D-21/54	SA-291	D-60/55	NA-291	D-90/56
Gramicidin	B-134	A-21/45	SB-134	A-60/46	NB-134	A-90/47
Gramine	G-109	C-21/51	SG-109	C-60/52	NG-109	C-90/53
Guaiazulene	G-110	B-21/48	SG-110	B-60/49	NG-110	B-90/50
Guaifenesin	G-112	C-21/51	SG-112	C-60/52	NG-112	C-90/53
Guanabenz	G-113	N-21/69	SG-113	N-60/70	NG-113	N-90/71
Guanethidine	G-114	C-21/51	SG-114	C-60/52	NG-114	C-90/53
Guanidine	G-115	C-21/51	SG-115	C-60/52	NG-115	C-90/53
Guanosine	N-281	C-21/51	SN-281	C-60/52	NN-281	C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Number	Catalog Number	Price Schedule/ Number	Catalog Number	Price Schedule/ Number
Haloperidol	C-505	B-21/48	SC-505	B-60/49	NC-505	B-90/50
Harmaline	C-506	B-21/48	SC-506	B-60/49	NC-506	B-90/50
Harmalol	H-104	A-21/45	SH-104	A-60/46	NH-104	A-90/47
Harmane	H-105	A-21/45	SH-105	A-60/46	NH-105	A-90/47
Harmine	C-507	B-21/48	SC-507	B-60/49	NC-507	B-90/50
Harmol	H-106	A-21/45	SH-106	A-60/46	NH-106	A-90/47
Hecogenin	H-107	B-21/48	SH-107	B-60/49	NH-107	B-90/50
Hecogenin Acetate	H-108	B-21/48	SH-108	B-60/49	NH-108	B-90/50
Hexestrol (Dihydro-DES)	E-161	C-21/51	SE-161	C-60/52	NE-161	C-90/53
Histamine	C-281	C-21/51	SC-281	C-60/52	NC-281	C-90/53
D-Histidine	Q-291	D-21/54	SQ-291	D-60/55	NQ-291	D-90/56
L-Histidine	Q-301	C-21/51	SQ-301	C-60/52	NQ-301	C-90/53
Homatropine	K-132	C-21/51	SK-132	C-60/52	NK-132	C-90/53
Hydralazine	C-291	C-21/51	SC-291	C-60/52	NC-291	C-90/53
Hydrochlorothiazide	D-151	C-21/51	SD-151	C-60/52	ND-151	C-90/53
Hydrocortisone	G-141	B-21/48	SG-141	B-60/49	NG-141	B-90/50
Hydrocortisone 21-Acetate	G-211	B-21/48	SG-211	B-60/49	NG-211	B-90/50
Hydrocortisone 21-Hemisuccinate	G-221	B-21/48	SG-221	B-60/49	NG-221	B-90/50
Hydrocortisone 21-Phosphate	G-231	B-21/48	SG-231	B-60/49	NG-231	B-90/50
5-Hydroxydopamine	H-101	D-21/54	SH-101	D-60/55	NH-101	D-90/56
6-Hydroxydopamine	H-102	D-21/54	SH-102	D-60/55	NH-102	D-90/56
17 α -Hydroxypregnenolone	P-121	C-21/51	SP-121	C-60/52	NP-121	C-90/53
11 α -Hydroxyprogesterone	P-151	C-21/51	SP-151	C-60/52	NP-151	C-90/53
17 α -Hydroxyprogesterone	P-141	C-21/51	SP-141	C-60/52	NP-141	C-90/53
5-Hydroxy-L-Tryptophan	H-103	B-21/48	SH-103	B-60/49	NH-103	B-90/50
Hydroxyurea	N-291	C-21/51	SN-291	C-60/52	NN-291	C-90/53
L-Hyoscyamine	K-134	C-21/51	SK-134	C-60/52	NK-134	C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Use
date/
number

1/50
1/50
1/47
1/47
1/50
1/47
1/50
1/50
1/53
1/53
1/56
1/53
1/53
1/53
1/50
1/50
1/50
1/50
1/56
1/56
1/53
1/53
1/53
1/50
1/53
1/53

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Page Schedule/Number	Catalog Number	Price Page Schedule/Number	Catalog Number	Price Page Schedule/Number
Ibuprofen	X-181	B-21/48	SX-181	B-60/49	NX-181	B-90/50
Imipramine	C-508	C-21/51	SC-508	C-60/52	NC-508	C-90/53
Indomethacin	X-151	B-21/48	SX-151	B-60/49	NX-151	B-90/50
Indoprofen	I-101	B-21/48	SI-101	B-60/49	NI-101	B-90/50
Indoxyl Acetate	I-102	B-21/48	SI-102	B-60/49	NI-102	B-90/50
Inosine	I-103	C-21/51	SI-103	C-60/52	NI-103	C-90/53
Inositol	V-321	C-21/51	SV-321	C-60/52	NV-321	C-90/53
5-Iodo-2'-Deoxyuridine	N-302	B-21/48	SN-302	B-60/49	NN-302	B-90/50
D-Isoleucine	Q-311	D-21/54	SQ-311	D-60/55	NQ-311	D-90/56
L-Isoleucine	Q-321	C-21/51	SQ-321	C-60/52	NQ-321	C-90/53
Isoproterenol	C-171	C-21/51	SC-171	C-60/52	NC-171	C-90/53
Isoxyrin	I-104	B-21/48	SI-104	B-60/49	NI-104	B-90/50
Isoxicam	I-105	B-21/48	SI-105	B-60/49	NI-105	B-90/50
Isoxsuprine	I-106	B-21/48	SI-106	B-60/49	NI-106	B-90/50
Kainic Acid	K-101	D-21/54	SK-101	D-60/55	NK-101	D-90/56
Kanamycin	Z-200	B-21/48	SZ-200	B-60/49	NZ-200	B-90/50
Ketamine	K-102	B-21/48	SK-102	B-60/49	NK-102	B-90/50
Ketoprofen	K-103	C-21/51	SK-103	C-60/52	NK-103	C-90/53
Khellin	C-215	C-21/51	SC-215	C-60/52	NC-215	C-90/53
Labetalol	C-301	C-21/51	SC-301	C-60/52	NC-301	C-90/53
Lanatoside C	C-225	D-21/54	SC-225	D-60/55	NC-225	D-90/56
Lauric Acid	F-121	C-21/51	SF-121	C-60/52	NF-121	C-90/53
D-Leucine	Q-331	D-21/54	SQ-331	D-60/55	NQ-331	D-90/56
L-Leucine	Q-341	C-21/51	SQ-341	C-60/52	NQ-341	C-90/53
Levamisole	I-113	B-21/48	SI-113	B-60/49	NI-113	B-90/50
Lidocaine	C-311	C-21/51	SC-311	C-60/52	NC-311	C-90/53
Lignoceric Acid	F-211	B-21/48	SF-211	B-60/49	NF-211	B-90/50

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release			60-Day Release			90-Day Release		
	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number
Linoleic Acid	F-171		B-21/48	SF-171		B-60/49	NF-171		B-90/50
Linolenic Acid	F-181		B-21/48	SF-181		B-60/49	NF-181		B-90/50
DL- α Lipoic Acid	V-331		B-21/48	SV-331		B-60/49	NV-331		B-90/50
L-Lobeline	L-101		D-21/54	SL-101		D-60/55	NL-101		D-90/56
Lomustine	L-102		B-21/48	SL-102		B-60/49	NL-102		B-90/50
D-Lysine	Q-351		D-21/54	SQ-351		D-60/55	NQ-351		D-90/56
L-Lysine	Q-361		C-21/51	SQ-361		C-60/52	NQ-361		C-90/53
D-Mannitol	D-161		C-21/51	SD-161		C-60/52	ND-161		C-90/53
Mechlorethamine	Z-210		A-21/45	SZ-210		A-60/46	NZ-210		A-90/47
Meclizine	I-114		C-21/51	SI-114		C-60/52	NI-114		C-90/53
Medroxyprogesterone Acetate (MPA)	P-161		A-21/45	SP-161		A-60/46	NP-161		A-90/47
Mefenamic Acid	I-115		C-21/51	SI-115		C-60/52	NI-115		C-90/53
Megestrol Acetate	P-231		B-21/48	SP-231		B-60/49	NP-231		B-90/50
Melatonin	M-101		B-21/48	SM-101		B-60/49	NM-101		B-90/50
Melphalan	B-135		D-21/54	SB-135		D-60/55	NB-135		D-90/56
6-Mercaptopurine	Z-220		B-21/48	SZ-220		B-60/49	NZ-220		B-90/51
Mesterolone (See Controlled Substances Page 8)	M-103		D-21/54	SM-103		D-60/55	NM-103		D-90/56
Mesterone (See Controlled Substances Page 8)	M-102		C-21/51	SM-102		C-60/52	NM-102		C-90/53
Mestranol	E-251		B-21/48	SE-251		B-60/49	NE-251		B-90/50
Methandriol (See Controlled Substances Page 8)	A-231		C-21/51	SA-231		C-60/52	NA-231		C-90/53
Methandriol Dipropionate (See Controlled Substances Page 8)	A-261		B-21/48	SA-261		B-60/49	NA-261		B-90/50
Methazolamide	M-104		B-21/48	SM-104		B-60/49	NM-104		B-90/50
Methimazole	T-151		C-21/51	ST-151		C-60/52	NT-151		C-90/53
D-Methionine	Q-371		C-21/51	SQ-371		C-60/52	NQ-371		C-90/53
L-Methionine	Q-381		C-21/51	SQ-381		C-60/52	NQ-381		C-90/53
Methotrexate	Z-230		E-21/57	SZ-230		E-60/58	NZ-230		E-90/59
Methoxamine	C-235		D-21/54	SC-235		D-60/55	NC-235		D-90/56

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ase
chedule/
number

/50
/50
/50
/56
/50
/56
/53
/53
/47
/53
/47
/53
/50
/50
/56
/51
/56
/53
/50
/53
/50
/53
/53
/59
/56

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/Number	Catalog Number	Price Schedule/Number	Catalog Number	Price Schedule/Number
Methyl L-Dopa	C-509	B-21/48	SC-509	B-60/49	NC-509	B-90/50
Methyl Prednisolone	G-241	D-21/54	SG-241	D-60/55	NG-241	D-90/56
Methyl Testosterone (See Mesterolone) (See Controlled Substances Page 8)	M-103	D-21/54	SM-103	D-60/55	NM-103	D-90/56
Methyl Thiouracil	T-161	C-21/51	ST-161	C-60/52	NT-161	C-90/53
1-Methyl-D-Tryptophan	We can custom make any dose and any release time. (PLEASE INQUIRE)					
1-Methyl-DL-Tryptophan	We can custom make any dose and any release time. (PLEASE INQUIRE)					
1-Methyl-L-Tryptophan	We can custom make any dose and any release time. (PLEASE INQUIRE)					
Metoprolol	C-510	C-21/51	SC-510	C-60/52	NC-510	C-90/53
Metronidazole	B-179	B-21/48	SB-179	B-60/49	NB-179	B-90/50
Metyrapone	M-141	C-21/51	SM-141	C-60/52	NM-141	C-90/53
Mifepristone (RU-486)	We can custom make any dose and any release time. (PLEASE INQUIRE)					
Minocycline	B-169	D-21/54	SB-169	D-60/55	NB-169	D-90/56
Minoxidil	C-255	E-21/57	SC-255	E-60/58	NC-255	E-90/59
Mithramycin A	Z-240	H-21/60	SZ-240	H-60/61	NZ-240	H-90/62
Mitomycin C	Z-250	H-21/60	SZ-250	H-60/61	NZ-250	H-90/62
Monensin	B-157	B-21/48	SB-157	B-60/49	NB-157	B-90/50
Moxalactam	B-180	A-21/45	SB-180	A-60/46	NB-180	A-90/47
Myristic Acid	F-131	C-21/51	SF-131	C-60/52	NF-131	C-90/53
Nadolol	N-102	D-21/54	SN-102	D-60/55	NN-102	D-90/56
Nafoxidine	E-441	E-21/57	SE-441	E-60/58	NE-441	E-90/59
Naloxone	C-511	D-21/45	SC-511	D-60/46	NC-511	D-90/47
Naltrexone	We can custom make any dose and any release time. (PLEASE INQUIRE)					
Nandrolone (19-Nortestosterone) (See Controlled Substances Page 8)	A-251	B-21/48	SA-251	B-60/49	NA-251	B-90/50
Naphazoline	C-513	C-21/51	SC-513	C-60/52	NC-513	C-90/53
Naproxen	X-221	C-21/51	SX-221	C-60/52	NX-221	C-90/53
Neomycin Sulfate	B-136	C-21/51	SB-136	C-60/52	NB-136	C-90/53
Neostigmine	C-123	B-21/48	SC-123	B-60/49	NC-123	B-90/50

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release			60-Day Release			90-Day Release		
	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number
Nervonic Acid	F-221		A-21/45	SF-221		A-60/46	NF-221		A-90/47
Niacin	V-341		C-21/51	SV-341		C-60/52	NV-341		C-90/53
Niacinamide	V-351		C-21/51	SV-351		C-60/52	NV-351		C-90/53
Nicotine	K-135		B-21/48	SK-135		B-60/49	NK-135		B-90/50
Nicotinic Acid	K-136		B-21/48	SK-136		B-60/49	NK-136		B-90/50
Nifedipine	C-321		B-21/48	SC-321		B-60/49	NC-321		B-90/50
Nifenazone	C-124		B-21/48	SC-124		B-60/49	NC-124		B-90/50
Niflumic Acid	X-116		B-21/48	SX-116		B-60/49	NX-116		B-90/50
Nimesulide	N-104		C-21/51	SN-104		C-60/52	NN-104		C-90/53
Nitro-L-Arginine	N-101		C-21/51	SN-101		C-60/52	NN-101		C-90/53
Norepinephrine	C-121		B-21/48	SC-121		B-60/49	NC-121		B-90/50
Norethindrone	P-171		B-21/48	SP-171		B-60/49	NP-171		B-90/50
Norethindrone Acetate	P-181		A-21/45	SP-181		A-60/46	NP-181		A-90/47
Norethynodrel	P-201		B-21/48	SP-201		B-60/49	NP-201		B-90/50
Norgestrel	P-241		D-21/54	SP-241		D-60/55	NP-241		D-90/56
19-Nortestosterone (Nandrolone) <small>(See Controlled Substances Page 8)</small>	A-251		B-21/48	SA-251		B-60/49	NA-251		B-90/50
19-Nortestosterone 17-Decanoate <small>(See Controlled Substances Page 8)</small>	A-252		A-21/45	SA-252		A-60/46	NA-252		A-90/47
19-Nortestosterone 17-Propionate <small>(See Controlled Substances Page 8)</small>	A-321		B-21/48	SA-321		B-60/49	NA-321		B-90/50
Nortriptyline	C-402		C-21/51	SC-402		C-60/52	NC-402		C-90/53
Noscapine	C-514		C-21/51	SC-514		C-60/52	NC-514		C-90/53
Novobiocin	B-137		B-21/48	SB-137		B-60/49	NB-137		B-90/50
Nystatin (Mycostatin)	B-138		B-21/48	SB-138		B-60/49	NB-138		B-90/50
Oleic Acid	F-191		B-21/48	SF-191		B-60/49	NF-191		B-90/50
Ouabain	C-331		B-21/48	SC-331		B-60/49	NC-331		B-90/50
Oxytetracycline	B-139		C-21/51	SB-139		C-60/52	NB-139		C-90/53
Palmitic Acid	F-141		C-21/51	SF-141		C-60/52	NF-141		C-90/53
Palmitoleic Acid	F-201		A-21/45	SF-201		A-60/46	NF-201		A-90/47

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ase
dule/
nber

1/47
1/53
1/53
1/50
1/50
1/50
1/50
1/50
1/50
1/53
1/53
1/50
1/50
1/47
1/50
1/56
1/50
1/47
1/50
1/53
1/53
1/50
1/50
1/50
1/50
1/53
1/53
1/50
1/50
1/53
1/53
1/47

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Page Schedule/Number	Catalog Number	Price Page Schedule/Number	Catalog Number	Price Page Schedule/Number
Papaverine	C-341	B-21/48	SC-341	B-60/49	NC-341	B-90/50
D-Penicillamine	B-140	B-21/48	SB-140	B-60/49	NB-140	B-90/50
DL-Penicillamine	B-141	B-21/48	SB-141	B-60/49	NB-141	B-90/50
L-Penicillamine	B-142	B-21/48	SB-142	B-60/49	NB-142	B-90/50
Penicillin-G (Benzylpenicillin)	B-143	C-21/51	SB-143	C-60/52	NB-143	C-90/53
Phenelzine	C-515	C-21/51	SC-515	C-60/52	NC-515	C-90/53
Pheniramine	C-516	B-21/48	SC-516	B-60/49	NC-516	B-90/50
D-Phenylalanine	Q-391	C-21/51	SQ-391	C-60/52	NQ-391	C-90/53
L-Phenylalanine	Q-401	C-21/51	SQ-401	C-60/52	NQ-401	C-90/53
Phenylbutazone	I-116	C-21/51	SI-116	C-60/52	NI-116	C-90/53
L-Phenylephrine	C-517	B-21/48	SC-517	B-60/49	NC-517	B-90/50
Physostigmine (See Eserine)	K-129	B-21/48	SK-129	B-60/49	NK-129	B-90/50
Pimozide	P-116	A-21/45	SP-116	A-60/46	NP-116	A-90/47
Pindolol	C-351	B-21/48	SC-351	B-60/49	NC-351	B-90/50
Piroxicam	X-231	B-21/48	SX-231	B-60/49	NX-231	B-90/50
Placebo Control Pellets	C-111	See page 17	SC-111	See page 18	NC-111	See page 19
cis-Platinum	Z-260	D-21/54	SZ-260	D-60/55	NZ-260	D-90/56
trans-Platinum	Z-266	D-21/54	SZ-266	D-60/55	NZ-266	D-90/56
Polymyxin B Sulfate	B-144	C-21/51	SB-144	C-60/52	NB-144	C-90/53
Potassium Iodide	T-167	C-21/51	ST-167	C-60/52	NT-167	C-90/53
Prazosin	C-265	E-21/57	SC-261	E-60/58	NC-261	E-90/59
Prednisolone	G-151	B-21/48	SG-151	B-60/49	NG-151	B-90/50
Prednisone	G-161	B-21/48	SG-161	B-60/49	NG-161	B-90/50
Pregnenolone	P-111	C-21/51	SP-111	C-60/52	NP-111	C-90/53
Probenecid	I-117	C-21/51	SI-117	C-60/52	NI-117	C-90/53
Probucol	P-113	B-21/48	SP-113	B-60/49	NP-113	B-90/50
Procainamide	C-519	C-21/51	SC-519	C-60/52	NC-519	C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number
Procaine	P-112	C-21/51	SP-112	C-60/52	NP-112	C-90/53
Proflavine	P-115	C-21/51	SP-115	C-60/52	NP-115	C-90/53
Progesterone	P-131	B-21/48	SP-131	B-60/49	NP-131	B-90/50
Proglumide	P-114	C-21/51	SP-114	C-60/52	NP-114	C-90/53
D-Proline	Q-411	D-21/54	SQ-411	D-60/55	NQ-411	D-90/56
L-Proline	Q-421	C-21/51	SQ-421	C-60/52	NQ-421	C-90/53
Promethazine	C-421	C-21/51	SC-421	C-60/52	NC-421	C-90/53
Propranolol	C-361	C-21/51	SC-361	C-60/52	NC-361	C-90/53
6-n-Propyl-2-Thiouracil	T-141	C-21/51	ST-141	C-60/52	NT-141	C-90/53
Prostacyclin (See Prostaglandin I ₂)	R-120	N-21/69	SR-120	N-60/70	NR-120	N-90/71
Prostaglandin A ₁	R-111	N-21/69	SR-111	N-60/70	NR-111	N-90/71
Prostaglandin A ₂	R-112	N-21/69	SR-112	N-60/70	NR-112	N-90/71
Prostaglandin B ₁	R-113	N-21/69	SR-113	N-60/70	NR-113	N-90/71
Prostaglandin B ₂	R-114	N-21/69	SR-114	N-60/70	NR-114	N-90/71
Prostaglandin D ₂	R-115	N-21/69	SR-115	N-60/70	NR-115	N-90/71
Prostaglandin E ₁	R-116	N-21/69	SR-116	N-60/70	NR-116	N-90/71
Prostaglandin E ₂	R-117	N-21/69	SR-117	N-60/70	NR-117	N-90/71
Prostaglandin F _{1α}	R-118	N-21/69	SR-118	N-60/70	NR-118	N-90/71
Prostaglandin F ₂	R-119	N-21/69	SR-119	N-60/70	NR-119	N-90/71
Prostaglandin I ₂ (Prostacyclin)	R-120	N-21/69	SR-120	N-60/70	NR-120	N-90/71
Puerarin	K-139	D-21/54	SK-139	D-60/55	NK-139	D-90/56
Puromycin	B-145	E-21/57	SB-145	E-60/58	NB-145	E-90/59
Putrescine	P-117	C-21/51	SP-117	C-60/52	NP-117	C-90/53
Pyrazinamide	P-118	C-21/51	SP-118	C-60/52	NP-118	C-90/53
Pyrilamine	C-520	C-21/51	SC-520	C-60/52	NC-520	C-90/53
Quinacrine	B-160Q	C-21/51	SB-160Q	C-60/52	NB-160Q	C-90/53
Quinidine	C-367	C-21/51	SC-367	C-60/52	NC-367	C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Dose/ Schedule/ Number	Product	21-Day Release		60-Day Release		90-Day Release				
		Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number
/53	Quinine	K-141		C-21/51	SK-141		C-60/52	NK-141		C-90/53
/53	Rescinnamine	C-275		B-21/48	SC-275		B-60/49	NC-275		B-90/50
/50	Reserpine	C-181		C-21/51	SC-181		C-60/52	NC-181		C-90/53
/53	Retinal	V-131		B-21/48	SV-131		B-60/49	NV-131		B-90/50
/56	all trans-Retinoic Acid (ATRA)	V-111		B-21/48	SV-111		B-60/49	NV-111		B-90/50
/53	13-cis-Retinoic Acid	V-115		E-21/57	SV-115		E-60/58	NV-115		E-90/59
/53	Retinol	V-121		B-21/48	SV-121		B-60/49	NV-121		B-90/50
/53	Retinol Acetate	V-141		C-21/51	SV-141		C-60/52	NV-141		C-90/53
/53	Retinol Palmitate	V-151		C-21/51	SV-151		C-60/52	NV-151		C-90/53
/71	Rifampicin	B-146		B-21/48	SB-146		B-60/49	NB-146		B-90/50
/71	Rifamycin	B-147		B-21/48	SB-147		B-60/49	NB-147		B-90/50
/71	Salbutamol	C-285		E-21/57	SC-285		E-60/58	NC-285		E-90/59
/71	Scopine	K-142		B-21/48	SK-142		B-60/49	NK-142		B-90/50
/71	Securinine	K-143		D-21/54	SK-143		D-60/55	NK-143		D-90/56
/71	D-Serine	Q-431		C-21/51	SQ-431		C-60/52	NQ-431		C-90/53
/71	L-Serine	Q-441		C-21/51	SQ-441		C-60/52	NQ-441		C-90/53
/71	Serotonin	C-161		C-21/51	SC-161		C-60/52	NC-161		C-90/53
/71	Sodium Butyrate	F-125		B-21/48	SF-125		B-60/49	NF-125		B-90/50
/71	Sodium Iodide	T-181		C-21/51	ST-181		C-60/52	NT-181		C-90/53
/71	Solasodine	K-144		D-21/54	SK-144		D-60/55	NK-144		D-90/56
/56	(-)-Sparteine	K-145		C-21/51	SK-145		C-60/52	NK-145		C-90/53
/59	Spermidine	N-301		B-21/48	SN-301		B-60/49	NN-301		B-90/50
/53	Spermine	N-311		B-21/48	SN-311		B-60/49	NN-311		B-90/50
/53	Spiramycin	B-148		B-21/48	SB-148		B-60/49	NB-148		B-90/50
/53	Spirolactone	M-161		B-21/48	SM-161		B-60/49	NM-161		B-90/50
/53	Stanozolol	A-331		B-21/48	SA-331		B-60/49	NA-331		B-90/50
/53	Stearic Acid	F-151		C-21/51	SF-151		C-60/52	NF-151		C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release			60-Day Release			90-Day Release		
	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number
Streptomycin Sulfate	B-149		C-21/51	SB-149		C-60/52	NB-149		C-90/53
Streptozotocin	Z-280		A-21/45	SZ-280		A-60/46	NZ-280		A-90/47
Strychnine (See Controlled Substances Page 8)	K-148		C-21/51	SK-148		C-60/52	NK-148		C-90/53
Sulfabenzamide	B-150		C-21/51	SB-150		C-60/52	NB-150		C-90/53
Sulfinpyrazone	I-118		C-21/51	SI-118		C-60/52	NI-118		C-90/53
Sulindac	I-119		B-21/48	SI-119		B-60/49	NI-119		B-90/50
(-)Sulpiride	S-101		B-21/48	SS-101		B-60/49	NS-101		B-90/50
(±)Sulpiride	S-102		C-21/51	SS-102		C-60/52	NS-102		C-90/53
Tamoxifen Citrate	E-351		A-21/45	SE-351		A-60/46	NE-351		A-90/47
Tamoxifen (Free Base)	E-361		A-21/45	SE-361		A-60/46	NE-361		A-90/47
Testosterone (See Controlled Substances Page 8)	Special dosing for Immuno- Deficient Mice. See pages 78-80.								
Testosterone (See Controlled Substances Page 8)	A-151		B-21/48	SA-151		B-60/49	NA-151		B-90/50
Testosterone Benzoate (See Controlled Substances Page 8)	A-171		B-21/48	SA-171		B-60/49	NA-171		B-90/50
Testosterone Acetate (See Controlled Substances Page 8)	A-181		B-21/48	SA-181		B-60/49	NA-181		B-90/50
Testosterone Cypionate (See Controlled Substances Page 8)	A-281		B-21/48	SA-281		B-60/49	NA-281		B-90/50
Testosterone Enanthate (See Controlled Substances Page 8)	A-191		B-21/48	SA-191		B-60/49	NA-191		B-90/50
Testosterone 17β-Hemisuccinate (See Controlled Substances Page 8)	A-201		A-21/45	SA-201		A-60/46	NA-201		A-90/47
Testosterone Propionate (See Controlled Substances Page 8)	A-211		B-21/48	SA-211		B-60/49	NA-211		B-90/50
Tetracycline	B-151		A-21/45	SB-151		A-60/46	NB-151		A-90/47
Theobromine	C-381		C-21/51	SC-381		C-60/52	NC-381		C-90/53
Theophylline	C-211		C-21/51	SC-211		C-60/52	NC-211		C-90/53
Thiabendazole	B-162		C-21/51	SB-162		C-60/52	NB-162		C-90/53
Thiacetazone	B-159		C-21/51	SB-159		C-60/52	NB-159		C-90/53
Thiamphenicol	B-160		B-21/48	SB-160		B-60/49	NB-160		B-90/50
Thiobarbital	T-145		C-21/51	ST-145		C-60/52	NT-145		C-90/53
6-Thioguanine	Z-290		B-21/48	SZ-290		B-60/49	NZ-290		B-90/50
D-Threonine	Q-451		C-21/51	SQ-451		C-60/52	NQ-451		C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ase

chedule/
number

/53

/47

/53

/53

/53

/50

/50

/53

/47

/47

80.

/50

/50

/50

/50

/50

/47

/50

/47

/53

/53

/53

/53

/50

/53

/50

/53


Product	21-Day Release		60-Day Release		90-Day Release				
	Catalog Number	Price Page	Schedule/ Number	Catalog Number	Price Page	Schedule/ Number			
L-Threonine	Q-461		C-21/51	SQ-461		C-60/52	NQ-461		C-90/53
Thymidine	N-321		B-21/48	SN-321		B-60/49	NN-321		B-90/50
Thyroglobulin	T-201		D-21/54	ST-201		D-60/55	NT-201		D-90/56
Thyroid Releasing Hormone	T-211		H-21/60	ST-211		H-60/61	NT-211		H-90/62
Thyroid Stimulating Hormone	T-221		H-21/60	ST-221		H-60/61	NT-221		H-90/62
DL-Thyronine	T-111		B-21/48	ST-111		B-60/49	NT-111		B-90/50
D-Thyroxine	T-121		B-21/48	ST-121		B-60/49	NT-121		B-90/50
L-Thyroxine (T4)	T-131		B-21/48	ST-131		B-60/49	NT-131		B-90/50
Timolol	T-101		D-21/54	ST-101		D-60/55	NT-101		D-90/56
Tolazoline	C-391		C-21/51	SC-391		C-60/52	NC-391		C-90/53
Tomatidine	K-150		D-21/54	SK-150		D-60/55	NK-150		D-90/56
Tomatine	K-151		E-21/57	SK-151		E-60/58	NK-151		E-90/59
Tranlycypromine	C-521		B-21/48	SC-521		B-60/49	NC-521		B-90/50
Triamcinolone	G-251		B-21/48	SG-251		B-60/49	NG-251		B-90/50
Triamcinolone Acetonide	G-261		B-21/48	SG-261		B-60/49	NG-261		B-90/50
Triamcinolone Diacetate	G-271		B-21/48	SG-271		B-60/49	NG-271		B-90/50
Triamterene	D-171		C-21/51	SD-171		C-60/52	ND-171		C-90/53
3,3',5-Triiodo-DL-Thyronine	T-251		A-21/45	ST-251		A-60/46	NT-251		A-90/47
3,3',5-Triiodo-L-Thyronine (T3)	T-261		A-21/45	ST-261		A-60/46	NT-261		A-90/47
Tripelennamine	C-522		C-21/51	SC-522		C-60/52	NC-522		C-90/53
Tropine	K-152		B-21/48	SK-152		B-60/49	NK-152		B-90/50
Tropinone	K-153		B-21/48	SK-153		B-60/49	NK-153		B-90/50
Tryptamine	T-102		C-21/51	ST-102		C-60/52	NT-102		C-90/53
D-Tryptophan	Q-471		C-21/51	SQ-471		C-60/52	NQ-471		C-90/53
L-Tryptophan	Q-481		C-21/51	SQ-481		C-60/52	NQ-481		C-90/53
D-Tyrosine	Q-491		D-21/54	SQ-491		D-60/55	NQ-491		D-90/56
L-Tyrosine	Q-501		C-21/51	SQ-501		C-60/52	NQ-501		C-90/53

ALPHABETICAL PRODUCT LISTING

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

Product	21-Day Release			60-Day Release			90-Day Release		
	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number	Catalog Number	Price Page	Schedule/Number
Uridine	N-331		C-21/51	SN-331		C-60/52	NN-331		C-90/53
D-Valine	Q-511		C-21/51	SQ-511		C-60/52	NQ-511		C-90/53
L-Valine	Q-521		C-21/51	SQ-521		C-60/52	NQ-521		C-90/53
Vancomycin	B-152		D-21/54	SB-152		D-60/55	NB-152		D-90/56
Verapamil	C-411		B-21/48	SC-411		B-60/49	NC-411		B-90/50
Veratrine	K-154		D-21/54	SK-154		D-60/55	NK-154		D-90/56
Vinblastine	Z-300		H-21/60	SZ-300		H-60/61	NZ-300		H-90/62
Vincamine	K-155		D-21/54	SK-155		D-60/55	NK-155		D-90/56
Vincristine	Z-310		D-21/54	SZ-310		D-60/55	NZ-310		D-90/56
Vitamin B ₁ (Thiamine)	V-161		C-21/51	SV-161		C-60/52	NV-161		C-90/53
Vitamin B ₂ (Riboflavin)	V-171		C-21/51	SV-171		C-60/52	NV-171		C-90/53
Vitamin B ₆ (Pyridoxine)	V-181		C-21/51	SV-181		C-60/52	NV-181		C-90/53
Vitamin B ₁₂ (Cyanocobalamin)	V-191		B-21/48	BV-191		B-60/49	NV-191		B-90/50
Vitamin C (Ascorbic Acid)	V-201		C-21/51	SV-201		C-60/52	NV-201		C-90/53
Vitamin D ₂ (Ergocalciferol)	V-211		C-21/51	SV-211		C-60/52	NV-211		C-90/53
Vitamin D ₃ (Cholecalciferol)	V-221		C-21/51	SV-221		C-60/52	NV-221		C-90/53
Vitamin E (Tocopherol)	V-231		B-21/48	SV-231		B-60/49	NV-231		B-90/50
Vitamin H (d-Biotin)	V-241		B-21/48	SV-241		B-60/49	NV-241		B-90/50
Vitamin K ₁	V-251		C-21/51	SV-251		C-60/52	NV-251		C-90/53
Vitamin K ₃ (Menadione)	V-261		C-21/51	SV-261		C-60/52	NV-261		C-90/53
Xanthinol Nicotinate	B-153		B-21/48	SB-153		B-60/49	NB-153		B-90/50
Yohimbine	C-401		C-21/51	SC-401		C-60/52	NC-401		C-90/53
α-Zearalenol	Z-101		N-21/69	SZ-101		N-60/70	NZ-101		N-90/71
β-Zearalenol	Z-102		N-21/69	SZ-102		N-60/70	NZ-102		N-90/71
Zearalenone	Z-103		N-21/69	SZ-103		N-60/70	NZ-103		N-90/71
Zopepirac	I-120		B-21/48	SI-120		B-60/49	NI-120		B-90/50

INNOVATIVE RESEARCH OF AMERICA



Our pellets have a guaranteed shelf life of 3 years from the time that you receive them.

The Choice Is Evident



ORDERING INFORMATION

• **Mail**

Innovative Research of America, Inc.
2 North Tamiami Trail
Suite 404
Sarasota, Florida 34236 USA

• **Phone**

(941) 365-1406
(941) 365-1506
(800) 421-8171 (USA/Canada)

• **Fax**

(941) 365-1703
(941) 365-1803
(800) 643-4345 (USA/Canada)
(800) 648-6030 (USA/Canada)

• **Internet / E-Mail**

<http://www.innovrsrch.com> (website)
pellets@innovrsrch.com (e-mail)

IRA's website features our company profile, the latest product technology and **on-line ordering**.



AMERICAN EXPRESS,
VISA AND MASTERCARD ACCEPTED.
Purchase Order Forms are in the back of the catalog.

Custom Pellets Information Form on page 95.

THE DIFFERENCE IS
CONSISTENCY AND UNIFORMITY.



Bank Wire Payment Information

Payment via bank wire should be directed as follows:

BB&T Bank
1800 Second St., Suite 100
Sarasota, Florida 34236
Routing # (ABA) 263191387
Electronic Transfers # 263191387

In favor of:
Innovative Research of America
2 North Tamiami Trail
Suite 404
Sarasota, FL 34236
Checking Account: #0000147816154
Swift Code: BRBTUS33



Ushering In The Age Of Innovative Research


IRA

STOCK PELLET PRICE SCHEDULES (PAGES 45-71)

This section of Price Schedules is for our stock products listed on pages 45-71 with our stock doses and releases (21 Day, 60 Day, 90 Day).

If there is a product, dose or release that is of interest not displayed in this catalog, please inquire.

Products are sold in lots of 25, 50, 100 and 200 pellets.



For Immuno-Deficient Mouse Studies:

Special doses and references for Cyproterone Acetate, Flutamide, 17 β -Estradiol, Tamoxifen (Free Base), Testosterone and 5 α -Dihydrotestosterone (5 α -DHT)

Please see pages 73-80.

We Save You Time





PRICE SCHEDULE A-21

The price schedule below applies to all the products that are given the A-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1666	\$3144	\$5792
0.010	\$876	\$1668	\$3148	\$5800
0.025	\$883	\$1682	\$3176	\$5856
0.05	\$888	\$1692	\$3196	\$5896
0.1	\$893	\$1702	\$3216	\$5936
0.25	\$898	\$1712	\$3236	\$5976
0.5	\$908	\$1732	\$3276	\$6138
1.5	\$918	\$1752	\$3316	\$6178
2.5	\$928	\$1772	\$3356	\$6216
5.0	\$940	\$1796	\$3404	\$6312
7.5	\$951	\$1829	\$3409	\$6409
10.0	\$971	\$1859	\$3479	\$6499
15.0	\$989	\$1909	\$3579	\$6649
25.0	\$1019	\$1964	\$3659	\$6869
35.0	\$1049	\$1999	\$3729	\$7009
50.0	\$1089	\$2069	\$3809	\$7195
75.0	\$1119	\$2199	\$3959	\$7299
100.0	\$1209	\$2317	\$4279	\$7629
150.0	\$1329	\$2499	\$4649	\$8449
200.0	\$1449	\$2749	\$4875	\$8799

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

More Time For Creative Research



PRICE SCHEDULE A-60

The price schedule below applies to all the products that are given the A-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$7275
0.5	\$1030	\$1915	\$3675	\$7285
1.5	\$1035	\$1945	\$3755	\$7295
2.5	\$1040	\$1955	\$3775	\$7300
5.0	\$1045	\$1965	\$3785	\$7350
7.5	\$1056	\$1981	\$3830	\$7400
10.0	\$1066	\$1996	\$3846	\$7500
15.0	\$1170	\$2125	\$4065	\$7999
25.0	\$1175	\$2130	\$4095	\$8005
35.0	\$1180	\$2146	\$4146	\$8010
50.0	\$1200	\$2226	\$4306	\$8015
75.0	\$1249	\$2362	\$4406	\$8260
100.0	\$1349	\$2562	\$4679	\$8460
150.0	\$1479	\$2822	\$4975	\$8910
200.0	\$1649	\$3162	\$5375	\$9249

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Time Release Pellets - The Affordable Solution

PRICE SCHEDULE A-90

The price schedule below applies to all the products that are given the A-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1162	\$2195	\$4090	\$7672
0.5	\$1163	\$2198	\$4092	\$7673
1.5	\$1164	\$2199	\$4095	\$7674
2.5	\$1165	\$2200	\$4100	\$7675
5.0	\$1180	\$2225	\$4140	\$7676
7.5	\$1195	\$2245	\$4180	\$7800
10.0	\$1210	\$2256	\$4220	\$7850
15.0	\$1325	\$2390	\$4475	\$8548
25.0	\$1335	\$2396	\$4495	\$8555
35.0	\$1340	\$2406	\$4501	\$8600
50.0	\$1345	\$2486	\$4661	\$8750
75.0	\$1389	\$2622	\$4933	\$9000
100.0	\$1489	\$2822	\$5333	\$9250
150.0	\$1619	\$3022	\$5533	\$9750
200.0	\$1789	\$3362	\$5713	\$10250

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

The Picture Suddenly Gets Clearer



PRICE SCHEDULE B-21

The price schedule below applies to all the products that are given the B-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1666	\$3144	\$5792
0.010	\$876	\$1668	\$3148	\$5800
0.025	\$883	\$1682	\$3176	\$5856
0.05	\$888	\$1692	\$3196	\$5896
0.1	\$893	\$1702	\$3216	\$5936
0.25	\$898	\$1712	\$3236	\$5976
0.5	\$908	\$1732	\$3276	\$6138
1.5	\$918	\$1752	\$3316	\$6178
2.5	\$928	\$1772	\$3356	\$6216
5.0	\$940	\$1796	\$3404	\$6312
7.5	\$950	\$1828	\$3408	\$6408
10.0	\$970	\$1858	\$3478	\$6498
15.0	\$979	\$1894	\$3529	\$6579
25.0	\$999	\$1929	\$3579	\$6698
35.0	\$1009	\$1944	\$3609	\$6798
50.0	\$1019	\$1964	\$3629	\$6848
75.0	\$1029	\$1979	\$3679	\$6898
100.0	\$1049	\$1999	\$3729	\$6948
150.0	\$1079	\$2049	\$3879	\$7198
200.0	\$1099	\$2099	\$4075	\$7398

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Pellets Help Put Research In The Proper Perspective

PRICE SCHEDULE B-60

The price schedule below applies to all the products that are given the B-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1037	\$1950	\$3761	\$7275
0.5	\$1038	\$1955	\$3775	\$7285
1.5	\$1039	\$1960	\$3795	\$7295
2.5	\$1040	\$1962	\$3810	\$7300
5.0	\$1044	\$1964	\$3814	\$7349
7.5	\$1050	\$1970	\$3825	\$7400
10.0	\$1060	\$1985	\$3835	\$7500
15.0	\$1125	\$2035	\$3866	\$7700
25.0	\$1130	\$2065	\$3945	\$7800
35.0	\$1140	\$2080	\$3975	\$7850
50.0	\$1195	\$2145	\$4015	\$7900
75.0	\$1199	\$2175	\$4045	\$7950
100.0	\$1225	\$2235	\$4075	\$8000
150.0	\$1250	\$2275	\$4205	\$8200
200.0	\$1280	\$2295	\$4435	\$8400

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

The Research Puzzle Need Not Be Unsolved



PRICE SCHEDULE B-90

The price schedule below applies to all the products that are given the B-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1162	\$2195	\$4090	\$7672
0.5	\$1163	\$2198	\$4092	\$7673
1.5	\$1164	\$2199	\$4095	\$7674
2.5	\$1165	\$2200	\$4100	\$7675
5.0	\$1179	\$2224	\$4139	\$7676
7.5	\$1191	\$2241	\$4171	\$7677
10.0	\$1206	\$2255	\$4201	\$7678
15.0	\$1285	\$2365	\$4300	\$8100
25.0	\$1294	\$2370	\$4350	\$8200
35.0	\$1295	\$2375	\$4390	\$8250
50.0	\$1320	\$2380	\$4430	\$8300
75.0	\$1335	\$2395	\$4470	\$8350
100.0	\$1350	\$2445	\$4510	\$8400
150.0	\$1365	\$2475	\$4550	\$8450
200.0	\$1380	\$2515	\$4590	\$8700

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Here Is The Better Alternative

PRICE SCHEDULE C-21

The price schedule below applies to all the products that are given the C-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1666	\$3144	\$5792
0.010	\$876	\$1668	\$3148	\$5800
0.025	\$883	\$1682	\$3176	\$5856
0.05	\$888	\$1692	\$3196	\$5896
0.1	\$893	\$1702	\$3216	\$5936
0.25	\$898	\$1712	\$3236	\$5976
0.5	\$908	\$1732	\$3276	\$6056
1.5	\$918	\$1752	\$3316	\$6136
2.5	\$928	\$1772	\$3356	\$6216
5.0	\$940	\$1796	\$3404	\$6312
7.5	\$949	\$1827	\$3407	\$6407
10.0	\$959	\$1842	\$3442	\$6452
15.0	\$969	\$1857	\$3477	\$6497
25.0	\$979	\$1894	\$3529	\$6549
35.0	\$989	\$1912	\$3554	\$6574
50.0	\$999	\$1929	\$3579	\$6598
75.0	\$1009	\$1944	\$3609	\$6679
100.0	\$1019	\$1964	\$3629	\$6749
150.0	\$1029	\$1979	\$3679	\$6799
200.0	\$1049	\$1999	\$3729	\$6899

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Your Research Time Is Under Your Control



PRICE SCHEDULE C-60

The price schedule below applies to all the products that are given the C-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$6800
0.5	\$1030	\$1915	\$3675	\$6850
1.5	\$1035	\$1945	\$3755	\$6950
2.5	\$1040	\$1955	\$3775	\$7000
5.0	\$1045	\$1965	\$3785	\$7050
7.5	\$1050	\$1970	\$3795	\$7095
10.0	\$1055	\$1975	\$3805	\$7145
15.0	\$1065	\$1990	\$3835	\$7195
25.0	\$1075	\$2005	\$3865	\$7245
35.0	\$1085	\$2020	\$3885	\$7295
50.0	\$1095	\$2035	\$3915	\$7345
75.0	\$1105	\$2050	\$3945	\$7395
100.0	\$1120	\$2065	\$3975	\$7445
150.0	\$1145	\$2080	\$4005	\$7495
200.0	\$1170	\$2195	\$4035	\$7545

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Reassuring... Eliminates Uncertainties

PRICE SCHEDULE C-90

The price schedule below applies to all the products that are given the C-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1120	\$2125	\$3980	\$7200
0.5	\$1135	\$2150	\$4020	\$7300
1.5	\$1150	\$2175	\$4060	\$7350
2.5	\$1165	\$2200	\$4100	\$7400
5.0	\$1180	\$2225	\$4140	\$7450
7.5	\$1185	\$2240	\$4170	\$7485
10.0	\$1200	\$2265	\$4210	\$7535
15.0	\$1215	\$2290	\$4250	\$7585
25.0	\$1230	\$2315	\$4290	\$7635
35.0	\$1245	\$2340	\$4330	\$7685
50.0	\$1260	\$2365	\$4370	\$7735
75.0	\$1275	\$2390	\$4410	\$7785
100.0	\$1290	\$2415	\$4450	\$7835
150.0	\$1305	\$2425	\$4490	\$7885
200.0	\$1320	\$2445	\$4530	\$7935

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Pellets... The Time Machines



PRICE SCHEDULE D-21

The price schedule below applies to all the products that are given the D-21 price code. Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1671	\$3183	\$5967
0.010	\$876	\$1675	\$3191	\$5979
0.025	\$883	\$1689	\$3218	\$5999
0.05	\$888	\$1699	\$3223	\$6009
0.1	\$893	\$1729	\$3228	\$6019
0.25	\$915	\$1749	\$3308	\$6027
0.5	\$939	\$1795	\$3378	\$6143
1.5	\$975	\$1849	\$3428	\$6247
2.5	\$999	\$1895	\$3498	\$6363
5.0	\$1009	\$1949	\$3608	\$6527
7.5	\$1019	\$1964	\$3629	\$6748
10.0	\$1029	\$1979	\$3729	\$6898
15.0	\$1049	\$1999	\$3749	\$7025
25.0	\$1079	\$2049	\$3779	\$7098
35.0	\$1129	\$2109	\$3879	\$7199
50.0	\$1199	\$2299	\$4179	\$7699
75.0	\$1309	\$2449	\$4429	\$8199
100.0	\$1419	\$2549	\$4779	\$8499
150.0	\$1649	\$3049	\$5579	\$10199
200.0	\$1869	\$3449	\$6079	\$11199

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



It Is Only A Matter Of Time Release Pellets

PRICE SCHEDULE D-60

The price schedule below applies to all the products that are given the D-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$6800
0.5	\$1030	\$1915	\$3675	\$6850
1.5	\$1035	\$1945	\$3755	\$6950
2.5	\$1040	\$1955	\$3775	\$7000
5.0	\$1125	\$2075	\$3890	\$7050
7.5	\$1135	\$2125	\$3905	\$7345
10.0	\$1145	\$2195	\$3965	\$7445
15.0	\$1175	\$2225	\$4005	\$7545
25.0	\$1200	\$2245	\$4025	\$7645
35.0	\$1245	\$2295	\$4275	\$7995
50.0	\$1295	\$2445	\$4425	\$8195
75.0	\$1445	\$2645	\$4825	\$8695
100.0	\$1545	\$2845	\$5075	\$8995
150.0	\$1845	\$3345	\$5875	\$10695
200.0	\$2245	\$3745	\$6375	\$11695

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Solid Pellets For Better Solutions



PRICE SCHEDULE D-90

The price schedule below applies to all the products that are given the D-90 price code. Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1120	\$2125	\$3980	\$7200
0.5	\$1135	\$2150	\$4020	\$7300
1.5	\$1150	\$2175	\$4060	\$7350
2.5	\$1165	\$2200	\$4100	\$7400
5.0	\$1235	\$2315	\$4240	\$7750
7.5	\$1249	\$2329	\$4280	\$8000
10.0	\$1265	\$2395	\$4405	\$8195
15.0	\$1325	\$2445	\$4505	\$8495
25.0	\$1385	\$2485	\$4575	\$8545
35.0	\$1485	\$2575	\$4725	\$8895
50.0	\$1625	\$2775	\$4875	\$9095
75.0	\$1725	\$2875	\$5275	\$9475
100.0	\$2145	\$3245	\$5575	\$9675
150.0	\$2440	\$3845	\$6175	\$10875
200.0	\$2545	\$4145	\$6775	\$12195

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Timing Is Everything

PRICE SCHEDULE E-21

The price schedule below applies to all the products that are given the E-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on 21.

Products are sold in lots of 25, 50 and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$897	\$1712	\$3228
0.01	\$905	\$1728	\$3251
0.05	\$910	\$1731	\$3274
0.1	\$913	\$1732	\$3280
0.25	\$933	\$1792	\$3389
0.5	\$962	\$1825	\$3458
1.5	\$976	\$1850	\$3481
2.5	\$991	\$1873	\$3561
5.0	\$1014	\$1922	\$3619
7.5	\$1060	\$1939	\$3676
10.0	\$1106	\$1972	\$3734
15.0	\$1170	\$2110	\$4079
25.0	\$1278	\$2483	\$4824
35.0	\$1439	\$2964	\$5779
50.0	\$2354	\$4694	\$8254
75.0	\$3532	\$6827	\$12778
100.0	\$4444	\$8304	\$16099

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Consistency Is Important



PRICE SCHEDULE E-60

The price schedule below applies to all the products that are given the E-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$947	\$1812	\$3428
0.01	\$955	\$1828	\$3451
0.05	\$960	\$1831	\$3474
0.1	\$963	\$1832	\$3480
0.25	\$983	\$1892	\$3589
0.5	\$1012	\$1925	\$3658
1.5	\$1026	\$1950	\$3681
2.5	\$1041	\$1973	\$3761
5.0	\$1064	\$2022	\$3819
7.5	\$1085	\$2114	\$3976
10.0	\$1131	\$2147	\$4034
15.0	\$1195	\$2285	\$4379
25.0	\$1403	\$2658	\$5124
35.0	\$1624	\$3139	\$6079
50.0	\$2479	\$4869	\$8554
75.0	\$3657	\$7002	\$13078
100.0	\$4569	\$8479	\$16199

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Close The Gap With Good Results

PRICE SCHEDULE E-90

The price schedule below applies to all the products that are given the E-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$997	\$1912	\$3628
0.01	\$1005	\$1928	\$3651
0.05	\$1010	\$1931	\$3674
0.1	\$1013	\$1932	\$3680
0.25	\$1033	\$1992	\$3789
0.5	\$1062	\$2025	\$3858
1.5	\$1076	\$2050	\$3881
2.5	\$1091	\$2073	\$3961
5.0	\$1114	\$2122	\$4019
7.5	\$1210	\$2289	\$4276
10.0	\$1256	\$2322	\$4334
15.0	\$1320	\$2460	\$4679
25.0	\$1528	\$2833	\$5424
35.0	\$1689	\$3314	\$6379
50.0	\$2604	\$5044	\$8854
75.0	\$3782	\$7177	\$13378
100.0	\$4694	\$8654	\$16499

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Discover The Ultimate Time-Saving Device



PRICE SCHEDULE H-21

The price schedule below applies to all the products that are given the H-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$905	\$1735	\$3305
0.005	\$915	\$1750	\$3330
0.01	\$925	\$1765	\$3355
0.025	\$935	\$1780	\$3380
0.05	\$945	\$1795	\$3405
0.1	\$955	\$1810	\$3430
0.25	\$975	\$1845	\$3485
0.5	\$1050	\$1965	\$3610
1.0	\$1225	\$2235	\$4135
2.5	\$1625	\$3135	\$5575
5.0	\$2825	\$5485	\$9575
7.5	\$4150	\$8245	\$13275
10.0	\$4745	\$8445	\$16775

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



An Instrument Of Success

PRICE SCHEDULE H-60

The price schedule below applies to all the products that are given the H-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$955	\$1835	\$3505
0.005	\$965	\$1850	\$3530
0.01	\$975	\$1865	\$3555
0.025	\$985	\$1880	\$3580
0.05	\$995	\$1895	\$3605
0.1	\$1005	\$1910	\$3630
0.25	\$1025	\$1945	\$3685
0.5	\$1100	\$2065	\$3810
1.0	\$1325	\$2435	\$4535
2.5	\$1725	\$3335	\$5975
5.0	\$2925	\$5685	\$9975
7.5	\$4250	\$8445	\$13675
10.0	\$4845	\$8645	\$17175

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

A Tool For Change



PRICE SCHEDULE H-90

The price schedule below applies to all the products that are given the H-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$1005	\$1935	\$3705
0.005	\$1015	\$1950	\$3730
0.01	\$1025	\$1965	\$3755
0.025	\$1035	\$1980	\$3780
0.05	\$1045	\$1995	\$3805
0.1	\$1055	\$2010	\$3830
0.25	\$1075	\$2045	\$3885
0.5	\$1150	\$2165	\$4010
1.0	\$1425	\$2635	\$4735
2.5	\$1825	\$3535	\$6175
5.0	\$3025	\$5885	\$10175
7.5	\$4350	\$8645	\$13875
10.0	\$4945	\$8845	\$17375

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



A Tool For Discovery

PRICE SCHEDULE L-21

The price schedule below applies to all the products that are given the L-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1671	\$3183	\$5967
0.01	\$876	\$1675	\$3191	\$5979
0.025	\$883	\$1689	\$3218	\$5999
0.05	\$888	\$1699	\$3223	\$6009
0.1	\$893	\$1729	\$3228	\$6019
0.25	\$915	\$1749	\$3308	\$6027
0.5	\$939	\$1795	\$3378	\$6143
1.5	\$975	\$1849	\$3428	\$6247
2.5	\$999	\$1895	\$3498	\$6363
5.0	\$1009	\$1949	\$3608	\$6527
7.5	\$1019	\$1964	\$3629	\$6748
10.0	\$1029	\$1979	\$3729	\$6898
15.0	\$1049	\$1999	\$3749	\$7025

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Pellets Capture The Change In Research



PRICE SCHEDULE L-60

The price schedule below applies to all the products that are given the L-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.01	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$6800
0.5	\$1030	\$1915	\$3675	\$6850
1.5	\$1035	\$1945	\$3755	\$6950
2.5	\$1040	\$1955	\$3775	\$7000
5.0	\$1125	\$2075	\$3890	\$7050
7.5	\$1135	\$2125	\$3905	\$7345
10.0	\$1145	\$2195	\$3965	\$7445
15.0	\$1175	\$2225	\$4005	\$7545

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



The Perfect Gift Of Time

PRICE SCHEDULE L-90

The price schedule below applies to all the products that are given the L-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS			
	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.01	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1120	\$2125	\$3980	\$7200
0.5	\$1135	\$2150	\$4020	\$7300
1.5	\$1150	\$2175	\$4060	\$7350
2.5	\$1165	\$2200	\$4100	\$7400
5.0	\$1235	\$2315	\$4140	\$7450
7.5	\$1249	\$2329	\$4280	\$8000
10.0	\$1265	\$2395	\$4405	\$8195
15.0	\$1325	\$2445	\$4505	\$8495

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Options For Excellence



PRICE SCHEDULE M-21

The price schedule below applies to all the products that are given the M-21 price code. Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.05	\$875	\$1649	\$3159
0.1	\$900	\$1725	\$3259
0.5	\$952	\$1835	\$3450
5.0	\$1265	\$2410	\$4579
15.0	\$1365	\$2549	\$4779

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



We Deliver What You Expect With Confidence

PRICE SCHEDULE M-60

The price schedule below applies to all the products that are given the M-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.05	\$925	\$1700	\$3230
0.1	\$950	\$1775	\$3305
0.5	\$1002	\$1885	\$3525
5.0	\$1315	\$2460	\$4755
15.0	\$1415	\$2600	\$4855

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

Reduce Experimental Variables



PRICE SCHEDULE M-90

The price schedule below applies to all the products that are given the M-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.05	\$975	\$1775	\$3305
0.1	\$1000	\$1825	\$3380
0.5	\$1052	\$1935	\$3575
5.0	\$1365	\$2510	\$4805
15.0	\$1465	\$2650	\$4905

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

DIGNITY IS
IMPORTANT
ON ANY
SCALE...



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM



Increase Data Reproducibility

PRICE SCHEDULE N-21

The price schedule below applies to all the products that are given the N-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.


Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$905	\$1735	\$3305
0.005	\$915	\$1750	\$3330
0.01	\$925	\$1765	\$3355
0.025	\$935	\$1780	\$3380
0.05	\$945	\$1795	\$3405
0.1	\$955	\$1810	\$3430
0.25	\$1129	\$2146	\$3986
0.5	\$1345	\$2555	\$4775
1.0	\$1755	\$3345	\$6030

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*

THE SHORTEST DISTANCE BETWEEN
YOU AND GOOD RESEARCH
RESULTS IS **IRA**.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT
WWW.INNOVRSRCH.COM

More Time For Creative Research



PRICE SCHEDULE N-60

The price schedule below applies to all the products that are given the N-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$955	\$1835	\$3505
0.005	\$965	\$1850	\$3530
0.01	\$975	\$1865	\$3555
0.025	\$985	\$1880	\$3580
0.05	\$995	\$1895	\$3605
0.1	\$1005	\$1910	\$3630
0.25	\$1179	\$2246	\$4135
0.5	\$1395	\$2655	\$4925
1.0	\$1805	\$3445	\$6180

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*



We Put Management In Time

PRICE SCHEDULE N-90

The price schedule below applies to all the products that are given the N-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRICE/NUMBER OF PELLETS		
	25 pellets	50 pellets	100 pellets
0.001	\$1005	\$1935	\$3705
0.005	\$1015	\$1950	\$3730
0.01	\$1025	\$1965	\$3755
0.025	\$1035	\$1980	\$3780
0.05	\$1045	\$1995	\$3805
0.1	\$1055	\$2010	\$3830
0.25	\$1229	\$2346	\$4285
0.5	\$1445	\$2755	\$5075
1.0	\$1855	\$3545	\$6330

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE.*




We Help Manage Time



PRECISION TROCHAR

Please view pages 81 and 123 for trochar and pellet
implantation information.



(Trochar can also be used for tissue transplantation.)



Pellets Capture The Change In Research

IRA

SPECIAL DOSE PELLETS FOR TUMOR GROWTH AND REGRESSION IN IMMUNO-DEFICIENT MICE

It has been established that the growth and regression of estrogen-dependent and androgen-dependent tumor tissue in mice is dependent upon three factors:

1. The tumor tissue itself
2. A healthy and untraumatized mouse
3. Exogenous estrogen/androgen or anti-estrogen/anti-androgen ready-to-implant pellets from Innovative Research of America

NOTE: In this section, the pricing for the most commonly used 60 Day Release and 90 Day Release pellets in mice are listed for the below products. You may also view the selected references for these specific pellets on pages 74-80 and additional references citing the use of these products on pages 109-122.

Available Special Common Doses for 60 Days or 90 Days		Pellet Size in Diameter	Available Special Common Doses for 60 Days or 90 Days		Pellet Size in Diameter
17 β -Estradiol	17 β -Estradiol	3mm	Testosterone	17 β -Estradiol	3mm
17 β -Estradiol	17 β -Estradiol	3mm	5 α -DHT	17 β -Estradiol	3mm
17 β -Estradiol	17 β -Estradiol	3mm	Progesterone	17 β -Estradiol	3mm
17 β -Estradiol	17 β -Estradiol	3mm	17 α -OH Progesterone	17 β -Estradiol	3mm
Progesterone (Free Base)	Progesterone	3mm	Progesterone		
Progesterone					



**Please inquire directly with us if further assistance is required regarding a product of interest.*

What You Get Out Of Your Research Is Only As Good As What You Put Into It



Thesis
No. 1
thru

NC

NE

NE

NE

NE

NE

Ca
Nu



Thesis
No. 1
thru

SC

SE

SE

SE

SE

SE

Ca
Nu



17 β -ESTRADIOL AND TAMOXIFEN PELLETS FOR TUMOR GROWTH & REGRESSION IN IMMUNO-DEFICIENT MICE.

It has been established that the growth and regression of estrogen-dependent tumor tissue in mice is dependent upon three factors:

1. The tumor tissue itself.
2. A healthy and untraumatized mouse.
3. Exogenous estrogen or anti-estrogen ready-to-implant pellets from Innovative Research of America.

The most commonly used 60-day and 90-day pellets in mice are listed below in these charts:

60-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
SE-121	17 β -Estradiol	1.7	3.0mm	\$1036	\$1949	\$3760	\$7270
SE-121	17 β -Estradiol	0.72	3.0mm	\$1035	\$1948	\$3759	\$7269
SE-121	17 β -Estradiol	0.36	3.0mm	\$1034	\$1947	\$3758	\$7268
SE-121	17 β -Estradiol	0.18	3.0mm	\$1033	\$1946	\$3757	\$7267
SE-361	Tamoxifen (free base)	5.0	3.0mm	\$1045	\$1965	\$3815	\$7350
SC-111	Placebo	N/A	3.0mm	\$781	\$1518	\$2951	\$5374

These pellets are designed for simple subcutaneous implantation in mice with a 10 Gauge Precision Trochar (Catalog No. MP-182 - \$240.00 each). NOTE: Other products and dosages that can also be used in mouse studies are found throughout this catalog.

90-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
NE-121	17 β -Estradiol	1.7	3.0mm	\$1161	\$2194	\$4085	\$7670
NE-121	17 β -Estradiol	0.72	3.0mm	\$1160	\$2193	\$4084	\$7669
NE-121	17 β -Estradiol	0.36	3.0mm	\$1159	\$2192	\$4083	\$7668
NE-121	17 β -Estradiol	0.18	3.0mm	\$1158	\$2191	\$4082	\$7667
NE-361	Tamoxifen (free base)	5.0	3.0mm	\$1180	\$2225	\$4140	\$7750
NC-111	Placebo	N/A	3.0mm	\$814	\$1574	\$3049	\$5528

These pellets are designed for simple subcutaneous implantation in mice with a 10 Gauge Precision Trochar (Catalog No. MP-182-\$240.00 each). NOTE: Other products and dosages that can also be used in mouse studies are found throughout this catalog.

17 β -ESTRADIOL

ACTA Neurochirurgica, 140 (1): 82-86, 1998
 Acta Physiologica Scandinavica, 176 (3): 177-184, 2002
 American Association for Cancer Research (AACR), 2003
 American Journal of Obstetrics and Gynecology, 184 (3): 303-308, 2001
 American Journal of Pathology, 153 (6): 1993-2006, 1998
 American Journal of Pathology, 158 (2): 639-646, 2001
 American Journal of Pathology, 161 (3): 909-918, 2002
 American Journal of Pathology, 163 (5): 1713-1719, 2003
 American Journal of Pathology, 163 (6): 2531-2541, 2003
 American Journal of Physiology: Endocrinology and Metabolism, 282 (1): E139-E146, 2002
 American Journal of Physiology: Endocrinology and Metabolism, 283 (4): E623-E630, 2002
 American Journal of Physiology: Gastrointestinal and Liver Physiology, 290 (2): G269-G276, 2006
 American Journal of Physiology: Heart and Circulatory Physiology, 284 (5): H1560-H1569, 2003
 American Journal of Physiology: Heart and Circulatory Physiology, 290 (5): H2043-H2050, 2006
 American Journal of Physiology: Renal Physiology, 283 (5): F934-F943, 2002
 American Journal of Physiological Society, 102: 1387-1393, 2007
 American Society for Nutritional Sciences, 134: 1929-1934, 2004
 Anti-Cancer Drugs, 15 (10): 991-996, 2004
 Anticancer Research, 8 (6): 1233-1240, 1988
 Applied Spectroscopy, 58 (1): 1-9, 2004
 Arteriosclerosis, Thrombosis, and Vascular Biology, 25: 1910-1916, 2005
 Biochemical and Biophysical Research Communications, 297 (1): 83-90, 2002
 Biochemical and Biophysical Research Communications, 329 (3): 888-897, 2005
 Biochemical Pharmacology, 57 (3): 309-312, 1999
 Biochemical Pharmacology, 57 (9): 1047-1058, 1999
 Biochimica et Biophysica Acta (BBA): Molecular Cell Research, 1591 (1-3): 109-118, 2002
 Biological Procedures Online, 5 (1): 211-221, 2003
 Brain Research, 1022 (1-2): 148-156, 2004
 Brain Research, 1052 (1): 105-111, 2005
 Brain Research, 912 (1): 79-88, 2001
 Breast Cancer Research and Treatment, 45 (2): 99-107, 1997
 Breast Cancer Research and Treatment, 60 (1): 15-28, 2000
 Breast Cancer Research and Treatment, 78 (1): 1-6, 2003
 Breast Cancer Research and Treatment, 78 (2): 205-216, 2003
 Breast Cancer Research and Treatment, 79 (3): 287-299, 2003
 Breast Cancer Research and Treatment, 85 (3): 229-238, 2004
 Breast Cancer Research and Treatment, 92 (2): 141-149, 2005
 Breast Cancer Research and Treatment, 92 (3): 251-263, 2005
 Breast Cancer Research, 2 (2): 139-148
 Breast Cancer Research, 7 (6): R940-R952, 2005
 British Journal of Cancer, 64 (6): 1019-1024, 1999
 British Journal of Cancer, 80 (7): 1005-1011, 1999
 British Journal of Cancer, 86 (1): 136-142, 2002
 British Journal of Cancer, 88 (3): 470-471, 2003
 British Journal of Cancer, 89 (2): 385-390, 2003
 British Journal of Cancer, 90 (11): 2232-2242, 2004
 British Journal of Cancer, 90 (2): 430-435, 2004
 British Journal of Pharmacology, 140 (1): 195-201, 2003

17 β -ESTRADIOL (cont.)

Cancer Letters, 109 (1-2): 223-230, 1996
 Cancer Letters, 132 (1-2): 107-112, 1998
 Cancer Letters, 179 (1): 43-49, 2002
 Cancer Letters, 189 (1): 49-57, 2003
 Cancer Research, 48 (4): 1143-1147, 1988
 Cancer Research, 53 (14): 3229-3232, 1993
 Cancer Research, 53 (2): 283-290, 1993
 Cancer Research, 53 (9): 2168-2177, 1993
 Cancer Research, 53 (9): 2178-2187, 1993
 Cancer Research, 54 (21): 5511-5514, 1994
 Cancer Research, 55 (18): 4146-4150, 1995
 Cancer Research, 56 (19): 4328-4331, 1996
 Cancer Research, 56 (9): 1965-1969, 1996
 Cancer Research, 57 (22): 5155-5161, 1997
 Cancer Research, 58 (2): 352-361, 1998
 Cancer Research, 58 (21): 4851-4857, 1998
 Cancer Research, 59 (15): 3646-3651, 1999
 Cancer Research, 59 (19): 5023-5029, 1999
 Cancer Research, 59 (6): 1347-1355, 1999
 Cancer Research, 60 (1): 42-46, 2000
 Cancer Research, 60 (11): 3081-3087, 2000
 Cancer Research, 60 (12): 3254-3261, 2000
 Cancer Research, 60 (17): 4804-4811, 2000
 Cancer Research, 60 (2): 213-218, 2000
 Cancer Research, 60 (24): 7094-7098, 2000
 Cancer Research, 61 (10): 4229-4237, 2001
 Cancer Research, 61 (2): 532-537, 2001
 Cancer Research, 61 (24): 8887-8895, 2001
 Cancer Research, 61 (5): 1786-1790, 2001
 Cancer Research, 61 (6): 2547-2551, 2001
 Cancer Research, 61 (7): 2857-2861, 2001
 Cancer Research, 61 (7): 2917-2922, 2001
 Cancer Research, 61 (8): 3443-3449, 2001
 Cancer Research, 62 (13): 3868-3875, 2002
 Cancer Research, 62 (5): 1439-1442, 2002
 Cancer Research, 62 (6): 1904-1909, 2002
 Cancer Research, 62 (7): 1948-1951, 2002
 Cancer Research, 62 (7): 2141-2150, 2002
 Cancer Research, 63 (10): 2425-2435, 2003
 Cancer Research, 63 (19): 6516-6522, 2003
 Cancer Research, 63 (24): 8742-8748, 2003
 Cancer Research, 63 (24): 8912-8921, 2003
 Cancer Research, 63 (9): 2139-2144, 2003
 Cancer Research, 64 (1): 415-422, 2004
 Cancer Research, 64 (11): 3958-3965, 2004
 Cancer Research, 64 (12): 4302-4308, 2004
 Cancer Research, 64 (13): 4539-4546, 2004
 Cancer Research, 64 (14): 4875-4886, 2004
 Cancer Research, 64 (17): 6127-6136, 2004
 Cancer Research, 64 (17): 6200-6206, 2004
 Cancer Research, 64 (3): 977-984, 2004
 Cancer Research, 64 (4): 1419-1424, 2004
 Cancer Research, 64 (5): 1737-1743, 2004
 Cancer Research, 65 (1): 18-25, 2005
 Cancer Research, 65 (1): 317-324, 2005
 Cancer Research, 65 (21): 9962-9970, 2005
 Cancer Research, 65 (3): 681-685, 2005
 Cancer Research, 65 (4): 1459-1470, 2005

Additional references for 17 β -Estradiol on pages 112-117

cont.

SAMPLES OF REFERENCES / IMMUNO-DEFICIENT MICE STUDIES

17 β -ESTRADIOL (cont.)

Cancer Research, 65 (9): 3815-3822, 2005
 Cancer Research, 66 (6): 3271-3277, 2006
 Cancer Research, 66 (7): 3667-3672, 2006
 Cancer Research, 66 (9): 4789-4794, 2006
 Cancer Research, 66 (12): 6063-6071, 2006
 Cancer Research, 61 (21): 10230-10240, 2007
 Cancer Research, 67 (18): 8439-8443, 2007
 Cancer Research, 67 (11): 5505-5512, 2007
 Cancer Research, 67 (9): 4254-4263, 2007
 Cancer Research, 67: 5865-5871, 2007
 Cancer Research, 67 (24): 11732-11741, 2007
 Cancer Research, 67 (7): 3412-3421, 2007
 Cancer Research, 67: 2062-2071, 2007
 Cancer Research, 67 (20): 9929-9936, 2007
 Cancer Research, 67 (23): 11463-11469, 2007
 Cancer Research, 67 (17): 8032-8042, 2007
 Cancer Science, 94 (6): 501-507, 2003
 Cancer Therapy: Preclinical, 13 (6): 1892-1902, 2007
 Cancer, Chemotherapy, and Pharmacology, 43 (3): 183-197, 1999
 Cancer, Immunology, and Immunotherapy, 51 (10): 557-564, 2002
 Carcinogenesis, 19 (11): 1895-1900, 1998
 Carcinogenesis, 26 (3): 587-595, 2005
 Carcinogenesis, 26 (4): 771-778, 2005
 Carcinogenesis, 26 (9): 1527-1535, 2005
 Cell, 130: 811-823, 2007
 Cell and Tissue Research, 304: 51-58, 2001
 Cell Growth and Differentiation, 4 (3): 193-201, 1993
 Cell Proliferation, 34 (4): 223-233, 2001
 Chemistry and Biology, 11 (6): 787-797, 2004
 Circulation Research, 93 (2): 170-177, 2003
 Circulation, 102 (24): 2983-2989, 2000
 Circulation, 103 (3): 435-441, 2001
 Circulation, 107 (24): 3059-3065, 2003
 Circulation, 108 (25): 3115-3121, 2003
 Circulation, 111 (12): 1492-1498, 2005
 Circulation, 97 (22): 2197-2201, 1998
 Clinical and Experimental Metastasis, 17 (4): 323-330, 1999
 Clinical and Experimental Metastasis, 21 (1): 65-74, 2004
 Clinical Cancer Research, 10 (12): 4038-4047, 2004
 Clinical Cancer Research, 10 (18): 6058-6065, 2004
 Clinical Cancer Research, 10 (22): 7703-7711, 2004
 Clinical Cancer Research, 10 (23): 8059-8067, 2004
 Clinical Cancer Research, 10 (4): 1530-1534, 2004
 Clinical Cancer Research, 11 (12): 4601-4609, 2005
 Clinical Cancer Research, 11 (15): 5390-5395, 2005
 Clinical Cancer Research, 11 (2): 931-936, 2005
 Clinical Cancer Research, 11 (22): 8195-8200, 2005
 Clinical Cancer Research, 11 (4): 1483-1489, 2005
 Clinical Cancer Research, 11 (5): 1983-1989, 2005
 Clinical Cancer Research, 11 (9): 3392-3401, 2005
 Clinical Cancer Research, 12 (1): 281-288, 2006
 Clinical Cancer Research, 12 (11): 3280-3287, 2006
 Clinical Cancer Research, 4 (9): 2245-2251, 1998
 Clinical Cancer Research, 5 (11): 3632-3638, 1999
 Clinical Cancer Research, 6 (11): 4373-4380, 2000
 Clinical Cancer Research, 6 (9): 3621-3628, 2000
 Clinical Cancer Research, 7 (10): 3166-3177, 2001
 Clinical Cancer Research, 7 (11): 3544-3550, 2001

17 β -ESTRADIOL (cont.)

Clinical Cancer Research, 7 (11): 3613-3624, 2001
 Clinical Cancer Research, 7 (4): 1061-1072, 2001
 Clinical Cancer Research, 7 (7): 2050-2056, 2001
 Clinical Cancer Research, 8 (4): 1008-1013, 2002
 Clinical Cancer Research, 8 (5): 1003-1007, 2002
 Clinical Cancer Research, 8 (5): 1008-1013, 2002
 Clinical Cancer Research, 8 (6): 1932-1939, 2002
 Clinical Cancer Research, 9 (15): 5514-5520, 2003
 Clinical Cancer Research, 9 (5): 1877-1884, 2003
 Clinical Cancer Research, 9 (6): 2350-2356, 2003
 Clinical Cancer Research, 9 (8): 2933-2939, 2003
 Clinical Cancer Research, 12 (11): 3280-3287, 2006
 Clinical Cancer Research, 13 (16): 4909-4919, 2007
 Clinical Cancer Research, 13: 5020-5027, 2007
 Clinical Cancer Research, 13 (3): 1061-1067, 2007
 Cytokine, 25 (2): 45-51, 2004
 Department of Neurology Series of Reports, 60: 2002
 Development, 132 (17): 3923-3933, 2005
 Developmental Brain Research, 122 (2): 149-155, 2000
 Diabetes, 51 (7): 2158-2169, 2002
 Endocrinology, 135 (6): 2615-2622, 1994
 Endocrinology, 136 (11): 4996-5003, 1995
 Endocrinology, 141 (2): 809-820, 2000
 Endocrinology, 142 (4): 1497-1505, 2001
 Endocrinology, 143 (2): 636-646, 2002
 Endocrinology, 148 (3): 1131-1143, 2007
 Endocrinology, 148 (8): 3618-3624, 2007
 Estrogen, Social Recognition Memory, and HPA Axis, 2002
 Estrogen, Social Recognition Memory, and HPA Axis, 2003
 European Journal of Cancer, 34 (3): 384-388, 1998
 European Journal of Cancer, 37 (12): 1545-1553, 2001
 European Journal of Endocrinology, 142 (4): 307-314, 2000
 European Journal of Heart Failure, 7 (7): 1079-1084, 2005
 Experimental Eye Research, 80 (3): 413-423, 2005
 Experimental Neurology, 197 (1): 197-205, 2006
 FASEB Journal Express, 18 (3): 565-567, 2004
 FASEB Journal, 16 (6): 555-564, 2002
 Federation of European Biochemical Societies (FEBS) Letters, 440 (3): 403-408, 1998
 Fertility and Sterility, 78 (5): 973-978, 2002
 Fertility and Sterility, 80 (Supplement 2): 832-838, 2003
 Fertility and Sterility, 82 (3): 673-678, 2004
 Gastroenterology, 127 (1): 239-249, 2004
 Gene Therapy, 5 (2): 240-246, 1998
 Gene Therapy, 7 (3): 241-248, 2000
 Genes Chromosomes and Cancer, 1 (1): 48-58, 1989
 Genome Biology, 7 (4): 2006
 Hormones and Behavior, 47 (3): 350-357, 2005
 Hypertension, 36 (5): 774-779, 2000
 Hypertension, 42 (6): 1157-1163, 2003
 International Journal of Cancer, 107 (2): 177-182, 2003
 International Journal of Cancer, 107 (4): 535-540, 2003
 International Journal of Cancer, 108 (1): 8-14, 2003
 International Journal of Cancer, 108 (6): 922-929, 2004
 International Journal of Cancer, 110 (5): 767-774, 2004
 International Journal of Cancer, 113 (2): 316-328, 2005
 International Journal of Cancer, 116 (6): 847-852, 2005
 International Journal of Cancer, 118 (5): 1316-1320, 2006

Additional references for 17 β -Estradiol on pages 112-117

cont.

SAMPLES OF REFERENCES / IMMUNO-DEFICIENT MICE STUDIES

17 β -ESTRADIOL (cont.)

International Journal of Cancer, 66 (5): 669-677, 1996
 International Journal of Cancer, 81 (3): 309-313, 1999
 International Journal of Cancer, 87 (5): 716-723, 2000
 International Journal of Gynecological Cancer, 13 (2): 103-110, 2003
 International Journal of Oncology, 20 (4): 813-818, 2002
 International Journal of Oncology, 21 (1): 73-80, 2002
 International Journal of Oncology, 22 (4): 835-841, 2003
 Investigative Ophthalmology and Visual Science, 44 (3): 1221-1229, 2003
 Investigative Ophthalmology and Visual Science, 44 (4): 1740-1746, 2003
 JNCI, 99 (9): 694-705, 2007
 Journal of Applied Physiology, 97 (2): 756-763, 2004
 Journal of Applied Physiology, 97 (4): 1234-1244, 2004
 Journal of Applied Physiology, 102 (5): 1387-1393, 2007
 Journal of Biological Chemistry, 227 (42): 39858-39866, 2002
 Journal of Biological Chemistry, 269 (42): 26449-26455, 1994
 Journal of Biological Chemistry, 276 (26): 23763-23768, 2001
 Journal of Biological Chemistry, 276 (45): 42259-42267, 2001
 Journal of Biological Chemistry, 277 (42): 39858-39866, 2002
 Journal of Biological Chemistry, 278 (9): 7580-7590, 2003
 Journal of Biological Chemistry, 279 (10): 8602-8607, 2004
 Journal of Biological Chemistry, 280 (29): 27022-27028, 2005
 Journal of Biological Chemistry, 282 (19): 14328-14336, 2007
 Journal of Cardiovascular Electrophysiology, 13 (3): 276-280, 2002
 Journal of Cardiovascular Pharmacology, 43 (5): 607-615, 2004
 Journal of Cell Biology, 148 (4): 779-790, 2000
 Journal of Clinical Endocrinology and Metabolism, 89 (3): 1089-1095, 2004
 Journal of Clinical Investigation, 106 (11): 1373-1379, 2000
 Journal of Clinical Investigation, 106 (6): 763-771, 2000
 Journal of Clinical Investigation, 107 (3): 333-340, 2001
 Journal of Clinical Investigation, 109 (12): 1625-1633, 2002
 Journal of Clinical Investigation, 109 (4): 541-548, 2002
 Journal of Clinical Investigation, 110 (4): 453-462, 2002
 Journal of Clinical Investigation, 116 (1): 209-216, 2006
 Journal of Clinical Investigation, 117 (1): 218-228, 2007
 Journal of Immunological Methods, 272 (1-2): 177-187, 2003
 Journal of Immunology, 152 (5): 2377-2384, 1994
 Journal of Immunology, 160 (10): 5098-5104, 1998
 Journal of Immunology, 166 (3): 2080-2089, 2001
 Journal of Immunology, 167 (4): 1886-1890, 2001
 Journal of Immunology, 174 (10): 6023-6029, 2005
 Journal of Immunology, 175 (3): 1415-1423, 2005
 Journal of Immunology, 176 (5): 2703-2710, 2006
 Journal of Inorganic Biochemistry, 77 (1): 117-120, 1999
 Journal of Lipid Research, 47 (4): 778-786, 2006
 Journal of Magnetic Resonance Imaging (JMRI), 6 (1): 195-202, 1996
 Journal of Neurochemistry, 79 (4): 796-803, 2001
 Journal of Neurochemistry, 80 (1): 191-196, 2002
 Journal of Neurochemistry, 87 (4): 1052-1055, 2003
 Journal of Neuro-Oncology, 34: 221-231, 1997
 Journal of Neuroscience Research, 77 (1): 119-126, 2004
 Journal of Neuroscience Research, 79 (3): 279-286, 2005
 Journal of Neuroscience, 22 (10): 4095-4102, 2002
 Journal of Nuclear Medicine, 44 (9): 1469-1478, 2003
 Journal of Nuclear Medicine, 46 (10): 1719-1726, 2005
 Journal of Nutrition, 131 (9): 2351-2357, 2001
 Journal of Nutrition, 132 (8): 2246-2250, 2002

17 β -ESTRADIOL (cont.)


Journal of Steroid Biochemistry and Molecular Biology, 84 (2-3): 361-367, 2003
 Journal of Steroid Biochemistry and Molecular Biology, 94 (5): 489-498, 2005
 Journal of Steroid Biochemistry, 27 (1-3): 493-498, 1987
 Journal of the American College of Cardiology, 41 (11): 2084-2092, 2003
 Journal of the National Cancer Institute, 96 (10): 739-749, 2004
 Journal of the National Cancer Institute, 96 (11): 875-878, 2004
 Journal of the National Cancer Institute, 96 (3): 210-218, 2004
 Journal of Virology, 73 (6): 5144-5148, 1999
 Laboratory Animal Science, 47 (1): 82-85, 1997
 Long-Term Estrogen Replacement and Social Memory, 2004
 Luminescence, 18 (4): 218-223, 2003
 Magnetic Resonance in Medicine, 46 (1): 31-38, 2001
 Metabolism, 52 (6): 659-661, 2003
 Molecular and Cellular Biology, 23 (19): 6887-6900, 2003
 Molecular Cancer, 65 (6): 2007
 Molecular Cancer Therapeutics, 1 (4): 239-246, 2002
 Molecular Cancer Therapeutics, 1 (6): 377-384, 2002
 Molecular Cancer Therapeutics, 2 (8): 729-737, 2003
 Molecular Cancer Therapeutics, 3 (12): 1565-1575, 2004
 Molecular Cancer Therapeutics, 3 (3): 233-244, 2004
 Molecular Cancer Therapeutics, 4 (12): 1837-1849, 2005
 Molecular Cancer Therapeutics, 5 (1): 1-7, 2006
 Molecular Cancer Therapeutics, 5 (2): 317-328, 2006
 Molecular Cancer Therapeutics, 5 (3): 685-692, 2006
 Molecular Cancer Therapeutics, 6 (9): 2458-2467, 2007
 Molecular Carcinogenesis, 19 (1): 54-66, 1997
 Molecular Endocrinology, 20 (1): 14-34, 2006
 Molecular Endocrinology, 20 (5): 996-1008, 2006
 Molecular Human Reproduction, 3 (4): 333-342, 1997
 Molecular Human Reproduction, 5 (12): 1141-1149, 1999
 Molecular Pharmacology, 65 (3): 730-743, 2004
 Molecular Therapy, 9 (4): 540-547, 2004
 Nature Biotechnology, 22 (3): 313-320, 2004
 Nature Biotechnology, 22 (6): 701-706, 2004
 Nature Medicine, 6 (4): 443-446, 2000
 Nature Medicine, 9 (8): 1026-1032, 2003
 Nature, 406 (6797): 742-747, 2000
 Neoplasia, 3 (2): 143-153, 2001
 Neoplasia, 9 (6): 487-494, 2007
 Neurobiology, 24 (7): 977-983, 2003
 Neuroendocrinology, 78 (3): 147-158, 2003
 Neuroreport, 10 (6): 1369-1372, 1999
 Neuroreport, 15 (1): 89-93, 2004
 Neuroscience, 121 (3): 659-666, 2003
 NMR in Biomedicine, 15 (2): 114-119, 2002
 NMR in Biomedicine, 17 (4): 170-180, 2004
 Nuclear Medicine and Biology, 28 (4): 397-399, 2001
 Nuclear Medicine and Biology, 31 (6): 761-770, 2004
 Nuclear Medicine and Biology, 32 (1): 51-58, 2005
 Obesity Research, 12 (4): 716-724, 2004
 Oncogene, 15 (17): 2093-2108, 1997
 Oncogene, 17 (18): 2235-2249, 1998
 Oncogene, 18 (13): 2241-2251, 1999
 Oncogene, 18 (39): 5435-5447, 1999

Additional references for 17 β -Estradiol on pages 112-117

cont.

17 β -ESTRADIOL (cont.)

Oncogene, 19 (38): 4337-4345, 2000
 Oncogene, 19 (8): 1605-1612, 2000
 Oncogene, 21 (18): 2805-2814, 2002
 Oncogene, 21 (25): 4000-4008, 2002
 Oncogene, 21 (8): 1159-1166, 2002
 Oncogene, 23 (57): 9295-9302, 2004
 Oncogene, 24 (16): 2677-2683, 2005
 Oncogene, 24 (19): 3166-3176, 2005
 Oncogene, 24 (5): 746-760, 2005
 Otolaryngology - Head and Neck Surgery, 120 (2): 262-264, 1999
 Physiology and Behavior, 74 (4-5): 653-658, 2001
 PNAS, 87 (6): 2314-2318, 1990
 PNAS, 93 (13): 6247-6251, 1996
 PNAS, 95 (5): 2648-2652, 1998
 PNAS, 95 (8): 4579-4583, 1998
 PNAS, 96 (23): 13023-13028, 1999
 PNAS, 96 (26): 15133-15136, 1999
 PNAS, 97 (4): 1754-1759, 2000
 PNAS, 97 (6): 2703-2708, 2000
 PNAS, 98 (23): 13391-13395, 2001
 Proceedings of the American Association of Cancer Research (AACR), 28: 235, 1987
 Proteomics, 4 (7): 2175-2183, 2004
 Regulatory Peptides, 124 (1): 7-17, 2005
 Society for Experimental Biology & Medicine: 754-761, 2007
 The Journal of Nuclear Medicine, 46 (11): 1866-1871, 2005
 Toxicological Sciences, 54 (2): 493-499, 2000
 Toxicological Sciences, 68 (2): 295-303, 2002



TAMOXIFEN

American Journal of Pathology, 15+B446:B5303 (6): 1993-2006, 1998
 American Journal of Physiology: Endocrinology and Metabolism, 283 (4): E623-E630, 2002
 American Journal of Physiology: Gastrointestinal and Liver Physiology, 283 (1): G27-G36, 2002
 American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 282 (3): R904-R907, 2001
 Breast Cancer Research and Treatment, 41 (1): 71-79, 1996
 Calcified Tissue International, 43 (6): 1988
 Cancer Letters, 62 (2): 107-114, 1992
 Cancer Research, 49 (15): 4090-4093, 1989
 Cancer Research, 49 (17): 4765-4769, 1989
 Cancer Research, 50 (11): 3189-3192, 1990
 Cancer Research, 53 (9): 2168-2177, 1993
 Cancer Research, 54 (21): 5511-5514, 1994
 Cancer Research, 54 (24): 6334-6337, 1994
 Cancer Research, 56 (19): 4328-4331, 1996
 Cancer Research, 57 (22): 5155-5161, 1997
 Cancer Research, 58 (2): 352-361, 1998
 Cancer Research, 60 (24): 7094-7098, 2000
 Cancer Research, 62 (7): 1948-1951, 2002
 Cancer Research, 63 (10): 2425-2434, 2003
 Cancer Research, 64 (5): 1737-1743, 2004
 Cancer Research, 65 (1): 18-25, 2005
 Cancer Research, 65 (3): 879-886, 2005
 Carcinogenesis, 8 (5): 699-703, 1987
 Cell Proliferation, 34 (4): 223-232, 2001
 Clinical Cancer Research, 4 (3): 697-711, 1998
 Clinical Cancer Research, 9 (8): 2933-2939, 2003
 Endocrinology, 136 (11): 4996-5003, 1995
 European Journal of Pharmacology, 483 (2-3): 155-162, 2004
 Hormone and Metabolic Research, 35 (11/12): 836-842, 2003
 Hormones and Behavior, 45 (4): 270-277, 2004
 International Journal of Cancer, 92 (3): 342-347, 2001
 Journal of Immunology, 175 (3): 1415-1423, 2005
 Journal of Magnetic Resonance Imaging (JMRI), 6 (1): 195-202, 1996
 Journal of Neuroendocrinology, 11 (10): 801-803, 1999
 Journal of Neuroendocrinology, 13 (7): 618-624, 2001
 Journal of Nutrition, 132 (8): 2246-2251, 2002
 Journal of Steroid Biochemistry, 27 (1-3): 493-498, 1987
 Journal of the Society for Gynecologic Investigation, 7 (4): 249-256, 2000
 Microbes and Infection, 7 (3): 485-493, 2005
 Molecular Brain Research, 108 (1-2): 121-128, 2002
 Molecular Endocrinology, 11 (7): 917-927, 1997
 Molecular Endocrinology, 20 (5): 996-1008, 2006
 Nature Immunology, 2 (1): 64-68, 2001
 Nature, 416 (6878): 334-338, 2002
 Neuroscience, 103 (2): 385-394, 2001
 Oncogene, 10 (12): 2435-2446, 1995
 Oncogene, 21 (25): 4000-4008, 2002
 Oncogene, 24 (19): 3166-3176, 2005
 PNAS, 93 (13): 6247-6251, 1996
 Proceedings of the American Association of Cancer Research (AACR), 28: 235, 1987

Additional references for 17 β -Estradiol on pages 112-117

Additional references for Tamoxifen on page 121

cont.

**TESTOSTERONE, 5 α -DIHYDROTESTOSTERONE, FLUTAMIDE
AND CYPROTERONE ACETATE
PELLETS FOR TUMOR GROWTH AND REGRESSION
IN IMMUNO-DEFICIENT MICE**

SEE PAGE 8 FOR ORDERING INFORMATION OF ANABOLIC STEROIDS

It has been established that the growth and regression of androgen-dependent tumor tissue in mice is dependent upon three factors.

1. The tumor tissue itself.
2. A healthy and untraumatized mouse.
3. Exogenous androgen or anti-hormone ready-to-implant pellets from Innovative Research of America.

The most commonly used 60-day and 90-day pellets in mice are listed below in these charts:

60-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
SA-151	Testosterone <small>(See Controlled Substances Page 8)</small>	12.5	3.0mm	\$1120	\$2025	\$3865	\$7699
SA-161	5 α -Dihydrotestosterone <small>(See Controlled Substances Page 8)</small>	12.5	3.0mm	\$1169	\$2124	\$4064	\$7998
SA-152	Flutamide	25.0	4.5mm	\$1130	\$2065	\$3945	\$7800
SC-114	Cyproterone Acetate	25.0	4.5mm	\$1403	\$2658	\$5124	N/A
SC-111	Placebo	N/A	3.0mm	\$794	\$1554	\$3004	\$5463

90-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
NA-151	Testosterone <small>(See Controlled Substances Page 8)</small>	12.5	3.0mm	\$1275	\$2290	\$4260	\$8099
NA-161	5 α -Dihydrotestosterone <small>(See Controlled Substances Page 8)</small>	12.5	3.0mm	\$1324	\$2389	\$4459	\$8498
NA-152	Flutamide	25.0	4.5mm	\$1294	\$2370	\$4350	\$8200
NC-114	Cyproterone Acetate	25.0	4.5mm	\$1528	\$2833	\$5424	N/A
NC-111	Placebo	N/A	3.0mm	\$832	\$1622	\$3123	\$5650

Note: Other products and dosages that can also be used in mouse studies are found throughout this catalog.

5 α -DIHYDROTTESTOSTERONE (5 α -DHT)

American Journal of Physiology: Cell Physiology, 274 (6): C1530-C1536, 1998
 American Journal of Physiology: Cell Physiology, 277 (1): C35-C42, 1999
 American Journal of Physiology: Endocrinology and Metabolism, 285 (1): 189-196, 2003
 American Journal of Physiology: Endocrinology and Metabolism, 285 (4): E812-E818, 2003
 American Journal of Physiology: Renal Physiology, 288 (3): F513-F520, 2005
 Biochimica et Biophysica Acta (BBA): Gene Structure and Expression, 1518 (1-2): 73-78, 2001
 Blood, 102 (2): 480-488, 2003
 Bone, 26 (1): 27-32, 2000
 Cancer Research, 50 (23): 7677-7681, 1990
 Cancer Research, 52 (19): 5171-5177, 1992
 Cancer Research, 59 (19): 5030-5036, 1999
 Cancer Research, 60 (21): 6134-6141, 2000
 Cardiovascular Research, 53 (3): 752-762, 2002
 Cerebral Cortex, 13 (3): 282-296, 2003
 Developmental Brain Research, 125 (1-2): 83-88, 2000
 Endocrinology, 130 (6): 703-714, 1992
 Endocrinology, 135 (4): 1605-1610, 1994
 Endocrinology, 135 (6): 2615-2622, 1994
 Endocrinology, 139 (2): 688-695, 1998
 Endocrinology, 140 (10): 4509-4515, 1999
 Endocrinology, 141 (12): 4698-4710, 2000
 Endocrinology, 141 (8): 2923-2929, 2000
 Endocrinology, 142 (11): 4652-4662, 2001
 Endocrinology, 142 (3): 1278-1283, 2001
 Endocrinology, 144 (10): 4478-4484, 2003
 Endocrinology, 144 (5): 2311-2318, 2003
 Endocrinology, 145 (1): 330-336, 2004
 Endocrinology, 145 (7): 3507-3522, 2004
 Endocrinology, 146 (2): 564-578, 2004
 Experimental Parasitology, 100 (4): 209-216, 2002
 Journal of Biological Chemistry, 268 (18): 13556-13564, 1993
 Journal of Biological Chemistry, 275 (22): 16536-16542, 2000
 Journal of Clinical Investigation, 108 (11): 1697-1704, 2001
 Journal of Clinical Investigation, 111 (9): 1319-1327, 2003
 Journal of Endocrinology, 189 (3): 519-528, 2006
 Journal of Experimental Medicine, 175 (5): 1409-1412, 1992
 Journal of Immunology, 159 (1): 1-6, 1997
 Journal of Immunology, 167 (4): 2060-2067, 2001
 Journal of Molecular Endocrinology, 21 (2): 217-223, 1998
 Journal of Neurobiology, 52 (4): 312-321, 2002

5 α -DIHYDROTTESTOSTERONE (5 α -DHT) (cont.)

Journal of Neurochemistry, 87 (4): 1052-1055, 2003
 Journal of Neuroimmunology, 146 (1-2): 144-152, 2004
 Journal of Orthopedic Research, 8 (4): 612-617, 1990
 Journal of Steroid Biochemistry and Molecular Biology, 52 (6): 575-580, 1995
 Journal of the National Cancer Institute, 67 (1): 51-56, 1981
 Liver, 20 (3): 228-233, 2000
 Molecular and Cellular Endocrinology, 120 (2): 133-138, 1996
 Molecular Endocrinology, 11 (7): 917-927, 1997
 Molecular Endocrinology, 13 (9): 1449-1459, 1999
 Molecular Endocrinology, 7 (7): 898-906, 1993
 Molecular Pharmacology, 65 (3): 730-743, 2004
 Neurology and Neuroscience, 2 (2): 277-286, 2002
 Neuroscience, 122 (3): 573-578, 2003
 Oncogene, 18 (39): 5435-5447, 1999
 PNAS, 100 (16): 9416-9421, 2003
 PNAS, 101 (6): 1673-1678, 2004
 PNAS, 91 (12): 5382-5386, 1994
 PNAS, 98 (9): 5211-5216, 2001
 Science, 298 (5594): 843-846, 2002
 Toxicological Sciences, 76 (1): 171-181, 2003
 American Journal of Kidney Diseases, 29 (2): 265-272, 1997
 American Journal of Obstetrics and Gynecology, 173 (5): 1491-1498, 1995
 American Journal of Obstetrics and Gynecology, 184 (3): 303-308, 2001
 American Journal of Physiology: Heart and Circulatory Physiology, 290 (4): H1610-H1616, 2006
 Biochemical and Biophysical Research Communications, 300 (1): 167-171, 2003
 Biochemical and Biophysical Research Communications, 326 (1): 181-187, 2005
 Bone, 19 (2): 107-114, 1996
 British Journal of Urology International, 96 (7): 1126-1130, 2005
 Cardiovascular Research, 57 (1): 28-36, 2003
 Cardiovascular Research, 65 (1): 148-157, 2005
 Cytokine, 25 (3): 110-118, 2004
 Diabetes, 54 (6): 1717-1728, 2005
 Drug Metabolism and Disposition, 34 (3): 377-482, 2006
 Experimental Neurology, 181 (2): 301-312, 2003
 Immunological Investigations, 32 (4): 259-273, 2003
 International Journal of Andrology, 25 (4): 210-214, 2002
 Journal of Trauma, Injury, Infection, and Critical Care, 44 (1): 78-85, 1998
 Molecular Carcinogenesis, 41 (3): 150-163, 2004
 Neuroscience, 116 (1): 213-222, 2003
 Pharmacology, Biochemistry, and Behavior, 78 (3): 513-522, 2004
 Shock, 24 (4): 318-323, 2005

Additional references for 5 α -DHT are on page 111

cont.

SAMPLES OF REFERENCES / IMMUNO-DEFICIENT MICE STUDIES

TESTOSTERONE

AAPS Journal, 3 (2): 2001
American Journal of Pathology, 159 (2): 753-764, 2001
American Journal of Pathology, 159 (3): 855-860, 2001
American Journal of Pathology, 160 (1): 219-226, 2002
American Journal of Pathology, 162 (2): 655-663, 2003
American Journal of Physiology: Heart and Circulatory Physiology, 284 (5): H1560-H1569, 2003
American Journal of Physiology: Heart and Circulatory Physiology, 290 (5): H2043-H2050, 2006
British Journal of Cancer, 81 (2): 242-251, 1999
Cancer Cell, 2 (2): 127-137, 2002
Cancer Cell, 5 (6): 565-574, 2004
Cancer Cell, 6 (5): 517-527, 2004
Cancer Research, 54 (23): 6049-6052, 1994
Cancer Research, 56 (13): 3042-3046, 1996
Cancer Research, 58 (14): 3009-3014, 1998
Cancer Research, 58 (24): 5718-5724, 1998
Cancer Research, 59 (19): 4761-4764, 1999
Cancer Research, 60 (15): 4033-4036, 2000
Cancer Research, 60 (18): 5165-5170, 2000
Cancer Research, 61 (7): 2892-2898, 2001
Cancer Research, 61 (8): 3256-3261, 2001
Cancer Research, 62 (18): 5254-5259, 2002
Cancer Research, 63 (10): 2470-2476, 2003
Cancer Research, 64 (14): 4774-4782, 2004
Cancer Research, 64 (24): 8867-8875, 2004
Cancer Research, 64 (5): 1712-1721, 2004
Cancer Research, 66 (1): 175-183, 2006
Cancer Research, 66 (11): 5723-5728, 2006
Clinical Cancer Research, 12 (8): 3870-3876, 2002
Clinical Cancer Research, 7 (4): 962-970, 2001
Clinical Cancer Research, 8 (12): 3870-3876, 2002
Clinical Cancer Research, 8 (4): 986-993, 2002
Clinical Cancer Research, 8 (5): 986-993, 2002
Clinical Cancer Research, 9 (12): 4529-4536, 2003
Cytometry, 35 (1): 2-10, 1999
Endocrinology, 140 (5): 2372-2381, 1999

TESTOSTERONE (cont.)

Endocrinology, 142 (1): 139-146, 2001
Endocrinology, 148 (7): 3089-3101, 2007
Endocrinology, 148 (7): 3383-3390, 2007
European Urology, 45 (3): 382-389, 2004
Experimental and Molecular Pathology, 79 (1): 23-32, 2005
International Journal of Cancer, 82 (3): 424-429, 1999
Journal of Andrology, 22 (4): 537-548, 2001
Journal of Biological Chemistry, 278 (1): 1-45, 2003
Journal of Biological Chemistry, 279 (8): 7119-7130, 2004
Journal of Cellular Physiology, 178 (3): 371-378, 1999
Journal of Clinical Investigation, 114 (12): 1774-1781, 2004
Journal of Clinical Investigation, 116 (1): 209-216, 2006
Journal of Nuclear Medicine, 45 (3): 519-525, 2004
Journal of Nuclear Medicine, 48 (3): 420-428, 2007
Journal of the National Cancer Institute, 85 (5): 394-398, 1993
Journal of the National Cancer Institute, 91 (21): 1869-1876, 1999
Journal of Urology, 161 (3): 945-949, 1999
Journal of Urology, 170 (2): 615-618, 2003
Molecular and Cellular Biology, 26 (3): 965-975, 2006
Molecular Endocrinology, 11 (4): 450-459, 1997
Nuclear Medicine and Biology, 29 (8): 783-790, 2002
Oncogene, 21 (33): 5069-5080, 2002
PNAS, 100 (1): 11896-11903, 2003
PNAS, 103 (6): 1888-1893, 2006
PNAS, 98 (6): 3589-3593, 2001
PNAS, 99 (3): 1527-1531, 2002
Prostate, 51 (2): 73-83, 2002
Prostate, 51 (4): 247-255, 2002
Prostate, 57 (1): 1-7, 2003
Prostate, 57 (1): 24-31, 2003
Prostate, 60 (2): 77-90, 2004
Prostate, 60 (2): 91-97, 2004
Prostate, 62 (4): 322-338, 2005
Prostate, 63 (1): 91-103, 2005

Additional references for Testosterone are on pages 121-122

IRA

IMPLANTATION


Implantation of our Time Release Pellets

Implantation of our time release pellets can be done with and without using our Precision Trochar. The following section contains information about our Trochar as well as offers two detailed recommended implantation procedures to fit your experimental needs.

For pellets ranging in size from 0.001 mg/pellet up to 5mg/pellet (3mm in diameter) our MP-182 10 Gauge Precision Trochar is suitable. Please view page 81 for further information regarding the use of our Trochar. Our Trochar is also suitable for tissue implantation.

For implantation of pellets larger than 5mg/pellet (3mm in diameter) in size, please view page 123 for our detailed recommended implantation procedure with and without using a Trochar.

NOTE: In order to ensure reliable and continued performance the pellet should not come in contact at the time of implantation with any organic solvent or exogenous fluid.



**Please inquire directly with us if further assistance is required regarding your pellet implantation needs.*

Pellets Capture The Change In Research





IRA

TROCHAR INFORMATION


Stainless steel reusable precision trochar with regular point needle and rounded stylet protruding 1/8" from needle point for easy implantation of small pellets up to 3mm in diameter (usually 0.001 mg up to 5 mg/pellet).

MP - 182	10 Gauge	\$ 240.00
MP - 181	12 Gauge	(Please Inquire)

NOTE: Physical restrictions on the pellet could alter the release rate. An injury to the muscle will cause local inflammation. The most ideal place to implant the pellet is where there is maximal space between the skin and the muscle such as the lateral side of the neck between the ear and the shoulder.

A. HOW TO USE TROCHAR FOR SMALL PELLETT IMPLANTATION

1. Put pellet in a standing position on needle of trochar, away from sharp edge and press gently.
2. Pellet should be stable in that position so that if trochar is pointed downward pellet will not fall.
3. Put obturator half way in trochar and hold with stronger hand. With other hand lift skin on the lateral side of the neck of the animal and insert trochar. When the pellet in the trochar contacts the skin, twist the trochar sideways and insert pellet. Then, push with obturator all the way. Total distance from incision is about 2 cm.



When either technique is properly executed no antibiotics or stitches are needed and the animal should not bleed.

IMPORTANT: In order to ensure reliable and continued performance, the pellet should not come in contact at the time of implantation with any organic solvent or exogenous fluid.

**Please inquire directly with us if further assistance is required regarding a product of interest.*

Discover The Ultimate Time-Saving Device





ATTENTION

The three parameters in successful estrogen-dependent tumor heterotransplantation in immuno-deficient mice are:

- 1) The tumor cells have to be mycoplasma-free, be grown to full monolayer (preferably with domes), and harvested with a rubber policeman (not with trypsin-EDTA) because these are epithelial cells and fare better as a clump. Metastasis depends on the metastatic potential of the cell sub-line.
- 2) The mouse should be healthy and always checked for staph infection and/or mouse pox.
 - Signs of mouse pox are dry skin and body weight loss.
 - Signs of staph infection are red rashes on one or more of the following sites:
 - (a) Nostrils
 - (b) Lips
 - (c) Vagina
 - (d) Anal Cavity

* Staph infection potentiates an immune buildup which hinders the tumor growth and metastasis and can lead to bladder stones.
- 3) The 17β -Estradiol pellet for estrogen dependent tumor growth and metastasis. We offer four doses (1.7mg/pellet, 0.72 mg/pellet, 0.36mg/pellet, and 0.18mg/pellet). All four doses support tumor growth, but at a different rate.

The highest dose is supposed to give the best and fastest results when the mouse and the cells are in the best condition. If the mouse and/or cells are not in the best condition, then the lower doses are options, however, it could take a little longer to achieve the results.



Maximum Flexibility

SAMPLE OF TESTIMONIALS

Major University School of Medicine, from Researcher

"I am writing to tell you of my experiences using your pellets. They are more reliable and more easily manipulated than other methods of drug delivery. They are less time consuming than injections and superior to silastic tubing. Our preliminary results with these pellets have been impressive..."

Veterans Administration, from Professor

"I was pleased to learn of the worldwide interest in our work which has been directed to you. Dr. X and I are appreciative of the excellent quality of the pellets that you have provided which gave uniform and predictable growth factor release both in this study and the earlier one reported in..."

National Institutes of Health, from Senior Scientist

"We purchased pellets from your company containing epidermal growth factor (EGF), insulin-like growth factor 1 (IGF), and transforming growth factor beta (TGFβ). Our results have been great, far beyond our expectations...I want to congratulate you and your staff for doing fast, reliable and excellent work."

Research Center, Major Medical School, from Professor

"We wish to let you know that, thanks to custom pellets made by your company, we are now able to ask questions about the formation of new blood vessels that were unapproachable until now. We have had great success using your pellets in the past, and anticipate using them extensively in the future. I have recommended your company to a number of associates, and I will continue to do so."

Major Pharmaceutical Company, from Director

"As we discussed over the telephone, I am sending you the rat data with subcutaneous pellets and rabbit data with oral pellets. We are very happy with your subcutaneous pellets. During the second and third weeks after implantation, we achieved the designated plasma levels (10 to 20ng/ml) with 20 or 40mg pellets. I would like to congratulate you and your associates for a job well done."

Keep It Simple



ORDERING INFORMATION

REQUIRED INFORMATION

Orders may be placed by telephone, fax, mail, online or e-mail. For your convenience, order forms can be found in the back of this catalog.

For the processing of each order, the following information is required:

- ... Purchase Order Number or Credit Card (see below)
- ... Ship-to address
- ... Bill-to address
- ... Catalog number and name of product
- ... Quantity, unit, dose, and release time

TO ORDER

• Mail

Innovative Research of America, Inc.
2 North Tamiami Trail
Suite 404
Sarasota, Florida 34236 USA

• Phone

(941) 365-1406
(941) 365-1506
(800) 421-8171 (USA/Canada)

• Fax

(941) 365-1703
(941) 365-1803
(800) 643-4345 (USA/Canada)
(800) 648-6030 (USA/Canada)

• Internet / E-mail

<http://www.innovrsrch.com> (website)
pellets@innovrsrch.com (e-mail)

IRA's website features our company profile, the latest product technology and **on-line ordering**.



AMERICAN EXPRESS, VISA & MASTERCARD ACCEPTED.



Purchase Order Forms - See back of Catalog.



Custom Pellets Information Form on page 95.

Bank Wire Payment Information

Payment via bank wire should be directed as follows:

BB&T Bank
1800 Second St., Suite 100
Sarasota, Florida 34236
Routing # (ABA) 263191387
Electronic Transfers #
263191387

In favor of:
Innovative Research of America
2 North Tamiami Trail
Suite 404
Sarasota, FL 34236
Checking Account: #0000147816154
Swift Code: BRBTUS33

TECHNICAL INQUIRIES

To receive technical assistance or request information about our product line, we encourage you to contact us via mail, phone, fax or e-mail.



It Is An Easier Way With IRA

IRA

DOXYCYCLINE & TETRACYCLINE IN MICE

Special Common Doses in a 21 Day, 60 Day and 90 Day Release Pellet



INNOVATIVE RESEARCH OF AMERICA
ALLOWS YOU TO CONTROL

TIME IN A PELLETT
CONSTANT PRODUCT RELEASE FOR A
SUCCESSFUL EXPERIMENT.

On the following pages are the most commonly used
21 Day, 60 Day and 90 Day Release pellets for the
products Doxycycline and Tetracycline in Mice.

Also available are a list of sample references citing the use
of these common doses. Further publications may be
viewed at our website: www.innovrsrch.com

**Please inquire directly with us if further assistance is required regarding a product of interest.*

Variables Vanish While Saving You Time





DOXYCYCLINE & TETRACYCLINE IN MICE

Please see the following page for information
on Doxycycline and Tetracycline in mice
and for specific references.



Time Release Pellets . . . Always On Time



DOXYCYCLINE AND TETRACYCLINE IN MICE

Listed below are the most commonly used 21-day, 60-day and 90-day release pellets in mice:

21-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose mg/pellet	Pellet Size	PRICE/NUMBER OF PELLETS			
				25	50	100	200
B-168	Doxycycline	15.0	3.0mm	\$989	\$1909	\$3579	\$6649
B-151	Tetracycline	15.0	3.0mm	\$989	\$1909	\$3579	\$6649
C-111	Placebo	N/A	3.0mm	\$752	\$1529	\$2974	\$5258

Note: Other Doxycycline and Tetracycline dosages may also be used and are found on pages 28 & 40.

60-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose mg/pellet	Pellet Size	PRICE/NUMBER OF PELLETS			
				25	50	100	200
SB-168	Doxycycline	42.0	4.5mm	\$1231	\$2276	\$4356	\$7699
SB-151	Tetracycline	42.0	4.5mm	\$1231	\$2276	\$4356	\$7699
SC-111	Placebo	N/A	4.5mm	\$858	\$1624	\$3084	\$5564

Note: Other Doxycycline and Tetracycline dosages may also be used and are found on pages 28 & 40.

90-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose mg/pellet	Pellet Size	PRICE/NUMBER OF PELLETS			
				25	50	100	200
NB-168	Doxycycline	63.0	6.0mm	\$1439	\$2672	\$4983	\$8545
NB-151	Tetracycline	63.0	6.0mm	\$1439	\$2672	\$4983	\$8545
NC-111	Placebo	N/A	6.0mm	\$899	\$1698	\$3213	\$5766

Note: Other Doxycycline and Tetracycline dosages may also be used and are found on pages 28 & 40.

SAMPLES OF REFERENCES / DOXYCYCLINE & TETRACYCLINE IN MICE

DOXYCYCLINE

Cancer Research, 62:1588-1591 (2002)
 Diabetes, 55 (12): 3520-3528 (2006)
 Gene, 369: 80-89 (2006)
 Human Molecular Genetics, 10 (19): 2039-2047 (2001)
 Journal of Clinical Investigation, 108 (2): 319-329 (2001)
 Journal of Gene Medicine, 7 (6): 817-828 (2004)
 Oncogene, 21: 4435-4447 (2002)
 PNAS, 95 (12): 580-585 (1998)
 PNAS, 97 (16): 9209-9214 (2000)
 PNAS, 99 (10): 6973-6978 (2002)
 Transgenic Research, 2 (12): 171-178 (2003)

TETRACYCLINE


Blood, 96 (6): 2108-2115 (2000)
 Cancer Research, 62 (5): 2749-2752 (2002)
 Cancer Research, 61 (7): 3110-3118 (2001)
 Development, 128: 1531-1538 (2001)

TETRACYCLINE (cont.)

European Molecular Biology Organization Journal, 16 (10): 2814-2825 (1997)
 Gene Therapy, 12 (5): 452-460, (2005)
 Gene Therapy, 12 (4): 80-89 (2006)
 Journal of Biological Chemistry, 272 (47): 29482-29486 (1997)
 Journal of Biological Chemistry, 276 (17): 13989-13994 (2001)
 Journal of Cellular Biochemistry, 59: 463-472 (1995)
 Journal of Immunology, 163: 4721-4727 (1999)
 Journal of National Cancer Institute, 19 (90): 1451-1460 (1998)
 Molecular and Cellular Biology, 21 (17): 5958-5969 (2001)
 Nature Biotechnology, 14: 499-503 (1996)
 Nature Biotechnology, 16: 757-761 (1998)
 Nucleic Acids Research, 24 (19): 3875-3877 (1996)
 Oncogene, 15 (7): 851-856 (1997)
 Oncogene, 18 (46): 6343-6356 (1999)
 PNAS, 91 (20): 9302-9306 (1994)
 PNAS, 92 (8): 3576-3580 (1995)
 Science, 273: 1384-1386 (1996)

PRECISION TROCHAR

Please see page 81 for information
on the 10-Gauge Precision Trochar.




More Time For Creative Research



Alphabetical stock product listings can be found on pages 21-42

Stock Pellet prices can be found on pages 45-71

Stock Pellet doses and prices for tumor studies in
mice can be found on pages 73-80



INNOVATIVE RESEARCH OF AMERICA

ALLOWS YOU TO CONTROL

TIME IN A PELLET

CONSTANT PRODUCT RELEASE FOR A

SUCCESSFUL EXPERIMENT.

Custom Pellet information can be found on pages 93-108.



Time in a Pellet . . . To Save You Time

IRA

HORMONE + HORMONE PELLETS

(Two to three hormones in one pellet)

The following price schedules are for 17 β -Estradiol + Progesterone combined in one pellet. These pellets are offered in several Estradiol/Progesterone ratios in 21 Day, 60 Day and 90 Day Release forms. For other hormone combinations please view pages 90-92.

Available Stock Combinations

17 β -Estradiol + Progesterone	17 β -Estradiol + Progesterone + Hydrocortisone	17 α -Ethinyl Estradiol + Norethindrone
17 β -Estradiol + Hydrocortisone	Hydrocortisone + Progesterone	Mestranol + Norethindrone

NOTE: In order to ensure reliable and continued performance the pellet should not come in contact at the time of implantation with any organic solvent or exogenous fluid.

**Please inquire directly with us if further assistance is required regarding a product of interest.*

Pellets Capture The Change In Research





HORMONE + HORMONE PELLETS

(Two or three hormones in one pellet)

Following are price schedules for 17 β -Estradiol + Progesterone combined in one pellet. The pellets are offered in several Estradiol/Progesterone ratios and in 21-day, 60-day or 90-day release forms. Other hormone combinations are on pages 90-92.

21-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
HH-111	17 β -Estradiol (0.1) + Progesterone (10.0)	10.1	\$1113	\$2110	\$3803	\$6883
HH-112	17 β -Estradiol (0.5) + Progesterone (10.0)	10.5	\$1128	\$2140	\$3848	\$6958
HH-113	17 β -Estradiol (0.1) + Progesterone (32.5)	32.6	\$1152	\$2196	\$3928	\$7094
HH-114	17 β -Estradiol (0.5) + Progesterone (32.5)	33.0	\$1167	\$2226	\$3973	\$7169
HH-115	17 β -Estradiol (any size) + Progesterone (any size)	—	\$1192	\$2251	\$4023	\$7244

60-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
SHH-111	17 β -Estradiol (0.1) + Progesterone (10.0)	10.1	\$1203	\$2237	\$4020	\$7227
SHH-112	17 β -Estradiol (0.5) + Progesterone (10.0)	10.5	\$1218	\$2267	\$4065	\$7302
SHH-113	17 β -Estradiol (0.1) + Progesterone (32.5)	32.6	\$1233	\$2282	\$4095	\$7347
SHH-114	17 β -Estradiol (0.5) + Progesterone (32.5)	33.0	\$1248	\$2312	\$4140	\$7422
SHH-115	17 β -Estradiol (any size) + Progesterone (any size)	—	\$1298	\$2362	\$4240	\$7572

90-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
NHH-111	17 β -Estradiol(0.1) + Progesterone (10.0)	10.1	\$1249	\$2274	\$4245	\$7585
NHH-112	17 β -Estradiol(0.5) + Progesterone (10.0)	10.5	\$1264	\$2290	\$4279	\$7599
NHH-113	17 β -Estradiol(0.1) + Progesterone (32.5)	32.6	\$1279	\$2326	\$4355	\$7725
NHH-114	17 β -Estradiol(0.5) + Progesterone (32.5)	33.0	\$1294	\$2373	\$4379	\$7799
NHH-115	17 β -Estradiol(any size) + Progesterone (any size)	—	\$1344	\$2415	\$4425	\$7825

17 β -Estradiol + Hydrocortisone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
HH-121	17 β -Estradiol (2.5) + Hydrocortisone (2.5)	5.0	\$1113	\$2110	\$3803	\$6883
HH-122	17 β -Estradiol (7.5) + Hydrocortisone (7.5)	15.0	\$1152	\$2196	\$3928	\$7094
HH-125	17 β -Estradiol (any size) + Hydrocortisone (any size)	—	\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
SHH-121	17 β -Estradiol (2.5) + Hydrocortisone (2.5)	5.0	\$1203	\$2237	\$4020	\$7227
SHH-122	17 β -Estradiol (7.5) + Hydrocortisone (7.5)	15.0	\$1233	\$2282	\$4090	\$7347
SHH-125	17 β -Estradiol (any size) + Hydrocortisone (any size)	—	\$1298	\$2362	\$4240	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
NHH-121	17 β -Estradiol (2.5) + Hydrocortisone (2.5)	5.0	\$1249	\$2274	\$4245	\$7585
NHH-122	17 β -Estradiol (7.5) + Hydrocortisone (7.5)	15.0	\$1279	\$2326	\$4355	\$7725
NHH-125	17 β -Estradiol (any size) + Hydrocortisone (any size)	—	\$1344	\$2415	\$4425	\$7825

17 β -Estradiol + Progesterone + Hydrocortisone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
HH-141	17 β -Estradiol (0.1) + Progesterone (10.0) + Hydrocortisone (1.0)	11.1	\$1113	\$2140	\$3803	\$6883
HH-142	17 β -Estradiol (0.3) + Progesterone (30.0) + Hydrocortisone (3.0)	33.3	\$1152	\$2196	\$3928	\$7094
HH-145	17 β -Estradiol (any size) + Progesterone (any size) + Hydrocortisone (any size)	—	\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
SHH-141	17 β -Estradiol (0.1) + Progesterone (10.0) + Hydrocortisone (1.0)	11.1	\$1203	\$2237	\$4020	\$7227
SHH-142	17 β -Estradiol (0.3) + Progesterone (30.0) + Hydrocortisone (3.0)	33.3	\$1233	\$2282	\$4090	\$7347
SHH-145	17 β -Estradiol (any size) + Progesterone (any size) + Hydrocortisone (any size)	—	\$1298	\$2362	\$4240	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
NHH-141	17 β -Estradiol (0.1) + Progesterone (10.0) + Hydrocortisone (1.0)	11.1	\$1249	\$2274	\$4245	\$7585
NHH-142	17 β -Estradiol (0.3) + Progesterone (30.0) + Hydrocortisone (3.0)	33.3	\$1279	\$2326	\$4355	\$7725
NHH-145	17 β -Estradiol (any size) + Progesterone (any size) + Hydrocortisone (any size)	—	\$1344	\$2415	\$4425	\$7825

Hydrocortisone + Progesterone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
HH-161	Hydrocortisone (1.0) + Progesterone (10.0)	11.0	\$1113	\$2110	\$3803	\$6883
HH-162	Hydrocortisone (3.0) + Progesterone (30.0)	33.0	\$1152	\$2196	\$3928	\$7094
HH-165	Hydrocortisone (any size) + Progesterone (any size)	—	\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
SHH-161	Hydrocortisone (1.0) + Progesterone (10.0)	11.0	\$1203	\$2237	\$4020	\$7227
SHH-162	Hydrocortisone (3.0) + Progesterone (30.0)	33.0	\$1233	\$2282	\$4090	\$7347
SHH-165	Hydrocortisone (any size) + Progesterone (any size)	—	\$1298	\$2362	\$4240	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
NHH-161	Hydrocortisone (1.0) + Progesterone (10.0)	11.0	\$1249	\$2274	\$4245	\$7585
NHH-162	Hydrocortisone (3.0) + Progesterone (30.0)	33.0	\$1279	\$2326	\$4355	\$7725
NHH-165	Hydrocortisone (any size) + Progesterone (any size)	—	\$1344	\$2415	\$4425	\$7825

17 α -Ethinyl Estradiol + Norethindrone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
HH-171	17 α -Ethinyl Estradiol (0.02) + Norethindrone (1.0)	1.02	\$1113	\$2110	\$3803	\$6883
HH-172	17 α -Ethinyl Estradiol (0.03) + Norethindrone (1.5)	1.53	\$1113	\$2111	\$3804	\$6884
HH-173	17 α -Ethinyl Estradiol (0.2) + Norethindrone (10.0)	10.20	\$1113	\$2112	\$3805	\$6885
HH-174	17 α -Ethinyl Estradiol (0.2) + Norethindrone (30.0)	30.20	\$1152	\$2196	\$3928	\$7094
HH-175	17 α -Ethinyl Estradiol (any size) + Norethindrone (any size)	—	\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
SHH-171	17 α -Ethinyl Estradiol (0.02) + Norethindrone (1.0)	1.02	\$1203	\$2237	\$4020	\$7227
SHH-172	17 α -Ethinyl Estradiol (0.03) + Norethindrone (1.5)	1.53	\$1233	\$2237	\$4020	\$7227
SHH-173	17 α -Ethinyl Estradiol (0.2) + Norethindrone (10.0)	10.20	\$1233	\$2237	\$4020	\$7227
SHH-174	17 α -Ethinyl Estradiol (0.2) + Norethindrone (30.0)	30.20	\$1233	\$2282	\$4290	\$7347
SHH-175	17 α -Ethinyl Estradiol (any size) + Norethindrone (any size)	—	\$1298	\$2362	\$4450	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
NHH-171	17 α -Ethinyl Estradiol (0.02) + Norethindrone (1.0)	1.02	\$1249	\$2274	\$4245	\$7585
NHH-172	17 α -Ethinyl Estradiol (0.03) + Norethindrone (1.5)	1.53	\$1249	\$2274	\$4245	\$7585
NHH-173	17 α -Ethinyl Estradiol (0.2) + Norethindrone (10.0)	10.20	\$1249	\$2274	\$4245	\$7585
NHH-174	17 α -Ethinyl Estradiol (0.2) + Norethindrone (30.0)	30.20	\$1279	\$2326	\$4355	\$7725
NHH-175	17 α -Ethinyl Estradiol (any size) + Norethindrone (any size)	—	\$1344	\$2415	\$4425	\$7825

Mestranol + Norethindrone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
HH-181	Mestranol (0.03) + Norethindrone (1.0)	1.03	\$1113	\$2110	\$3803	\$6883
HH-182	Mestranol (0.1) + Norethindrone (4.0)	4.10	\$1113	\$2110	\$3803	\$6883
HH-183	Mestranol (0.5) + Norethindrone (20.0)	20.50	\$1152	\$2196	\$3928	\$7094
HH-185	Mestranol (any size) + Norethindrone (any size)	—	\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
SHH-181	Mestranol (0.03) + Norethindrone (1.0)	1.03	\$1203	\$2237	\$4020	\$7227
SHH-182	Mestranol (0.1) + Norethindrone (4.0)	4.10	\$1203	\$2237	\$4020	\$7227
SHH-183	Mestranol (0.5) + Norethindrone (20.0)	20.50	\$1233	\$2282	\$4095	\$7347
SHH-185	Mestranol (any size) + Norethindrone (any size)	—	\$1298	\$2362	\$4240	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS			
			25	50	100	200
NHH-181	Mestranol (0.03) + Norethindrone (1.0)	1.03	\$1249	\$2274	\$4245	\$7585
NHH-182	Mestranol (0.1) + Norethindrone (4.0)	4.10	\$1249	\$2274	\$4245	\$7585
NHH-183	Mestranol (0.5) + Norethindrone (20.0)	20.50	\$1279	\$2326	\$4355	\$7725
NHH-185	Mestranol (any size) + Norethindrone (any size)	—	\$1344	\$2415	\$4425	\$7825



CUSTOM PELLETS

The Closest Thing Yet To An Ideal Drug Delivery Method

In addition to the listed stock items on pages 21-42, Innovative Research of America provides scientists with an efficient and innovative Custom Pellets Department for products and sizes that are not carried in stock.

Our innovative process, tailored for any specific product, gives scientists time release pellets that consistently deliver the active product *in vivo*.

Custom pellets minimize the experimental variables, extend the product shelf life, and help avoid the "peak and valley" effects produced by conventional delivery methods.

The Alternative Solution

Whether the custom product is a small peptide or a large protein, a lymphokine or a cytokine, a growth factor or an antibody, an anti-hormone or an inhibitor, we have the proper technology that produces ready-to-implant custom pellets.

When supplied with your product and the required information on page 95, we will design the proper matrix with regard to dosage and release rate to provide you with the finished product in a ready-to-implant pellet form.

Each Custom order will include (25 Placebo Pellets)

FREE of charge for each individual choice of dose.

We can also design time-release pellets in a variety of sizes, shapes and doses. Please inquire.

Use Time Release Pellets Or Take Your Chances





CUSTOM PELLETS PRICE LIST


RELEASE RATES

Number of Pellets	Up to 21 days Cat. No. X-999	Up to 60 days Cat. No. SX-999	Up to 90 days Cat. No. NX-999
25	\$1250	\$1425	\$1550
50	\$2125	\$2425	\$2600
100	\$3800	\$4200	\$4500
200	\$7100	\$7800	\$8400

*Each Custom Order will include 25 Placebo Pellets Free of Charge.
Above Prices are for one product in one dose.
Prices for additional Placebo Pellets can be found on Pages 17-19.

These prices do not apply to 1/16" diameter, 3/32" diameter, rod shaped or special shaped pellets. See page 94 for small size custom pellets.

We can also design tools to make time-release pellets in any size, shape or dose.
PLEASE INQUIRE.



We Put More Than Time In Our Pellets



SMALL SIZE CUSTOM PELLETS

1/16" (1.5 mm) diameter and 3/32" (2.25 mm) diameter.


In keeping with the innovative standards of our company, Innovative Research of America provides the scientific community with small size pellet services. These pellets are designed especially for experiments that have pellet size restrictions.

Small size pellets are available in two different sizes, 1/16" (1.5 mm) diameter and 3/32" (2.25 mm) diameter and can be prepared into any thickness and varying lengths of release time up to 90 days.

When ordering small size pellets, please indicate the size.

The minimum order of the small size preparation is 25 pellets.

Quantity	Cat. No.	Description	Release Rate	Price
25	Y-999	One product in one dose	Up to 21 days	\$1300
25	CY-999	Placebo for one product in one dose	Up to 21 days	\$1050
25	SY-999	One product in one dose	Up to 60 days	\$1475
25	SCY-999	Placebo for one product in one dose	Up to 60 days	\$1225
25	NY-999	One product in one dose	Up to 90 days	\$1625
25	NCY-999	Placebo for one product in one dose	Up to 90 days	\$1325



We can also design tools to make time-release pellets in any size, shape or dose.
PLEASE INQUIRE.



Go With The Pellet That Delivers

CUSTOM PELLETS INFORMATION FORM

In order to help us prepare the highest quality Custom Pellets that *precisely* meet your needs and specifications we require that you complete and submit a copy of this form with each order.

Please Attach Purchase Order Along With Shipping and Billing Addresses. Allow 4-6 weeks for delivery.

PURCHASE ORDER NUMBER: _____

INSTITUTION: _____

INVESTIGATOR'S NAME: _____ E-MAIL ADDRESS: _____

TELEPHONE NUMBER: _____ FAX NUMBER: _____

COMPOUND NAME OR CODE NAME (no controlled substances accepted and should be clearly labeled for research purpose only)

IS THE ABOVE COMPOUND A CONTROLLED SUBSTANCE? YES NO

IS THE ABOVE COMPOUND LABELED FOR RESEARCH PURPOSE ONLY? YES NO

AMOUNT OF COMPOUND SHIPPED: _____

CHEMICAL IDENTITY/MOLECULAR WEIGHT: _____

INTRINSIC SOLUBILITY: WATER, ALCOHOL, LIPID: _____

HEAT, COLD, LIGHT SENSITIVITY: _____

HALF-LIFE OF COMPOUND IN ANIMAL: _____

DESIRED BLOOD LEVELS : _____

REQUIRED PELLET RELEASE TIME & DOSE PER PELLET: _____

NUMBER OF PELLETS REQUESTED: _____

ANIMAL: GENDER, AVERAGE WEIGHT, AGE: _____

TOXICITY: _____

It is the responsibility of the investigator to provide all proteins, growth factors and peptides in a crystalline, powder or lyophilized form. IRA will be happy to provide, if necessary, a matrix stabilizer to increase the mass of the product. Due to residual loss in our multi-stage process, supply at least 50% more product than you request in pellet form. Please include your completed order form with Custom Pellet information form.

INNOVATIVE RESEARCH OF AMERICA CONTACT INFORMATION:

2 NORTH TAMiami TRAIL, SUITE 404

SARASOTA, FLORIDA 34236 USA

PHONE:

(941) 365-1406

(941) 365-1506

(800) 421-8171 (USA/Canada)

FAX:

(941) 365-1703

(941) 365-1803

(800) 643-4345 (USA/Canada)

(800) 648-6030 (USA/Canada)

INTERNET / E-MAIL:

<http://www.innovrsrch.com>

pellets@innovrsrch.com

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Acetyl-(LYSO, NLE3)-Y2-MSH AMIDE

Journal of Endocrinology, 191: 677-686 (2006)

Acetylsalicylic Acid (ASA)

Cancer, 71 (2): 486-492 (1993)

Comparative Medicine, 55 (5): 452-458 (2001)

Adenine

Proceedings of the National Academy of Sciences (PNAS), 97 (12): 6716-6721 (1997)

Aldactone

Hypertension, 41 (2): 201-206 (2003)

Allodihydrocortisone

Molecular Endocrinology, 11 (7): 917-927 (1997)

Allopregnanolone

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 278 (3): R684-R691 (2000)

Amifostine

International Journal of Radiation Biology, 78 (6): 535-543 (2002)

Amphiregulin

Development, 132 (17): 3923-3933 (2005)

Anastrozole

Experimental Physiology, 98 (1): 161-171 (2013)

5 α -Androstan-3 α , 17 β -diol

Molecular Endocrinology, 10 (4): 380-392 (1996)

Molecular Endocrinology, 11 (7): 917-927 (1997)

2, (5 α)-Androsten-17 β -ol

Experimental Eye Research, 51 (6): 659-666 (1995)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

Angiotensin II

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 278 (3): R640-R645 (2000)

American Journal of Physiology: Renal Physiology, 277 (1): F41-F47 (1999)

Arteriosclerosis, Thrombosis and Vascular Biology, 25 (2): 365-371 (2005)

Circulation, 104 (3): 346-351 (2001)

EMBO Journal, 22 (24): 6471-6482 (2003)

Public Library of Science (PLoS ONE), 7 (4): e35632 (2012)

Anti-Viral

American Journal of Physiology: Endocrinology and Metabolism, 292 (1): E40-E48 (2007) (**Indinavir**)

Cancer Research, 65 (18): 8256-8265 (2005) (**Nelfinavir**)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (**Amprenavir**)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (**Indinavir**)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (**Nelfinavir**)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (**Saquinavir**)

Seventh European Conference on Clinical Aspects and Treatment of HIV Infection, 31-34 (1999) (**Indinavir**)

Seventh European Conference on Clinical Aspects and Treatment of HIV Infection, 31-34 (1999) (**Nelfinavir**)

Arimidex

Molecular Endocrinology, 11 (7): 917-927 (1997)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Asoprisnil

Steroids, 74 (13-14): 1015-1024 (2009)

Atrazine

Basic and Clinical Pharmacology and Toxicology, 102: 139-145 (2008)

Toxicology and Applied Pharmacology, 214 (1): 69-77 (2006)

Bazedoxifene

Clinical Cancer Research, 19 (9): 2420-2431 (2013)

Bisphenol A (BPA)

Biology of Reproduction, 85 (3): 490-497 (2011)

Cancer Causes and Control, 20 (7): 1029-1037 (2009)

Dissertation, 1-214 (2008)

International Journal of Andrology, 33 (2): 385-393 (2010)

Molecular Cancer Therapeutics, 5 (12): 3181-3190 (2006)

Public Library of Science (PLoS) Genetics, 3 (1): e5 (2007)

Reproductive Toxicology, 24 (2): 240-252 (2007)

Brilliant Blue G (BBG)

Journal of Neuroscience, 27 (35): 9525-9535 (2007)

Calimycin

Prostate, 13 (1): 103-117 (1988)

Camostat Mesilate (CM)

American Journal of Physiology: Renal Physiology, 303 (8): F1126-F1135 (2012)

American Journal of Physiology: Renal Physiology, 305 (2): F174-F181 (2013)

Carvedilol

American Journal of Physiology: Heart and Circulatory Physiology, 287 (3): H1003-H1012 (2004)

Casodex (Bicalutamide)

Endocrinology, 154 (9): 3168-3177 (2013)

Proceedings of the National Academy of Sciences (PNAS), 108 (12): 4938-4943 (2011)

CDB-4124

Cancer Prevention Research, 4 (3): 414-424 (2011)

Cholera Toxin

Carcinogenesis, 9 (7): 1113-1119 (1988)

Clordecone

Environmental Health Perspectives, 113: 323-328 (2005)

Toxicology, 218 (2): 81-89 (2006)

Compound A (CpdA)

Journal of Bone and Mineral Research, 27 (11): 2242-2250 (2012)

Cortisol Hemisuccinate

Placenta, 31: 1064-1069 (2010)

CP-113,818

Chembiochem, 10 (8): 1344-1347 (2009)

Neuron, 44 (2): 227-238 (2004)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

CRE (CRE-decoy)

Proceedings of the National Academy of Sciences (PNAS), 99 (24): 15626-15631 (2002)

Cyclosporin A

Behavioural Brain Research, 104 (1-2): 179-187 (1999)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

3, 5-Diiodothyropropionic Acid (DITPA)

American Journal of Physiology: Heart and Circulatory Physiology, 296: H1551-H1557 (2007)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 294: R1504-R1509 (2008)

Canadian Journal of Physiology and Pharmacology, 85 (3-4): 311-318 (2007)

Journal of Physiology and Pharmacology, 85: 311-318 (2004)

Dihydroprogesterone

Brain Research, 766 (1-2): 19-28 (1997)

European Journal of Neuroscience, 16 (9): 1731-1740 (2002)

Experimental Eye Research, 51 (6): 659-666 (1995)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

Molecular Endocrinology, 11 (7): 917-927 (1997)

5 β -Dihydroprogesterone (5 β -DHP)

American Journal of Obstetrics and Gynecology, 192 (4): 1304-1315 (2005)

Dizolcipine Maleate (MK-801)

Journal of Pharmacology and Experimental Therapeutics, 311 (1): 8-13 (2004)

DPN

American Journal of Respiratory and Critical Care Medicine, 184 (6): 715-723 (2011)

Biology of Sex Differences, 3 (1): 24 (2012)

Clinical Cancer Research, 18 (16): 4385-4396 (2012)

FASEB Journal, 26 (10): 3993-4002 (2012)

Epiandrosterone

Molecular Endocrinology, 11 (7): 917-927 (1997)

ERB-041

Steroids, 74 (13-14): 1015-1024 (2009)

17 β -Estradiol 3-Sulfate

Anticancer Research, 32 (7): 2769-2782 (2012)

4-Estren-3 α , 17 β -diol

Endocrinology, 147 (4): 1986-1996 (2006)

Journal of Clinical Investigation, 111 (11): 1651-1664 (2003)

Journal of Clinical Investigation, 116 (9): 2500-2509 (2006)

Journal of Immunology, 171 (12): 6936-6940 (2003)

Journal of Neuroimmunology, 149 (1): 84-89 (2004)

Journal of Neuroscience Research, 77 (1): 119-126 (2004)

Neurology, 52 (6): 1230-1238 (1999)

Proceedings of the National Academy of Sciences (PNAS), 91 (12): 5382-5386 (1994)

Science, 298 (5594): 843-846 (2002)

ETA Receptor Antagonist

Circulation, 95 (7): 1918-1929 (1997)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Fadrozole

International Journal of Parasitology, 32 (11): 1379-1387 (2002)
Journal of Comparative Neurology, 475 (1): 83-94 (2004)
Journal of Neurobiology, 54 (2): 370-379 (2003)

Fluorescein Isothiocyanate (FITC) - Inulin

Kidney International, 71 (3): 266-271 (2007)

Fluoxetine

Biological Psychiatry, 64 (8): 691-700 (2008)
Dissertation, 1-264 (2013)
European Journal of Neuroscience, 37 (2): 242-250 (2013)
Journal of Clinical Endocrinology and Metabolism, 95 (2): 1-10 (2010)
Journal of Endocrinology, 209 (1): 45-54 (2011)
Journal of Neuroscience, 29 (37): 11451-11460 (2009)
Molecular Brain, 4: 10 (2011)
Nature Neuroscience, 13 (6): 745-754 (2010)
Neuropsychopharmacology, 38 (6): 909-920 (2013)

G-1

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 11 (4): 262-274 (2011)
Journal of Molecular Endocrinology, 51 (1): 191-202 (2013)
Public Library of Science (PLoS ONE), 7 (9): e43215 (2012)

GABA (Aminobutyric Acid)

Journal of Immunology, 173 (8): 5298-5304 (2004)
Journal of Neuroimmunology, 96 (1): 21-28 (1999)

Gangliosides

Circulatory Shock, 44 (1): 57-62 (1995)

Galardin

Molecular Cancer Therapeutics, 7 (9): 2758-2767 (2008)

Glucosamine

Biology of Reproduction, 89 (1): 16 (2013)

Glucose

Journal of Perinatal Medicine, 29 (6): 476-485 (2001)

Growth Factors and Peptides

Aging: Immunology and Infectious Disease, 3 (1): 19-26 (1991) (**Ovine GH**)
American Journal of Physiology: Endocrinology and Metabolism, 279 (2): E314-E322 (2000) (**Ovine GH**)
American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 298: R824-R832 (2010) (**VEGF**)
American Journal of Physiology: Renal Physiology, 283 (6): F1296-F1303 (2002) (**S3226**)
American Journal of Clinical Nutrition, 83 (Supplement): S470-S474 (2006) (**IL-1B**)
American Society for Nutritional Sciences, 130 (9): 2361-2366 (2000) (**Protease Inhibitor**)
Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, (Chapter 2): 1-160 (2000) (**Neuropeptide Y (NPY)**)
Annals of New York Academy of Sciences, 638: 306-315 (1991) (**bFGF**)
Annals of Surgery, 2: 1-9 (1995) (**TGF-β1**)
Annals of Surgery, 222 (2): 146-154 (1995) (**TGF-β1**)
Anticancer Research, 8: 1233-1240 (1988) (**IL-1B**)
Aquaculture Research, 35: 278-288 (2004) (**GnRH**)
Arteriosclerosis, Thrombosis and Vascular Biology, 23: 1204-1210 (2003) (**Neuropeptide Y (NPY)**)
Arteriosclerosis, Thrombosis and Vascular Biology, 25 (10): e20275-e2080 (2005) (**Neuropeptide Y (NPY)**)
Brain Research, 933: 130-138 (2002) (**VIP**)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Growth Factors and Peptides (cont.)

Cancer Cell, 9 (1): 23-32 (2006) (**Prolactin**)
Cancer Letters, 187 (1): 129-133 (2002) (**VEGF**)
Cancer Medicine, 1 (2): 275-288 (2012) (**IGF-1**)
Cancer Research, 56: 3540-3545 (1996) (**VEGF**)
Cancer Research, 57: 765-772 (1997) (**VEGF**)
Cancer Research, 65 (5): 1719-1728 (2005) (**Neuropeptide Y (NPY)**)
Carcinogenesis, 21: 113-116 (2000) (**FTI-276**)
Cardiovascular Research, 3 (52): 468-476 (2001) (**Endothelin-1**)
Cell Tissue Research, 300: 89-95 (2000) (**TGF-β3**)
Circulation, 95: 1918-1929 (1997) (**Endothelin-1 (ETA Receptor Antagonist)**)
Dissertation, 1-138 (2010) (**IGF-1**)
Endocrinology, 131 (4): 1657-1664 (1992) (**TGFα**)
Endocrinology, 147 (11): 5400-5411 (2006) (**Prolactin**)
Endocrine Reviews, 11 (4): 578-610 (1990) (**Rat GH**)
European Molecular Biology Organization, 18: 363-374 (1999) (**VEGF**)
Experimental Biology and Medicine, 235 (10): 1179-1184 (2010) (**Neuropeptide Y (NPY)**)
Experimental Lung Research, 8 (26): 773-790 (2000) (**FTI-276**)
Experimental Neurology, 163: 388-391 (2000) (**IL-1β**)
FASEB Journal, 13 (2): 325-329 (1999) (**bFGF**)
FASEB Journal, 27 (6): 2244-2255 (2013) (**Neuropeptide Y (NPY)**)
General and Comparative Endocrinology, 113: 146-154 (1999) (**VIP**)
Human Reproduction, 17 (2): 457-462 (2002) (**IGF-1**)
International Journal of Oncology, 20: 813-818 (2002) (**hPRL-G129R - Prolactin**)
Investigative Ophthalmology and Visual Sciences, 53 (1): 68-75 (2012) (**IGF-1**)
In Vitro Cellular and Developmental Biology - Animal, 36 (10): 657-666 (2000) (**FSH**)
In Vivo, 19: 667-674 (2005) (**IGF-1**)
Journal of American Association for Pediatric Ophthalmology and Strabismus, 10 (5): 424-429 (2006) (**IGF-1**)
Journal of Applied Physiology, 85 (2): 716-722 (1998) (**BMP**)
Journal of Bone and Mineral Research, 26 (12): 2886-2898 (2011) (**rCart Peptide (55-102)**)
Journal of Clinical Investigation, 99 (11): 2625-2634 (1997) (**VEGF**)
Journal of Clinical Investigation, 103 (2): 271-279 (1999) (**TRH**)
Journal of Clinical Investigation, 110 (4): 453-462 (2002) (**IgG**)
Journal of Clinical Investigation, 111 (12): 1853-1862 (2003) (**Neuropeptide Y (NPY)**)
Journal of Endocrinology, 160: 217-222 (1999) (**GHRH**)
Journal of Endocrinology, 161: 77-87 (1999) (**Rat GH**)
Journal of Endocrinology, 169: 389-396 (2001) (**GHRH**)
Journal of Medicinal Chemistry, 51 (15): 4632-4640 (2008) (**VEGF**)
Journal of Neurobiology, 34: 164-178 (1998) (**NGF**)
Journal of Neuroinflammation, 8: 175 (2011) (**IL-1β**)
Journal of Neuroscience, 20 (1): 149-155 (2000) (**IL-1β**)
Journal of Neuroscience, 21 (2): 363-371 (2001) (**NGF**)
Journal of Neurosurgery, 80: 484-490 (1994) (**IL-1β**)
Journal of Nutrition, 134 (9): 2482-2486 (2004) (**IGF-1**)
Journal of Pediatric Surgery, 30 (2): 198-203 (1995) (**TGF-β1**)
Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012) (**Rat GH**)
Journal of Surgical Research, 43: 322-328 (1987) (**EGF**)
Laboratory Investigation, 61 (5): 571-575 (1989) (**bFGF (IgG) (Anti-FGF)**)
Molecular and Cellular Biochemistry, 333 (1-2): 27-32 (2010) (**Neuropeptide Y (NPY)**)
Molecular Cancer Therapy, 2: 1243-1255 (2003) (**GIP**)
Nature, 13: 803-811 (2007) (**Neuropeptide Y (NPY)**)
Neurobiology of Aging, 32 (8): 1420-1434 (2011) (**Peptide 6**)
Neurochemistry International, 39 (5-6): 341-348 (2001) (**IL-1β**)
Oncogene, 22 (40): 6257-6265 (2003) (**FTI-276**)
Ophthalmic Research, 19: 82-94 (1987) (**Prolactin**)
Pancreas, 26 (4): 392-397 (2003) (**NGF (VEGF)**)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Growth Factors and Peptides (cont.)

Peptides, 24 (1): 99-106 (2003) (**Neuropeptide Y (NPY)**)
Peptides, 28 (2): 435-440 (2007) (**Neuropeptide Y (NPY)**)
Pharmacology and Toxicology, 84: 34-40 (1999) (**FGF**) (**VEGF**)
Physiological Research, 52: 743-748 (2003) (**VEGF**)
Plastic Reconstructive Surgery, 123 (2): 486-492 (2009) (**Neuropeptide Y (NPY)**)
Proceedings of the National Academy of Sciences (PNAS), 82 (21): 7340-7344 (1985) (**EGF**)
Proceedings of the National Academy of Sciences (PNAS), 88 (1): 21-25 (1991) (**EGF**)
Proceedings of the National Academy of Sciences (PNAS), 89 (10): 4658-4662 (1992) (**EGF**)
Proceedings of the National Academy of Sciences (PNAS), 93 (22): 12626-12630 (1996) (**EGF**)
Proceedings of the National Academy of Sciences (PNAS), 95 (12): 7727-7730 (1998) (**LIF**)
Proceedings of the National Academy of Sciences (PNAS), 97 (23): 12782-12787 (2000) (**bFGF**)
Transplantation Proceedings, 22 (2): 824-829 (1990) (**EGF**)
Transplantation Proceedings, 36 (4): 1178-1180 (2004) (**VEGF**)
Transplantation Proceedings, 40 (2): 452-454 (2008) (**VEGF**) (**NGF**)
Wound Repair and Regeneration, 5 (1): 77-88 (1997) (**bFGF**)

GW7604

Steroids, 74 (13-14): 1015-1024 (2009)

Heparin

American Journal of Pathology, 127 (3): 592-604 (1987)
Angiogenesis, 61: 381-385 (1992)
Comparative Medicine, 55 (5): 452-458 (1988)
Journal of Burn Care and Research, 19 (2): 95-101 (1998)
Science, 221 (4612): 719-726 (1983)
Transplantation Proceedings, 22 (2): 824-829 (1990)

Hexarelin

Growth Hormone and IGF Research, 20 (1): 49-54 (2009)

HS-142-1

Journal of Clinical Investigation, 94 (5): 1938-1946 (1994)

4-Hydroxyandrostene-3,17-dione (4-OHA)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 280 (3): R904-R907 (2001)

4-Hydroxyandrostenedione

Molecular Endocrinology, 11 (7): 917-927 (1997)

16 α -Hydroxyestrone (16 α -OHE1)

Bone, 33 (1): 124-131 (2003)
Journal of Endocrinology, 170 (1): 165-174 (2001)

4-Hydroxytamoxifen

Blood, 108 (7): 2416-2419 (2006)
Cancer Research, 56: 4315-4319 (1996)
Cancer Research, 58: 1779-1784 (1998)
Cancer Research, 60: 5803-5814 (2000)
Cancer Research, 60: 7094-7098 (2000)
Cell, 148 (4): 651-663 (2012)
Cell Proliferation, 4 (34): 223 (2001)
Journal of Cellular and Molecular Medicine, 17 (8): 936-957 (2013)
Journal of Steroid Biochemistry, 30 (16): 311-314 (1988)
Korean Journal of Laboratory Medicine, 24: 339-346 (2004)
Korean Journal of Laboratory Medicine, 25: 205-211 (2005)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

4-Hydroxytamoxifen (cont.)

Nature, 469: 102-106 (2011)

Open Cancer Journal, 3: 89-100 (2010)

Proceedings of the National Academy of Sciences (PNAS), 103 (24): 9232-9237 (2006)

ICI-182,780

American Journal of Obstetrics and Gynecology, 184 (3): 303-308 (2001)

Dissertation, 1-77 (2010)

Endocrinology, 144 (3): 785-795 (2003)

Molecular and Cellular Endocrinology, 292 (1-2): 50-62 (2008)

Molecular Endocrinology, 22 (3): 665-675 (2008)

Nature Medicine, 9 (8): 1081-1084 (2003)

Nature Medicine, 11 (2): 153-159 (2005)

Oncogene, 21 (25): 4000-4008 (2002)

Insulin

Biochemical Pharmacology, 36 (7): 1011-1016 (1987)

Canadian Journal of Physiology and Pharmacology, 80: 180-192 (2002)

Journal of Biological Chemistry, 268 (17): 12952-12957 (1993)

Journal of Neuroendocrinology, 9 (4): 307-316 (1997)

Journal of Experimental Medicine, 182 (3): 897-902 (1995)

IN-1130

American Journal of Physiology: Renal Physiology, 304 (5): F481-F490 (2013)

Isradipine

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812 (12): 1584-1590 (2011)

Biological Psychiatry, 65 (6): 518-526 (2009)

Disease Models and Mechanisms, 4 (5): 634-648 (2011)

Movement Disorders, 25 (1): s63-s70 (2010)

Nature, 447: 1081-1086 (2007)

Neurobiology of Disease, 41 (1): 67-70 (2010)

Keoxifene

Cancer Research, 50 (11): 3189-3192 (1990)

11-Ketotestosterone

Hormones and Behavior, 25 (3): 410-423 (1991)

Lactitol

Cellular Microbiology, 8 (7): 1086-1095 (2006)

Lazaroid

Laryngoscope, 110 (5): 727-738 (2000)

16 α -LE2

Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)

Leptin

Cancer Research, 72 (6): 1416-1427 (2012)

Neuroendocrinology, 67: 29-36 (1998)

Public Library of Science (PLoS ONE), 4 (2): e4602 (2009)

Public Library of Science (PLoS ONE), 7 (3): e34090 (2012)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Letrozole

Dissertation, 1-191 (2011)
Fertility and Sterility, 99 (3): 889-896 (2013)
Frontiers in Zoology, 10 (1): 8 (2013)

Leuprolide Acetate

Brain Research, 1466: 137-145 (2012)

Lipopolysaccharide (LPS)

Bone, 38 (3): 378-386 (2006)
Cardiovascular Pathology, 18 (1): 1-10 (2009)
Current Eye Research, 34 (6): 476-484 (2009)
Dissertation, 1-98 (2012)
Dissertation, 1-109 (2012)
Inflammation Research, 60 (7): 665-672 (2011)
Journal of Biomedical Materials Research (Part A), 100 (4): 918-928 (2012)
Journal of Immunology, 186: 5367-5375 (2011)
Journal of Nutritional Biochemistry, 21: 968-974 (2010)
Nutrition Research, 29 (7): 437-456 (2009)
Osteoporosis International, 21: 1841-1852 (2010)

Luteinizing Hormone (LH)

Neuroendocrinology, 94 (4): 313-322 (2011)

LY3201

Molecular Psychiatry, 18 (6): 674-680 (2013)
Proceedings of the National Academy of Sciences (PNAS), 109 (5): 1708-1712 (2012)
Proceedings of the National Academy of Sciences (PNAS), 110 (9): 3543-3548 (2013)

Manumycin

Biochemical Journal, 391 (1): 59-67 (2005)
Journal of Clinical Endocrinology and Metabolism, 86 (4): 1769-1777 (2000)

2-Methoxyestradiol

Clinical Immunology, 140 (1): 37-46 (2011)
Dissertation, 1-42 (2010)
Endocrine Journal, 54 (6): 1027-1031 (2007)

1-Methyl-DL-Tryptophan (1-MT)

Allergy, 64: 488-492 (2009)
American Journal of Respiratory Cell and Molecular Biology, 30 (3): 311-318 (2004)
American Journal of Transplantation, 12 (3): 610-619 (2012)
Arthritis and Rheumatism, 60 (5): 1342-1351 (2009)
Arthritis Research and Therapy, 9 (3): R50 (2007)
Blood, 106 (7): 2382-2390 (2005)
Blood, 110 (3): 1064-1072 (2007)
Cancer Research, 67 (2): 792-801 (2007)
Cellular and Molecular Immunology, 8: 31-40 (2011)
Cytokine, 34: 233-242 (2006)
Diabetes, 56: 1686-1693 (2007)
Dissertation, 1-140 (2011)
European Journal of Immunology, 35 (11): 3111-3118 (2005)
European Journal of Immunology, 36 (3): 690-700 (2006)
European Journal of Immunology, 39 (6): 1552-1563 (2009)
Gastroenterology, 125 (6): 1762-1773 (2003)
Gut, 59 (5): 595-604 (2010)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

1-Methyl-DL-Tryptophan (1-MT) (cont.)

International Journal of Cancer, 101 (2): 151-155 (2002)
Journal of Alzheimer's Disease, 28 (4): 905-915 (2012)
Journal of Clinical Investigation, 114 (2): 270-279 (2004)
Journal of Experimental Therapeutics and Oncology, 3 (6): 336-345 (2003)
Journal of Immunology, 171 (4): 1652-1655 (2003)
Journal of Immunology, 176: 6752-6761 (2006)
Journal of Immunology, 182: 3202-3212 (2009)
Journal of Immunology, 183: 6303-6312 (2009)
Journal of Immunology, 189 (1): 72-79 (2012)
Journal of Immunology, 191 (4): 1965-1975 (2013)
Journal of Infectious Diseases, 193 (2): 214-222 (2006)
Journal of Neuroimmunology, 129 (1): 186-196 (2002)
Journal of Reproductive Immunology, 61 (2): 67-77 (2004)
Journal of Virology, 80 (1): 270-280 (2006)
Nature Immunology, 2 (1): 64-68 (2001)
Nature Immunology, 3 (11): 1097-1101 (2002)
Nature Immunology, 4 (12): 1206-1212 (2003)
Nature Medicine, 10 (10): 1088-1094 (2004)
Nature Medicine, 11 (4): 312-319 (2005)
Nature Medicine, 13 (5): 579-586 (2007)
Oncogene, 27 (20): 2851-2857 (2008)
Science, 281 (5380): 1191-1193 (1998)
Transplant Immunology, 17 (1): 58-60 (2006)
Transplant Immunology, 22 (3-4): 172-178 (2010)
Transplantation, 83 (5): 663-667 (2007)

1-Methyl-D-Tryptophan

Immunity, 22: 633-642 (2005)
Journal of Clinical Investigation, 117 (9): 2570-2582 (2007)
Journal of Immunology, 183: 2475-2483 (2009)

1-Methyl-L-Tryptophan

Gastroenterology, 145 (2): 416-425 (2013)

Mifepristone (RU-486)

Alzheimer's and Dementia, 6 (4): S565 (2010)
American Journal of Physiology: Endocrinology and Metabolism, 256 (5): E682-E685 (1989)
American Journal of Physiology: Lung Cellular and Molecular Physiology, 281 (5): L1150-L1156 (2001)
American Journal of Physiology: Lung Cellular and Molecular Physiology, 284 (1): L197-L204 (2003)
American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 270 (1): R199-R206 (1996)
American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 296 (5): R1445-R1454 (2009)
Audiology and Neurotology, 14 (6): 423-431 (2009)
Brain, Behavior and Immunity, 19 (5): 413-422 (2005)
Brain, Behavior and Immunity, 25 (2): 340-348 (2011)
Cancer Prevention Research, 5 (5): 754-764 (2012)
Cancer Research, 67 (20): 9929-9936 (2007)
Clinical Cancer Research, 12: 4062-4071 (2006)
Contraception, 58 (1): 45-50 (1998)
Endocrine-Related Cancer, 19 (3): R35-R50 (2012)
Endocrinology, 141 (12): 4698-4710 (2000)
Endocrinology, 146 (10): 4340-4348 (2005)
Endocrinology, 151 (6): 2433-2442 (2010)
Fertility and Sterility, 82 (2): 430-436 (2004)
Genesis, 48 (10): 585-595 (2010)
International Immunology, 9 (1): 105-115 (1997)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Mifepristone (RU-486) (cont.)

Journal of Biological Chemistry, 273 (43): 27904-27910 (1998)
Journal of Experimental Medicine, 171 (4): 979-996 (1990)
Journal of Experimental Medicine, 181 (3): 901-914 (1995)
Journal of Molecular and Cellular Cardiology, 38 (4): 685-691 (2005)
Journal of Molecular Medicine, 87 (7): 703-712 (2009)
Journal of Neuroscience, 32 (22): 7563-7571 (2012)
Journal of Orthopaedic Research, 30 (2): 288-295 (2012)
Journal of the American College of Cardiology, 44 (11): 2221-2230 (2004)
Molecular and Cellular Biology, 30 (12): 3111-3125 (2010)
Molecular Endocrinology, 14 (7): 1075-1085 (2000)
Molecular Endocrinology, 18 (9): 2196-2207 (2004)
Neurobiology of Disease, 45 (1): 539-546 (2012)
Proceedings of the National Academy of Sciences (PNAS), 98 (10): 5898-5903 (2001)
Proceedings of the National Academy of Sciences (PNAS), 99 (17): 11187-11192 (2002)
Proceedings of the National Academy of Sciences (PNAS), 100 (5): 2951-2956 (2003)
Proceedings of the National Academy of Sciences (PNAS), 102 (39): 13789-13794 (2005)
Science, 314: 1467 (2006)
Steroids, 74 (13-14): 1015-1024 (2009)
Surgery, 125 (6): 594-601 (1999)
Surgery, 127 (6): 687-695 (2000)

MK-434

American Journal of Physiology: Endocrinology and Metabolism, 293: 507-514 (2007)

MNTDE

Journal of Immunology, 178: 908-917 (1997)

NBI-27914

Proceedings of the National Academy of Sciences (PNAS), 103 (9): 3462-3467 (2006)

Nedocromil Sodium

American Journal of Physiology: Heart and Circulatory Physiology, 287 (5): H2295-H2299 (2004)
American Journal of Physiology: Heart and Circulatory Physiology, 302 (3): H811-H817 (2012)
Hypertension, 53 (6): 1041-1047 (2009)
Inflammation Research, 55 (10): 408-415 (2006)
Journal of Cardiac Failure, 11 (7): 548-556 (2005)
Journal of Molecular and Cellular Cardiology, 49 (2): 245-250 (2010)
Public Library of Science (PLoS ONE), 8 (3): e60827 (2013)

Nimodipine

Acta Neurochirurgica Supplementum, 104 (4): 103-107 (2008)
American Journal of Physiology: Heart and Circulatory Physiology, 258 (5): H1395-H1401 (1990)
Archives of Facial Plastic Surgery, 12 (1): 49-52 (2010)
Behavioral Brain Research, 98 (1): 95-101 (1998)
Brain Research Bulletin, 39 (5): 311-316 (1996)
European Journal of Neuroscience, 31 (3): 478-490 (2010)
Experimental Brain Research, 117 (1): 111-119 (1997)
Hearing Research, 121 (1-2): 139-146 (1998)
Journal of Neuroscience Methods, 68 (2): 297-301 (1996)
Military Medicine, 166 (12): 74-75 (2001)
Molecular Brain Research, 110 (2): 193-202 (2003)
Nature Neuroscience, 9 (2): 251-259 (2006)
Neurobiology of Aging, 17 (3): 453-457 (1996)
Neurological Research, 24 (8): 775-780 (2002)
Neuroradiology, 49 (2): 129-137 (2007)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Nimodipine (cont.)

Pharmacology, Biochemistry and Behavior, 39 (3): 781-786 (1991)

Pharmacology, Biochemistry and Behavior, 44: 827-835 (1993)

Nitrosobis-(2oxopropyl)-amine (BOP)

Chemico-Biological Interactions, 66 (1-2): 111-119 (1988)

Nomegestrol

Fertility and Sterility, 78 (5): 973-978 (2002)

Noradrenaline (NA)

International Journal of Neuroscience, 62 (1-2): 123-140 (1992)

Norethisterone Acetate

Dissertation, 1-121 (2005)

Journal of Bone and Mineral Research, 8 (2): 219-230 (1993)

NS-398

Microbes and Infection, 8 (2): 478-486 (2006)

Oxandrolone

Experimental Eye Research, 51 (6): 659-666 (1995)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

PD123319

Public Library of Science (PLoS ONE), 7 (4): e35632 (2012)

PDFG-BB

FASEB Journal, 13: 325-329 (2003)

Pesticides and Related Products

United States Geological Society (USGS), The Society of Environmental Toxicology and Chemistry (SETAC) meeting, November, (2002) **(DDE) (Dieldin)**

United States Geological Society (USGS), Superfund Basic Research Program Annual Conference, November, (2002) **(DDE) (Dieldin)**

Phosphoramidon

Inflammation Research, 57 (7): 300-305 (2008)

PHTPP

American Journal of Respiratory and Critical Care Medicine, 184 (6): 715-723 (2011)

PJ34

Cardiovascular Research, 78: 158-166 (1989)

Ponasterone A

American Journal of Physiology: Heart and Circulatory Physiology, 295: H543-H554 (2008)

Cancer Research, 68: 4588-4596 (2008)

FASEB Journal, 14: 877-884 (2004)

Molecular and Cellular Biology, 26 (14): 5449-5469 (2006)

Molecular and Cellular Biology, 26 (19): 7116-7129 (2006)

Proceedings of the National Academy of Sciences (PNAS), 104 (41): 16170-16175 (2007)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

PPT

American Journal of Respiratory and Critical Care Medicine, 184 (6): 715-723 (2011)
Biology of Sex Differences, 3 (1): 24 (2012)

D-Propranolol

Canadian Journal of Physiology and Pharmacology, 90 (9): 1257-1268 (2012)

Quercetin

Journal of Steroid Biochemistry and Molecular Biology, 46 (4): 489-495 (1993)

Raloxifene

Cancer Research, 63 (15): 4426-4433 (2003)
Carcinogenesis, 26 (6): 1109-1116 (2005)
Journal of Clinical Investigation, 111 (11): 1651-1664 (2003)
Medical Principles and Practices, 13: 220-226 (2004)
Molecular Endocrinology, 24 (4): 735-744 (2010)
Neuroscience, 121 (3): 659-666 (2003)
Public Library of Science (PLOS ONE), 7 (12): e50802 (2012)
Steroids, 74 (13-14): 1015-1024 (2009)
Urology, 69 (6): 1221-1226 (2007)

Ranolazine

Circulation, 126 (18): 2208-2219 (2012)

Rapamycin

Ageing, 5 (2): 111-119 (2013)
American Journal of Pathology, 181 (1): 278-293 (2012)
Cancer Prevention Research, 3 (12): 1542-1551 (2010)
Journal of Cellular Physiology, 221 (3): 579-585 (2009)
Kidney International, 76: 178-182 (2009)

5 α Reductase Inhibitor (4MA)

Prostate, 10: 189-197 (1987)

Resveratrol

Journal of Nutrition, 136: 2542-2546 (2006)
Journal of Surgical Research, 179 (1): E141-E148 (2013)

S3226

American Journal of Physiology: Renal Physiology, 283 (6): F1296-F1303 (2002)

Sildenafil Citrate

Experimental Biology and Medicine, 229: 920-925 (2004)
International Journal of Impotence Research, 11 (1): S9-S14 (1999)

Synthroid

Cells, Tissues, and Organs, 173: 162-171 (2003)

Tacrolimus

Experimental Neurology, 248: 85-99 (2013)

Tamoxifen Methiodide

Dissertation, 1-89 (2003)

cont.

PROVEN EFFECTIVENESS

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDD™ Pellet System.

PRODUCT/JOURNAL

Tamoxifen (N-Desmethyl)

Journal of Steroid Biochemistry, 30 (16): 311-314 (1988)

Tetrodotoxin (TTX)

Journal of Cell Biology, 127 (5): 1435-1445 (1994)

Thalidomide

Molecular and Cellular Biochemistry, 129: 195-200 (1993)

Thrombin Inhibitor

Clinical Explanation Metastasis, 4 (3): 205-220 (1996)

Thyrotropin-Releasing Hormone (TRH)

Alcohol, 13 (6): 559-567 (1996)

Journal of Biological Chemistry, 281 (8): 5000-5007 (2006)

Journal of Clinical Investigation, 103 (2): 271-279 (1999)

Toremifene Citrate

Cancer Research, 62: 1370-1376 (2002)

Vitamin D3 Analog (EB1089)

Endocrinology, 139 (4): 2102-2110 (1998)

Journal of Dairy Science, 73 (2): 406-412 (1990)

Journal of Steroid Biochemistry and Molecular Biology, 84 (2): 181-192 (2003)

ZK-810630

Immunology Letters, 76 (3): 193-201 (2001)

Journal of Clinical Investigation, 114 (2): 270-279 (2004)

Journal of Experimental Therapeutics and Oncology, 3 (6): 336-345 (2003)

Journal of Immunology, 171 (4): 1652-1655 (2003)

Journal of Neuroimmunology, 129 (1): 186-196 (2002)

Journal of Reproductive Immunology, 61 (2): 67-77 (2004)

Journal of Virology, 80 (1): 270-280 (2006)

Nature Immunology, 2 (1): 64-68 (2001)

Nature Immunology, 3 (11): 1097-1101 (2002)


Nature Immunology, 4 (12): 1206-1212 (2003)

Nature Medicine, 10 (10): 1088-1094 (2004)

Nature Medicine, 11 (4): 312-319 (2005)

Science, 281 (5380): 1191-1193 (1998)

CONSISTENCY IS IMPORTANT



TIMING IS EVERYTHING

TIME • RELEASE • DOSE • DEPENDENT, REPRODUCIBILITY, RESULTS

In this section are references found in the years 2012 through 2013 citing the use of our innovative technology. To view all references and new entries on a daily basis, a complete list of publications can be found at our website: www.innovrsrch.com



REFERENCES

With Reliable Results, We Deliver.





SELECTED REFERENCES

PRODUCT / JOURNALS	CURRENT AVAILABILITY
--------------------	----------------------

2-Acetamidofluorene (2-AAF) Experimental and Molecular Pathology, 93 (1): 40-49 (2012) Public Library of Science (PLoS ONE), 7 (12): e51878 (2012)	STOCK
d-Aldosterone Journal of the Renin-Angiotensin-Aldosterone System, 13 (3): 353-359 (2012)	STOCK
Anastrozole Experimental Physiology, 98 (1): 161-171 (2013)	CUSTOM
Androstenedione Breast Cancer Research, 14 (5): R132 (2012)	STOCK
Asoprisnil Steroids, 74 (13-14): 1015-1024 (2009)	CUSTOM
5-Azacytidine Molecular and Cellular Biology, 33 (19): 3920-3935 (2013)	STOCK
Bazedoxifene Clinical Cancer Research, 19 (9): 2420-2431 (2013)	CUSTOM
Bromocriptine Mesylate Diabetes, 62 (5): 1646-1655 (2013)	STOCK
5-Bromo-2'-Deoxyuridine (BrDU) Experimental Gerontology, 48 (9): 973-984 (2013) Journal of Clinical Investigation, 123 (8): 3409-3419 (2013)	STOCK
Camostat Mesilate (CM) American Journal of Physiology: Renal Physiology, 303 (8): F1126-F1135 (2012) American Journal of Physiology: Renal Physiology, 305 (2): F173-F181 (2013)	CUSTOM
rCart Peptide (55-102) Journal of Bone and Mineral Research, 26 (12): 2886-2898 (2011)	CUSTOM
Casodex (Bicalutamide) Endocrinology, 154 (9): 3168-3177 (2013)	CUSTOM
Compound A (CpdA) Journal of Bone and Mineral Research, 27 (11): 2242-2250 (2012)	CUSTOM
Corticosterone American Journal of Hypertension, 16 (8): 685-688 (2003) Behavioral and Neural Biology, 60 (2): 103-109 (1993) Behavioural Brain Research, 238: 170-177 (2013) Brain Research Bulletin, 98: 10-22 (2013) British Journal of Pharmacology, 166 (8): 2417-2429 (2012) Conservation Physiology, 1 (1): 1-12 (2013) Dissertation, 1-223 (2001) Dissertation, 1-78 (2009) Dissertation, 1-108 (2011) Dissertation, 1-79 (2013) Endocrinology, 154 (8): 2807-2820 (2013) European Journal of Applied Physiology, 104 (5): 847-858 (2008) Evolutionary Biology, 39 (3): 348-358 (2012)	STOCK

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Corticosterone (cont.)

STOCK

General and Comparative Endocrinology, 178 (1): 139-144 (2012)
Hormones and Behavior, 64 (1): 161-171 (2013)
Journal of Applied Physiology, 108 (2): 298-305 (2010)
Journal of Avian Biology, 44 (4): 359-368 (2013)
Journal of Chemical Neuroanatomy, 48-49: 23-28 (2013)
Journal of Endocrinology, 219: 79-88 (2013)
Journal of Neuroimmunology, 100 (1-2): 243-251 (1999)
Neuropharmacology, 59 (6): 375-379 (2010)
Neuroscience, 190: 166-176 (2011)
Neuroscience, 222: 269-280 (2012)
Neuroscience Research, 51 (3): 319-327 (2005)
Neurotoxicology, 30 (6): 965-976 (2009)
Physiological and Biochemical Zoology, 81 (5): 641-650 (2008)
Physiology and Behavior, 75 (1): 207-215 (2002)
Prostate, 71 (3): 289-297 (2011)

Deoxycorticosterone Acetate (DOCA)

STOCK

ACS Chemical Neuroscience, 4 (1): 141-148 (2013)
American Journal of Hypertension, 25 (4): 421-429 (2012)
American Journal of Hypertension, 25 (4): 479-486 (2012)
American Journal of Physiology: Heart and Circulatory Physiology, 302 (11): H2243-H2249 (2012)
American Journal of Physiology: Heart and Circulatory Physiology, 302 (11): H2428-H2438 (2012)
American Journal of Physiology: Renal Physiology, 303 (8): F1207-F1215 (2012)
Arteriosclerosis, Thrombosis, and Vascular Biology, 33 (7): 1568-1579 (2013)
Cardiovascular Research, 94 (3): 510-518 (2012)
Cardiovascular Research, 96 (1): 120-129 (2012)
Cardiovascular Research, 98 (1): 37-46 (2013)
Current Cardiology Reviews, 6 (4): 291-297 (2010)
Dissertation, 1-115 (2012)
Dissertation, 1-151 (2012)
European Journal of Anaesthesiology: Neurosciences, 30: 103-103 (2013)
European Journal of Clinical Investigation, 39 (2): 116-125 (2009)
European Journal of Physiology, 456 (6): 1207-1216 (2008)
Hypertension, 59 (1): 167-172 (2012)
Hypertension, 60 (5): 1184-1191 (2012)
Hypertension, 60 (5): 1207-1212 (2012)
Hypertension, 61 (2): 270-277 (2013)
Hypertension, 61 (3): 716-722 (2013)
Hypertension, 61 (3): 730-736 (2013)
Hypertension, 62 (2): 302-309 (2013)
Journal of Cerebral Blood Flow and Metabolism, 32 (2): 368-375 (2012)
Journal of Cerebral Blood Flow and Metabolism, 33 (4): 483-489 (2013)
Journal of Clinical Investigation, 123 (7): 2803-2815 (2013)
Journal of Hypertension, 27 (2): 376-385 (2009)
Journal of Molecular and Cellular Cardiology, 56: 44-54 (2013)
Journal of the American Society of Hypertension, 7 (1): 14-23 (2013)
Kidney International, 80 (1): 51-60 (2011)
Life Sciences, 91 (13-14): 587-592 (2012)
Molecular Medicine, 17 (11-12): 1204-1212 (2011)
Public Library of Science (PLOS ONE), 7 (10): e48150 (2012)
Public Library of Science (PLOS ONE), 8 (8): e72857 (2013)

Dexamethasone

STOCK

Molecular Cancer Therapeutics, 11 (12): 2621-2632 (2012)

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Diethylstilbestrol (DES)

Clinical Science, 123 (8): 509-518 (2012)
 Proceedings of the National Academy of Sciences (PNAS), 109 (31): 12491-12496 (2012)

STOCK

5 α -Dihydrotestosterone (5 α -DHT)

Acta Physiologica Hungarica, 99 (3): 279-288 (2012)
 American Journal of Physiology: Heart and Circulatory Physiology, 301 (5): H1882-H1890 (2011)
 American Journal of Physiology: Renal Physiology, 302 (9): F1203-F1209 (2012)
 American Journal of Physiology: Renal Physiology, 305 (5): F753-F763 (2013)
 Arthritis & Rheumatism, 65 (9): 2392-2402 (2013)
 Behavioral Neuroscience, 127 (3): 400-414 (2013)
 Biological Psychiatry, 71 (7): 642-651 (2012)
 Biology of Sex Differences, 2 (1): 14 (2011)
 Biomed Research International, Volume 2013 (Article ID 320249): 1-12 (2013)
 Brain Research, 1429: 43-51 (2012)
 Dissertation, 1-123 (2012)
 Dissertation, 1-265 (2012)
 Dissertation, 1-116 (2013)
 Endocrine, 6 (1): 39-45 (1997)
 Experimental Eye Research, 96 (1): 88-97 (2012)
 Experimental Lung Research, 38 (4): 165-172 (2012)
 Experimental Neurology, 181 (2): 301-312 (2003)
 Experimental Physiology, 97 (5): 651-662 (2012)
 Evidence-Based Complementary and Alternative Medicine, Volume 2013 (Article ID 964070): 1-13 (2013)
 Fertility and Sterility, 99 (2): 573-578 (2012)
 Frontiers in Endocrinology, 2 (82): 1-15 (2011)
 Hormone and Metabolic Research, 41 (5): 356-362 (2009)
 International Journal of Andrology, 32 (4): 399-410 (2008)
 Journal of Biological Chemistry, 288 (29): 20843-20855 (2013)
 Journal of Cellular Biochemistry, 112 (12): 3638-3647 (2011)
 Journal of Cerebral Blood Flow and Metabolism, 33: 1549-1555 (2013)
 Journal of Endocrinology, 218 (2): 205-213 (2013)
 Journal of Neurobiology, 52 (3): 203-220 (2002)
 Journal of Neuroscience, 32 (36): 12312-12324 (2012)
 Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012)
 Journal of Steroid Biochemistry and Molecular Biology, 138: 100-106 (2013)
 Journal of the American Heart Association, 2 (4): e271 (2013)
 Life Sciences, 93 (4): 133-138 (2013)
 Menopause, 16 (3): 582-588 (2009)
 Molecular Endocrinology, 27 (1): 25-37 (2013)
 Molecular Therapy, 19 (11): 1999-2011 (2011)
 Neuroendocrinology, 97 (3): 271-282 (2013)
 Neuroscience, 122 (3): 573-578 (2003)
 Pharmaceutical Reports, 65 (2): 476-483 (2013)
 Public Library of Science (PLOS ONE), 8 (1): e54357 (2013)
 Public Library of Science (PLOS ONE), 8 (3): e55589 (2013)
 Translational Stroke Research, 4 (4): 447-461 (2013)

STOCK

Doxycycline

Journal of Surgical Research, 158 (2): 300 (2010)

STOCK

DPN

Biology of Sex Differences, 3 (1): 24 (2012)
 Clinical Cancer Research, 18 (16): 4385-4396 (2012)
 FASEB Journal, 26 (10): 3993-4002 (2012)

CUSTOM

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

ERB-041

Steroids, 74 (13-14): 1015-1024 (2009)

CUSTOM

17 β -Estradiol

ACS Nano, 5 (11): 9113-9121 (2011)

ACS Nano, 6 (5): 4530-4539 (2012)

Acta Medica Iranica, 50 (12): 789-797 (2012)

Acta Pharmacologica Sinica, 32 (11): 1402-1410 (2011)

Adipocyte, 2 (3): 165-169 (2013)

Age, 34 (4): 895-904 (2012)

American Journal of Obstetrics and Gynecology, 209 (1): 24.e1-24.e12 (2013)

American Journal of Pathology, 178 (6): 2450-2460 (2011)

American Journal of Pathology, 180 (3): 1189-1201 (2012)

American Journal of Pathology, 180 (6): 2536-2547 (2012)

American Journal of Pathology, 183 (1): 304-312 (2013)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 302 (1): R159-R165 (2012)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 302 (3): R331-R339 (2012)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 303 (6): R651-R657 (2012)

American Journal of Respiratory Cell and Molecular Biology, 49 (1): 135-142 (2013)

Anti-Cancer Agents in Medicinal Chemistry, 13 (8): 1178-1187 (2013)

Asian Pacific Journal of Cancer Prevention, 14 (1): 63-68 (2013)

Asian Pacific Journal of Cancer Prevention, 14 (4): 2185-2190 (2013)

Autoimmunity, 45 (5): 364-376 (2012)

Autonomic Neuroscience, 153 (102): 84-89 (2010)

Basic Research in Cardiology, 105 (4): 479-486 (2010)

Basic Research in Cardiology, 106 (4): 563-575 (2011)

Biochemical and Biophysical Research Communications, 434 (4): 740-745 (2013)

Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, 1501 (2): 125-137 (2000)

Biochimica et Biophysica Acta (BBA) – Molecular Cell Research, 1591 (13): 109-118 (2002)

Bioconjugate Chemistry, 12 (2): 213-219 (2001)

Bioconjugate Chemistry, 22 (11): 2304-2316 (2011)

Biological Research, 38 (2-3): 213-223 (2005)

Biological Trace Element Research, 93 (1): 155-169 (2003)

Biology of Reproduction, 86 (3): 68 (2012)

Biology of Sex Differences, 2 (1): 14 (2011)

Biology of Sex Differences, 3 (1): 24 (2012)

Blood, 120 (8): 1703-1712 (2012)

Brain Research, 937 (1-2): 58-65 (2002)

Brain Research, 1443: 64-74 (2012)

Brain Research, 1461: 76-86 (2012)

Brain Research, 1493: 90-98 (2013)

Brain Research, 1514: 107-122 (2013)

Brain Pathology, 23 (4): 462-475 (2013)

Breast Cancer Research, 15 (2): R21 (2013)

Breast Cancer Research, 15 (4): R55 (2013)

Breast Cancer Research, 15 (5): R87 (2013)

Breast Cancer Research and Treatment, 135 (3): 771-780 (2012)

British Journal of Cancer, 106 (6): 1117-1122 (2012)

British Journal of Cancer, 107 (1): 43-52 (2012)

British Journal of Cancer, 108 (11): 2291-2298 (2013)

Canadian Journal of Physiology and Pharmacology, 91 (10): 823-829 (2013)

Cancer Biology and Therapy, 6 (6): 936-941 (2007)

Cancer Biology and Therapy, 13 (11): 1026-1033 (2012)

Cancer Cell, 20 (3): 341-356 (2011)

Cancer Cell, 21 (3): 430-446 (2012)

Cancer Cell, 23 (6): 753-767 (2013)

STOCK

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

17 β -Estradiol (cont.)

STOCK

Cancer Gene Therapy, 20 (5): 282-289 (2013)
Cancer Gene Therapy, 20 (8): 461-468 (2013)
Cancer Letters, 332 (1): 102-109 (2013)
Cancer Letters, 339 (2): 175-184 (2013)
Cancer Letters, 339 (2): 214-225 (2013)
Cancer Medicine, 1 (2): 105-113 (2012)
Cancer Prevention Research, 5 (8): 1053-1060 (2012)
Cancer Research, 72 (19): 5048-5059 (2012)
Cancer Research, 73 (4): 1420-1433 (2013)
Cancer Research, 73 (7): 2070-2081 (2013)
Cancer Research, 73 (13): 1-11 (2013)
Cancer Research, 73 (13): 5449-5458 (2013)
Cancer Research, 73 (15): 4697-4710 (2013)
Cancer Research, 73 (15): 4885-4897 (2013)
Cancer Science, 102 (11): 2038-2042 (2011)
Cancer Science, 103 (6): 1000-1009 (2012)
Carcinogenesis, 30 (9): 1581-1590 (2009)
Carcinogenesis, 34 (10): 2271-2280 (2013)
Cell Cycle, 8 (4): 2266-2280 (2009)
Cell Death and Disease, 4 (8): e757 (2013)
Cell Death and Disease, 4 (8): e758 (2013)
Cell Metabolism, 17 (1): 49-60 (2013)
Cell Reports, 3 (2): 342-349 (2013)
Cell Reports, 4 (6): 1116-1130 (2013)
Cell Stem Cell, 1 (5): 555-567 (2007)
Cerebral Cortex, 22 (8): 1799-1812 (2012)
Circulation, 126 (16): 1993-2004 (2012)
Clinical and Cellular Immunology, 4 (3): 143 (2013)
Clinical and Experimental Metastasis, 11 (1): 15-26 (1993)
Clinical and Experimental Metastasis, 29 (5): 493-509 (2012)
Clinical Cancer Research, 18 (15): 4059-4069 (2012)
Clinical Cancer Research, 18 (20): 5816-5828 (2012)
Clinical Cancer Research, 18 (21): 5911-5923 (2012)
Clinical Cancer Research, 19 (7): 1760-1772 (2013)
Clinical Cancer Research, 19 (9): 2420-2431 (2013)
Clinical Cancer Research, 19 (14): 3881-3893 (2013)
Clinical Cancer Research, 19 (19): 5390-5401 (2013)
Clinical Cancer Research, 19 (19): 5413-5422 (2013)
Clinical Immunology, 140 (1): 37-46 (2011)
Clinical Science, 123 (8): 509-518 (2012)
Development, 140 (5): 1079-1089 (2013)
Diabetes, 62 (2): 424-434 (2013)
Dissertation, 1-120 (2006)
Dissertation, 1-272 (2010)
Dissertation, 1-42 (2012)
Dissertation, 1-52 (2012)
Dissertation, 1-180 (2012)
Dissertation, 2-253 (2012)
Dissertation, 1-83 (2013)
Drug Development Research, 69 (8): 526-534 (2008)
Drug Metabolism and Disposition, 40 (9): 1785-1796 (2012)
Elife, 2: e00358 (2013)
EMBO Molecular Medicine, 5 (9): 1335-1350 (2013)
Endocrine – Related Cancer, 20 (4): 515-525 (2013)
Endocrinology, 153 (9): 4412-4421 (2012)

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

17 β -Estradiol (cont.)

STOCK

- Endocrinology, 153 (9): 4470-4479 (2012)
Endocrinology, 153 (9): 4480-4490 (2012)
Endocrinology, 153 (10): 5011-5022 (2012)
Endocrinology, 153 (11): 5325-5333 (2012)
Endocrinology, 153 (11): 5467-5479 (2012)
Endocrinology, 154 (3): 1021-1028 (2013)
Endocrinology, 154 (6): 2222-2233 (2013)
European Journal of Neuroscience, 34 (5): 745-754 (2011)
European Journal of Nuclear Medicine and Molecular Imaging, 38 (11): 1967-1976 (2011)
European Journal of Nutrition, 51 (7): 861-870 (2012)
Experimental Cell Research, 317 (18): 2573-2581 (2011)
Experimental Clinical Cardiology, 17 (3): 95-100 (2012)
Experimental Eye Research, 96 (1): 88-97 (2012)
Experimental Lung Research, 38 (4): 165-172 (2012)
Experimental Neurology, 237 (1): 1-7 (2012)
FASEB Journal, 27 (1): 63-75 (2013)
FASEB Journal, 27 (9): 3711-3719 (2013)
Female Pelvic Medicine and Reconstructive Surgery, 18 (3): 148-152 (2012)
Food and Chemical Toxicology, 49 (9): 2279-2284 (2011)
Frontiers in Endocrinology, 2 (82): 1-15 (2011)
Frontiers in Neuroscience, 7 (13): 1-8 (2013)
Gastroenterology, 142 (4): 989-998 (2012)
General and Comparative Endocrinology, 176 (2): 144-150 (2012)
Genes and Cancer, 4 (1): 3-14 (2013)
Haematologica, 97 (8): 1131-1135 (2012)
Histology and Histopathology, 27 (8): 1047-1054 (2012)
Hypertension, 59 (3): 552-554 (2012)
Hypertension, 59 (3): 694-704 (2012)
Hormone and Metabolic Research, 41 (5): 356-362 (2009)
Hormone and Metabolic Research, 45 (7): 490-494 (2013)
Human Reproduction, 28 (8): 2253-2264 (2013)
Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 11 (4): 262-274 (2011)
In Vivo, 24 (4): 553-560 (2010)
Infection and Immunity, 81 (3): 733-739 (2013)
International Journal of Andrology, 32 (4): 399-410 (2008)
International Journal of Cancer, 121 (5): 1055-1058 (2007)
International Journal of Cancer, 132 (12): 2787-2798 (2013)
International Journal of Oncology, 39 (6): 1443-1453 (2011)
International Journal of Oncology, 42 (1): 179-187 (2013)
Japanese Journal of Cancer Research, 86 (8): 770-775 (1995)
Journal of Alzheimer's Disease, 18 (2): 429-445 (2009)
Journal of Applied Physiology, 112 (9): 1564-1575 (2012)
Journal of Applied Physiology, 113 (1): 149-158 (2012)
Journal of Autoimmunity, 37 (2): 95-103 (2011)
Journal of Autoimmunity, 38 (1): 1-9 (2012)
Journal of Autoimmunity, 38 (2-3): J135-J143 (2012)
Journal of Autoimmunity, 38 (2-3): J245-J253 (2012)
Journal of Biological Chemistry, 279 (32): 33696-33701 (2004)
Journal of Biological Chemistry, 287 (44): 37195-37205 (2012)
Journal of Biological Chemistry, 288 (5): 18022-18034 (2013)
Journal of Biological Chemistry, 288 (34): 24590-24599 (2013)
Journal of Biomedical Optics, 17 (11): 116017 (2012)
Journal of Cancer Therapy, 4: 32-40 (2013)
Journal of Cell Biology, 198 (3): 281-293 (2012)
Journal of Cellular Physiology, 219 (2): 477-484 (2009)

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

17 β -Estradiol (cont.)

STOCK

- Journal of Clinical Investigation, 122 (8): 2857-2870 (2012)
Journal of Clinical Investigation, 123 (6): 2551-2563 (2013)
Journal of Clinical Investigation, 123 (9): 3861-3875 (2013)
Journal of Clinical Investigation, 123 (10): 4324-4343 (2013)
Journal of Drug Targeting, 16 (7-8): 605-610 (2008)
Journal of Experimental Therapeutics and Oncology, 3 (1): 27-35 (2003)
Journal of Headache and Pain, 1 (1): P29 (2013)
Journal of Hypertension, 27 (6): 1284-1292 (2009)
Journal of Hypertension, 27 (8): 1602-1608 (2009)
Journal of Immunology, 190 (8): 4420-4430 (2013)
Journal of Inflammation Research, 6: 99-108 (2013)
Journal of Investigative Dermatology, 132 (12): 2838-2848 (2012)
Journal of Labelled Compounds and Radiopharmaceuticals, 55 (9): 346-353 (2012)
Journal of Laboratory and Clinical Medicine, 153 (6): 275-282 (2009)
Journal of Magnetic Resonance Imaging, 29 (5): 1071-1079 (2009)
Journal of Materials Chemistry B, 39 (1): 5288-5297 (2013)
Journal of Molecular and Cellular Cardiology, 53 (2): 268-276 (2012)
Journal of Neurobiology, 65 (2): 192-204 (2005)
Journal of Neuroendocrinology, 22 (10): 1082-1092 (2010)
Journal of Nuclear Medicine, 53 (4): 629-637 (2012)
Journal of Nuclear Medicine, 53 (12): 1943-1950 (2012)
Journal of Nuclear Medicine, 54 (9): 1630-1636 (2013)
Journal of Nutritional Biochemistry, 23 (6): 532-538 (2012)
Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012)
Journal of Steroid Biochemistry and Molecular Biology, 114 (3): 186-194 (2009)
Journal of the National Cancer Institute, 104 (17): 1320-1334 (2012)
Journal of the National Cancer Institute, 104 (19): 1485-1502 (2012)
Kidney International, 79 (4): 404-413 (2011)
Magnetic Resonance in Medicine, 69 (6): 1721-1734 (2013)
Magnetic Resonance Materials in Biology, Physics and Medicine, 6 (1): 44-52 (1998)
Menopause, 16 (3): 545-554 (2009)
Menopause, 19 (6): 680-690 (2012)
Menopause, 19 (8): 942-947 (2012)
Menopause, 20 (5): 504-510 (2013)
Menopause, 20 (8): 860-868 (2013)
Methods in Molecular Biology, 946 (Chapter 12): 181-204 (2013)
Molecular and Cellular Endocrinology, 375 (1-2): 149-156 (2013)
Molecular Biosystems, 7 (11): 3006-3020 (2011)
Molecular Cancer, 12 (59): 1-18 (2013)
Molecular Cancer Therapeutics, 12 (4): 542-552 (2013)
Molecular Cancer Therapeutics, 12 (5): 675-684 (2013)
Molecular Cancer Therapeutics, 12 (10): 2078-2087 (2013)
Molecular Carcinogenesis, 52 (7): 514-525 (2013)
Molecular Endocrinology, 27 (9): 1403-1414 (2013)
Molecular Endocrinology, 27 (9): 1415-1428 (2013)
Molecular Endocrinology, 27 (10): 1762-1775 (2013)
Molecular Human Reproduction, 19 (3): 169-176 (2013)
Molecular Imaging and Biology, 13 (6): 1183-1195 (2011)
Molecular Medicine, 18 (9): 913-929 (2012)
Molecular Metabolism, 2 (3): 227-242 (2013)
Molecular Pharmaceutics, 6 (2): 543-556 (2009)
Molecular Pharmaceutics, 10 (1): 69-76 (2013)
Molecular Pharmaceutics, 10 (1): 152-160 (2013)
Molecular Pharmaceutics, 10 (7): 2558-2567 (2013)
Molecular Pharmacology, 82 (6): 1241-1249 (2012)

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

17 β -Estradiol (cont.)

STOCK

- Molecular Psychiatry, 18 (6): 674-680 (2013)
Molecular Therapy – Nucleic Acids, 2 (9): e121 (2013)
Nanomedicine: Nanotechnology, Biology and Medicine, 9 (1): 122-129 (2012)
Nature Biotechnology, 31 (6): 539-544 (2013)
Nature Medicine, 18 (7): 1102-1111 (2012)
Nature Medicine, 18 (12): 1847-1856 (2012)
Neurobiology of Disease, 45 (1): 479-487 (2012)
Neurobiology of Learning and Memory, 94 (3): 422-433 (2010)
Neurobiology of Learning and Memory, 99: 50-58 (2013)
Nuclear Medicine and Biology, 40 (1): 52-59 (2013)
Oncogene, 29 (22): 3228-3240 (2010)
Oncogene, 31 (34): 3889-3900 (2012)
Oncology Reports, 30 (4): 1762-1772 (2013)
Oncotarget, 3 (8): 869-881 (2012)
Osteoporosis International, 22 (11): 2887-2893 (2011)
Physiological Genomics, 44 (6): 362-373 (2012)
Proceedings of the National Academy of Sciences (PNAS), 109 (33): 13331-13336 (2012)
Proceedings of the National Academy of Sciences (PNAS), 109 (45): 3119-3127 (2012)
Proceedings of the National Academy of Sciences (PNAS), 109 (48): 19822-19827 (2012)
Proceedings of the National Academy of Sciences (PNAS), 110 (5): E407-E414 (2013)
Proceedings of the National Academy of Sciences (PNAS), 110 (6): 2294-2299 (2013)
Proceedings of the National Academy of Sciences (PNAS), 110 (29): 11851-11856 (2013)
Proceedings of the National Academy of Sciences (PNAS), 110 (36): E3445-E3454 (2013)
Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 89 (2): 81-88 (2013)
Proteomics, 9 (10): 2750-2763 (2009)
Public Library of Science (PLoS ONE), 7 (11): e48220 (2012)
Public Library of Science (PLoS ONE), 7 (11): e48564 (2012)
Public Library of Science (PLoS ONE), 7 (11): e48601 (2012)
Public Library of Science (PLoS ONE), 7 (11): e50301 (2012)
Public Library of Science (PLoS ONE), 7 (12): e50749 (2012)
Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)
Public Library of Science (PLoS ONE), 7 (12): e52692 (2012)
Public Library of Science (PLoS ONE), 8 (1): e54022 (2013)
Public Library of Science (PLoS ONE), 8 (4): e61515 (2013)
Public Library of Science (PLoS ONE), 8 (5): e63146 (2013)
Public Library of Science (PLoS ONE), 8 (5): e64049 (2013)
Public Library of Science (PLoS ONE), 8 (5): e64069 (2013)
Public Library of Science (PLoS ONE), 8 (5): e65163 (2013)
Public Library of Science (PLoS ONE), 8 (6): e68637 (2013)
Public Library of Science (PLoS ONE), 8 (7): e68815 (2013)
Public Library of Science (PLoS ONE), 8 (8): e69291 (2013)
Public Library of Science (PLoS ONE), 8 (8): e70719 (2013)
Public Library of Science (PLoS ONE), 8 (8): e72210 (2013)
Public Library of Science (PLoS ONE), 8 (8): e72397 (2013)
Public Library of Science (PLoS ONE), 8 (9): e75288 (2013)
Public Library of Science (PLoS ONE), 9 (3): e1003311 (2013)
Public Library of Science (PLoS) Pathogens, 9 (4): e1003292 (2013)
Reproduction, 142 (5): 745-755 (2011)
Research Quarterly for Exercise and Sport, 82 (4): 693-701 (2011)
Scandinavian Journal of Clinical and Laboratory Investigation, 71 (7): 583-592 (2011)
Science Translational Medicine, 5 (169): ra12 (2013)
Stem Cells, 27 (5): 993-1005 (2009)
Stem Cells, 31 (4): 808-822 (2013)
Steroids, 74 (7): 555-561 (2009)
Steroids, 74 (13-14): 1015-1024 (2009)

SELECTED REFERENCES

PRODUCT / JOURNALS	CURRENT AVAILABILITY
--------------------	----------------------

<p>17β-Estradiol (cont.) Thrombosis Research, 126 (6): 504-510 (2010) Toxicology and Applied Pharmacology, 247 (2): 83-90 (2010) Vaccine, 28 (45): 7279-7287 (2010) Virology, 447 (1): 155-165 (2013)</p>	STOCK
<p>β-Estradiol 3-Benzoate American Journal of Physiology: Endocrinology and Metabolism, 302 (8): E979-E986 (2012) Biological Psychiatry, 71 (7): 642-651 (2012)</p>	STOCK
<p>17β-Estradiol + Progesterone Journal of Pathology, 225 (4): 565-573 (2011) Neuroscience, 184: 172-182 (2011)</p>	STOCK
<p>Estriol Dissertation, 1-180 (2012)</p>	STOCK
<p>Fluoxetine Dissertation, 1-264 (2013) European Journal of Neuroscience, 37 (2): 242-250 (2013) Nature Neuroscience, 13 (6): 745-754 (2010) Neuropsychopharmacology, 38 (6): 909-920 (2013)</p>	CUSTOM
<p>Flutamide American Journal of Pathology, 182 (2): 1-14 (2013) Behavioral Neuroscience, 127 (3): 400-414 (2013) Dissertation, 1-191 (2011) Dissertation, 1-15 (2013) Frontiers in Zoology, 10 (1): 8 (2013) Journal of Comparative Neurology, 431 (4): 444-459 (2001) Public Library of Science (PLoS ONE), 7 (12): e52009 (2012) Science, 339 (6123): 1084-1088 (2013)</p>	STOCK
<p>G-1 Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 11 (4): 262-274 (2011) Journal of Molecular Endocrinology, 51 (1): 191-202 (2013) Public Library of Science (PLoS ONE), 7 (9): e43215 (2012)</p>	CUSTOM
<p>Glucosamine Biology of Reproduction, 89 (1): 16 (2013)</p>	CUSTOM
<p>GW7604 Steroids, 74 (13-14): 1015-1024 (2009)</p>	CUSTOM
<p>Haloperidol Journal of Clinical Investigation, 123 (9): 3902-3913 (2013) Pharmacogenomics Journal, 12 (2): 147-155 (2012)</p>	STOCK
<p>Hexarelin Growth Hormone and IGF Research, 20 (1): 49-54 (2009)</p>	CUSTOM
<p>4-Hydroxytamoxifen Journal of Cellular and Molecular Medicine, 17 (8): 936-957 (2013)</p>	CUSTOM
<p>IN-1130 American Journal of Physiology: Renal Physiology, 304 (5): F481-F490 (2013)</p>	CUSTOM

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Insulin-Like Growth Factor-1 (IGF-1) Cancer Medicine, 1 (2): 275-288 (2012)	CUSTOM
Isradipine Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812 (12): 1584-1590 (2011)	CUSTOM
16α-LE2 Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)	CUSTOM
Letrozole Dissertation, 1-191 (2011) Fertility and Sterility, 99 (3): 889-896 (2013) Frontiers in Zoology, 10 (1): 8 (2013)	CUSTOM
Lipopolysaccharide (LPS) Cardiovascular Pathology, 18 (1): 1-10 (2009) Dissertation, 1-98 (2012) Inflammation Research, 60 (7): 665-672 (2011) Journal of Biomedical Materials Research (Part A), 100 (4): 918-928 (2012)	CUSTOM
Luteinizing Hormone (LH) Neuroendocrinology, 94 (4): 313-322 (2011)	CUSTOM
LY3201 Molecular Psychiatry, 18 (6): 674-680 (2013) Proceedings of the National Academy of Sciences (PNAS), 110 (9): 3543-3548 (2013)	CUSTOM
Medroxyprogesterone Acetate (MPA) Endocrinology, 153 (10): 4874-4882 (2012) International Journal of Oncology, 42 (1): 179-187 (2013) Journal of Cellular Physiology, 219 (2): 477-484 (2009) Journal of Immunology, 189 (7): 3449-3461 (2012) Menopause, 19 (7): 804-811 (2012)	STOCK
1-Methyl-DL-Tryptophan (1-MT) Journal of Immunology, 189 (1): 72-79 (2012) Journal of Immunology, 191 (4): 1965-1975 (2013) Oncogene, 27 (20): 2851-2857 (2008)	CUSTOM
1-Methyl-L-Tryptophan Gastroenterology, 145 (2): 416-425 (2013)	CUSTOM
Mifepristone (RU-486) Journal of Neuroscience, 32 (22): 7563-7571 (2012) Journal of Orthopaedic Research, 30 (2): 288-295 (2012) Neurobiology of Disease, 45 (1): 539-546 (2012) Steroids, 74 (13-14): 1015-1024 (2009)	CUSTOM
Nedocromil American Journal of Physiology: Heart and Circulatory Physiology, 302 (3): H811-H817 (2012) Public Library of Science (PLoS ONE), 8 (3): e60827 (2013)	CUSTOM
Neuropeptide Y (NPY) Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, (Chapter 2): 1-160 (2000) FASEB Journal, 27 (6): 2244-2255 (2013)	CUSTOM

SELECTED REFERENCES

PRODUCT / JOURNALS	CURRENT AVAILABILITY
--------------------	----------------------

<p>Nicotine Biological Trace Element Research, 46 (1-2): 67-78 (1994) Experimental Lung Research, 35 (2): 119-135 (2009)</p>	STOCK
<p>Norethindrone Menopause, 20 (5): 504-510 (2013)</p>	STOCK
<p>Ouabain Journal of Cardiovascular Pharmacology, 62 (2): 174-183 (2013)</p>	STOCK
<p>Peptide 6 Neurobiology of Aging, 32 (8): 1420-1434 (2011)</p>	CUSTOM
<p>PPT Biology of Sex Differences, 3 (1): 24 (2012)</p>	CUSTOM
<p>Prednisolone Annals of the New York Academy of Sciences, 1192 (1): 81-83 (2010) Arthritis and Rheumatism, 64 (11): 3649-3659 (2012) FASEB Journal, 25 (10): 3366-3376 (2011) Human Gene Therapy, 23 (3): 262-273 (2012) Joint Bone Spine, 80 (1): 77-81 (2013) Journal of Bone and Mineral Metabolism, 30 (5): 509-516 (2012) Journal of Bone and Mineral Research, 27 (11): 2242-2250 (2012) Vitamins and Hormones, 90: 163-186 (2012)</p>	STOCK
<p>Prednisone Journal of Bone and Mineral Metabolism, 28 (5): 532-539 (2010) Muscle and Nerve, 44 (1): 8-19 (2011)</p>	STOCK
<p>Pregnenolone Experimental Neurology, 233 (2): 677-685 (2012)</p>	STOCK
<p>Progesterone American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 302 (3): R331-R339 (2012) Biochemical and Biophysical Research Communications, 434 (4): 740-745 (2013) Biology of Reproduction, 86 (3): 68 (2012) Biology of Sex Differences, 2 (1): 14 (2011) Brain Research, 1361: 124-132 (2010) Cancer Research, 73 (15): 4697-4710 (2013) Carcinogenesis, 30 (9): 1581-1590 (2009) Development, 140 (17): 1397-1401 (2013) Disease Models and Mechanisms, 6 (5): 1198-1204 (2013) Endocrinology, 153 (10): 4874-4882 (2012) Endocrinology, 153 (11): 5467-5479 (2012) FASEB Journal, 27 (9): 3711-3719 (2013) General and Comparative Endocrinology, 176 (2): 144-150 (2012) Hormone and Metabolic Research, 45 (7): 490-494 (2013) Human Reproduction, 28 (8): 2253-2264 (2013) Journal of Neurochemistry, 122 (1): 185-195 (2012) Journal of Neuroendocrinology, 25 (3): 235-243 (2013) Journal of Neuroscience, 32 (42): 14664-14669 (2012) Journal of Sports Medicine and Physical Fitness, 42 (4): 481-487 (2002) Journal of Steroid Biochemistry and Molecular Biology, 83 (1): 199-209 (2002) Molecular Endocrinology, 27 (9): 1403-1414 (2013)</p>	STOCK

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Progesterone (cont.)	STOCK
Molecular Genetics and Genomics, 288 (5-6): 207-229 (2013)	
Nature Medicine, 19 (8): 1061-1066 (2013)	
Neurobiology of Disease, 45 (1): 479-487 (2012)	
Neuropathology and Applied Neurobiology, 30 (1): 80-89 (2004)	
Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 89 (2-3): 81-88 (2013)	
Public Library of Science (PLOS ONE), 7 (12): e50749 (2012)	
Public Library of Science (PLOS ONE), 8 (6): e68637 (2013)	
Public Library of Science (PLOS) Pathogens, 9 (4): e1003292 (2013)	
Research Quarterly for Exercise and Sport, 82 (4): 693-701 (2011)	
Stem Cells, 31 (4): 808-822 (2013)	
Steroids, 74 (13-14): 1015-1024 (2009)	
Propranolol	STOCK
FASEB Journal, 27 (9): 3871-3878 (2013)	
D-Propranolol	CUSTOM
Canadian Journal of Physiology and Pharmacology, 90 (9): 1257-1268 (2012)	
Prostaglandin D2	STOCK
Calcified Tissue International, 52 (6): 442-446 (1993)	
Raloxifene	CUSTOM
Public Library of Science (PLOS ONE), 7 (12): e50802 (2012)	
Steroids, 74 (13-14): 1015-1024 (2009)	
Ranolazine	CUSTOM
Circulation, 126 (18): 2208-2219 (2012)	
Rapamycin	CUSTOM
Aging, 5 (2): 111-119 (2013)	
American Journal of Pathology, 181 (1): 278-293 (2012)	
Rat Growth Hormone (GH)	CUSTOM
Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012)	
Resveratrol	CUSTOM
Journal of Surgical Research, 179 (1): E141-E148 (2013)	
all trans-Retinoic Acid (ATRA)	STOCK
Haematologica, 98 (3): 424-427 (2013)	
Journal of Experimental Medicine, 210 (4): 647-653 (2013)	
Journal of Immunotherapy, 32 (6): 552-564 (2009)	
Leukemia, 26 (7): 1630-1637 (2012)	
Leukemia, 26 (11): 2432-2435 (2012)	
Sodium Butyrate	STOCK
Molecular and Cellular Biology, 33 (19): 3920-3935 (2013)	
Spirolactone	STOCK
American Journal of Nephrology, 35 (1): 90-100 (2012)	
Journal of Human Hypertension, 27 (1): 1-6 (2013)	
Journal of the American Heart Association, 2 (1): e18 (2013)	
Streptozotocin	STOCK
American Journal of Obstetrics and Gynecology, 209 (1): 24.e1-24.e12 (2013)	

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Tacrolimus Experimental Neurology, 248: 85-99 (2013)	CUSTOM
Tamoxifen American Journal of Pathology, 183 (1): 304-312 (2013) Angiogenesis, 6 (1): 65-71 (2003) Anti-Cancer Agents in Medicinal Chemistry, 13 (8): 1178-1187 (2013) Cell Reports, 3 (4): 1153-1163 (2013) Clinical Cancer Research, 19 (9): 2420-2431 (2013) Journal of Clinical Investigation, 122 (8): 2857-2870 (2012) Journal of Comparative Neurology, 431 (4): 444-459 (2001) Molecular Cancer, 12 (9): 1-17 (2013) Oncogene, 29 (22): 3228-3240 (2010) Proceedings of the National Academy of Sciences (PNAS), 109 (51): 21140-21145 (2012) Public Library of Science (PLoS ONE), 8 (8): e72132 (2013) Steroids, 74 (13-14): 1015-1024 (2009) Translational Oncology, 6 (3): 244-255 (2013)	STOCK
Tamoxifen Citrate Cancer Research, 72 (19): 5048-5059 (2012) EMBO Molecular Medicine, 5 (5): 723-736 (2013)	STOCK
Tamoxifen (Free Base) Cancer Research, 73 (13): 5449-5458 (2013) FASEB Journal, 26 (10): 3993-4002 (2012) Journal of Experimental Medicine, 209 (9): 1611-1627 (2012)	STOCK
Testosterone American Journal of Physiology: Renal Physiology, 305 (5): 618-627 (2013) Arthritis and Rheumatism, 64 (8): 2518-2528 (2012) Biological Psychiatry, 71 (7): 642-651 (2012) Biology of Sex Differences, 2 (1): 14 (2011) Biomed Research International, Volume 2013 (Article ID 913179): 1-8 (2013) Brain Research, 1429: 43-51 (2012) Cancer Research, 73 (8): 2587-2597 (2013) Current Eye Research, 32 (5): 393-398 (2007) Diabetes, 61 (10): 2597-2608 (2012) Discrete and Continuous Dynamical Systems Series B, 18 (4): 945-967 (2013) Dissertation, 1-106 (2012) Endocrine – Related Cancer, 19 (6): 759-777 (2012) Experimental Neurology, 181 (2): 301-312 (2003) Experimental Physiology, 98 (1): 161-171 (2013) Hormones and Behavior, 61 (5): 678-685 (2012) Hormone and Metabolic Research, 45 (7): 490-494 (2013) Hypertension, 59 (3): 726-731 (2012) International Journal of Andrology, 32 (4): 399-410 (2008) Investigative Ophthalmology and Visual Science, 33 (8): 2537-2545 (1992) Journal of Alzheimer's Disease, 15 (1): 129-137 (2008) Journal of Clinical Investigation, 132 (2): 682-699 (2013) Journal of Neurobiology, 49 (1): 1-8 (2001) Journal of Neuroendocrinology, 24 (5): 737-747 (2012) Journal of Neuroscience, 32 (36): 12312-12324 (2012) Journal of Neuroscience, 33 (6): 2338-2355 (2013) Kidney International, 79 (4): 404-413 (2011) Molecular Imaging, 11 (5): 426-432 (2012)	STOCK

SELECTED REFERENCES

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Testosterone (cont.)

STOCK

Nature Protocols, 8 (5): 836-848 (2013)
Neurobiology of Disease, 45 (1): 479-487 (2012)
Prostate, 73 (12): 1251-1262 (2013)
Public Library of Science (PLoS ONE), 7 (11): e49970 (2012)
Public Library of Science (PLoS ONE), 8 (1): e53302 (2013)
Public Library of Science (PLoS ONE), 8 (1): e55062 (2013)
Public Library of Science (PLoS ONE), 8 (2): e55694 (2013)
Public Library of Science (PLoS ONE), 8 (2): e56903 (2013)
Public Library of Science (PLoS ONE), 8 (5): e63723 (2013)
Public Library of Science (PLoS ONE), 8 (5): e64503 (2013)
Public Library of Science (PLoS ONE), 8 (6): e65538 (2013)
Public Library of Science (PLoS ONE), 8 (7): e69398 (2013)
Radiation Oncology, 7 (1): 75 (2012)

Testosterone Propionate

STOCK

Behavioural Brain Research, 224 (2): 403-407 (2011)
Cerebral Cortex, 22 (8): 1799-1812 (2012)
Journal of Comparative Physiology A, 165 (1): 15-26 (1989)
Journal of Neurobiology, 30 (2): 231-245 (1996)
Journal of Neurobiology, 52 (3): 203-220 (2002)
Stem Cells, 30 (6): 1076-1086 (2012)

L-Thyroxine (T4)

STOCK

European Respiratory Journal, 41 (1): 104-114 (2013)
Journal of Clinical Investigation, 122 (10): 3737-3741 (2012)
Journal of Translational Medicine, 11 (1): 40 (2013)
Pulmonary Circulation, 2 (4): 434-442 (2012)
Toxicology, 225 (2-3): 119-127 (2006)



RECOMMENDED IMPLANTATION PROCEDURE

Depending on the physical size of the animal, multiple pellets can be implanted to build up the dose. We recommend starting with one pellet on each lateral side of the neck between the ear and the shoulder where there is maximal space between the skin and the muscle.

*Please Note - In order to ensure reliable and continued performance, the pellet and implantation site **should not** come in contact with any alcohol, ethanol, exogenous fluids or organic solvents. Please make sure your instruments are **dry** before use.

In order to implant a second pellet in the same incision pocket, the pellets should be side by side and not super imposed/stacked on top of each other.

The ideal site for pellet implantation is on the lateral side of the neck between the ear and the shoulder where there is maximal space between the skin and the muscle. This has three advantages:

- 1) Maximal space between the skin and the muscle so that the pellet sits comfortably
- 2) The animal cannot play with the pellet in that site
- 3) Other animals cannot play with the pellet in that site

*Please Note - the pellets arrive to you sterile. By design, the pellets have a sterile coating so even if one pellet falls on the bench, it is still sterile.

When this technique is properly executed, no antibiotics or stitches are needed and the animal should not bleed. In order to ensure reliable and continued performance, the pellet should not come in contact with any organic solvent or exogenous fluid.

If the pellet is a reasonable size (3mm in diameter - normally 0.001 mg/pellet up to 5mg/pellet), it can be implanted using our MP-182 10 Gauge Precision Trochar.

For pellet implantation without using our Trochar, the following technique can be used:

- 1) Lift the skin on the lateral side of the neck of the animal
- 2) Make an incision equal in diameter to that of the pellet
- 3) Make a pocket horizontally with a pair of forceps about 2cm beyond the incision site
- 4) Put the pellet into the pocket with forceps and angle it to the right or to the left



Purchase Order Form

(United States)

Innovative Research of America
 2 North Tamiami Trail, Suite 404
 Sarasota, Florida 34236
 Phone 941.365.1406
 Fax 941.365.1703

Please print or type all information

Institution: _____

P.O. Number: _____ **Date:** _____

Purchasing Agent: _____

Investigator: _____

Department: _____

Department: _____

Phone: _____ **Fax:** _____


Phone: _____ **Fax:** _____

Email: _____

Email: _____

Cat. No.	# Lots	Quantity/ Lots	Product Description	Dosage	Release Time	Price/ Lot	Total Price
							\$

American Express, MasterCard, and Visa accepted.



Account #: _____

Expiration Date: _____

Name on Card: _____

Subtotal: \$ _____

Shipping and Handling: \$ _____
 (Via Federal Express)

Total: \$ _____

Ship To:

Attn: _____

Bill To:

Attn: _____

PLEASE COPY THIS FORM FOR FUTURE ORDERING

International Order Form

Innovative Research of America

2 North Tamiami Trail, Suite 404

Sarasota, Florida 34236

Phone 941.365.1406

Fax 941.365.1703

Please print or type all information

Institution: _____

P.O. Number: _____ **Date:** _____

Purchasing Agent: _____

Investigator: _____

Department: _____

Department: _____




Phone: _____ **Fax:** _____

Phone: _____ **Fax:** _____

Email: _____

Email: _____

Cat. No.	# Lots	Quantity/ Lots	Product Description	Dosage	Release Time	Price/ Lot	Total Price
							\$

A Proforma Invoice will be provided for advance payment. See Bank Wire information on this form.
 American Express, MasterCard, and Visa    accepted.
 Account #: _____
 Expiration Date: _____
 Name on Card: _____

Subtotal: \$ _____
Shipping and Handling: \$ _____
 (Via Federal Express)
Total: \$ _____

*Note: Recipient is responsible for all duties and taxes on any orders shipped outside the United States

Signature Required _____

Ship To:

Attn: _____

Bill To:

Attn: _____

Bank Wire Payment Information

Payment via bank wire should be directed as follows:
BB&T Bank In favor of:
 1800 Second St., Suite 100 Innovative Research of America
 Sarasota, Florida 34236 2 North Tamiami Trail
 Routing # (ABA) 263191387 Sarasota, FL 34236
 Elect. Transfers # 263191387 Checking Account: #0000147816154
 Swift Code: BRBTUS33

Accounts Payable/Financial Information

Contact Name: _____
Phone: _____ **Fax:** _____
Email: _____

PLEASE COPY THIS FORM FOR FUTURE ORDERING

We now have an additional **PATENT** page on our website where you can search numerous patents issued citing the use of our innovative technology. To view a complete list of patents entered on a daily basis please visit our website: www.innovrsrch.com



IRA PATENTS

Reliable Delivery System for Global Discoveries



Hormone and Drug Pellets for Biomedical Research

*Our mission is to standardize the drug delivery technology.
We are dedicated to helping investigators take charge of
product delivery by expanding their abilities to do
meaningful and reproducible research!*



Innovative Research of America
2 North Tamiami Trail, Fourth Floor
Sarasota, Florida 34236 USA

Contact Us:

Tel: (941) 365-1406

(941) 365-1506

  (800) 421-8171

Fax: (941) 365-1703

(941) 365-1803

(800) 643-4345  

(800) 643-6030  

Website: www.innovsrch.com

Email us at: pellets@innovsrch.com